• Projektdatenbank

Projektdatenbank

Suchen, sortieren und filtern

 

Sortierung

  • –
  • Fördersumme ↑
  • Fördersumme ↓
  • Beginn ↑
  • Beginn ↓
  • Ende ↑
  • Ende ↓
  • Titel ↑
  • Titel ↓

Standort

  • –
  • Berlin
  • Extern
  • Greifswald
  • Göttingen
  • Hamburg/Kiel/Lübeck
  • Heidelberg/Mannheim
  • München
  • RheinMain

Projektart

  • –
  • DZG Innovation Cluster
  • Daten- und Probennutzung
  • Digitale Technologien
  • Exzellenzprogramm
  • Ideen-Wettbewerb
  • Internationale Kooperation
  • Klinische Studie
  • Kompetenznetze
  • Kooperation mit Externen
  • OMICs
  • Shared Expertise (SE)
  • Standortprojekt
  • Translational Research Project

Topic

  • –
  • Gavazzi et
  • protein based therapy
  • setzen sich zunehmend in der spät-translationalen Entwicklung von Strategien für die Regeneration bei Herzmuskelschwäche durch. Seit 2011 wurden im Deutschen Primatenzentrum (DPZ) die Gr
  • v.a. Weißbüschelaffen und Rhesusaffen
  • wobei letztere als Kontrollen dienen. • Erfassung von Blutdruck und Herzrate mittels implantierba
  • DNA/RNA based
  • Die wissenschaftlichen Ziele des beantragten Projektes sind: · Proof-of-Concept eines neuen elektro-mechanischen Bildgebungsverfahrens zur hoch-aufgelösten raum-zeitlichen Charakterisierung kardialer Arrhythmien im Langendorff-pefundierten Ganzherz (Schwe
  • Die überwiegende Zahl von Patienten mit Linksherzinsuffizienz NYHA III und NYHA IV weisen erhöhte pulmonal-arterielle Drücke von =19 mmHg im Sinne einer Borderline-pulmonalen Hypertonie (PH) bzw. =25 mmHg im Sinne einer manifesten PH auf (Ghio
  • Health services/health systems research
  • In einer Pilotstudie untersuchen wir das Auftreten kardiovaskulärer Schädigungen im Zeitverlauf der Diabetesentstehung in männlichen NZO- und C57B6/J-Mäusen
  • Inflammatory heart diseases
  • Mechanisms in ischemia/reperfusion
  • Nicht-humane Primatenmodelle
  • angiogenesis
  • arteriosclerosis
  • cardiac hypertrophy/remodeling
  • cardiomyocyte function
  • endothelial cells/vascular function
  • genetics of cardiovascular diseases
  • iPSC
  • imaging
  • inflammation/vascular inflammation
  • miRNAS/IncRNA
  • other arrhythmias
  • platelet function/thrombosis mechanisms
  • stem cells/cardiac regeneration
  • vascular remodelling/altering

SE-Merkmal

  • –
  • SE-Anbieter
  • SE-Partner

SE-Nummer

  • –
  • SE 001
  • SE 004
  • SE 005
  • SE 006
  • SE 006/SE 160
  • SE 012
  • SE 014
  • SE 017
  • SE 018
  • SE 019
  • SE 020
  • SE 022
  • SE 024
  • SE 025
  • SE 028
  • SE 029
  • SE 030
  • SE 031
  • SE 034
  • SE 040
  • SE 041
  • SE 042 und SE 047
  • SE 043
  • SE 047
  • SE 048
  • SE 049
  • SE 050
  • SE 056
  • SE 057
  • SE 058
  • SE 060
  • SE 060/SE 080
  • SE 062
  • SE 063
  • SE 066
  • SE 067
  • SE 068
  • SE 078
  • SE 080
  • SE 081
  • SE 092
  • SE 094
  • SE 095
  • SE 097
  • SE 099
  • SE 100
  • SE 101
  • SE 102
  • SE 103
  • SE 104
  • SE 105
  • SE 106
  • SE 108
  • SE 109
  • SE 112
  • SE 113
  • SE 117
  • SE 118
  • SE 119
  • SE 120
  • SE 121
  • SE 122
  • SE 123
  • SE 124
  • SE 126
  • SE 127
  • SE 129
  • SE 131
  • SE 134
  • SE 136
  • SE 137
  • SE 138
  • SE 139
  • SE 140
  • SE 141
  • SE 144
  • SE 150
  • SE 152
  • SE 155
  • SE 157
  • SE 158
  • SE 159
  • SE 161
  • SE 163
  • SE 165
  • SE 166
  • SE 169
  • SE 170
  • SE 171
  • SE 173
  • SE 174
  • SE 177
1567 Einträge insgesamt
Letzte Aktualisierung am 29.08.2023

VAD-DZHK3: Early versus late left ventricular assist device implantation in patients awaiting cardiac transplantation
ID 81X1100301
Institution Deutsches Herzzentrum Berlin
Projektleiter Volkmar Falk
Standort Berlin
Projektart Klinische Studie
Fördersumme 2253994.00€ 2.253.994,00
Beginn 2013-06-0101.06.2013
Ende 2024-06-3030.06.2024
Projektdetails
end-stage heart disease, ventricular assist device (VAD)
https://vad.dzhk.de/

TransitionCHF-DZHK2: Systolische Dysfunktion / Systolic Dysfunction to Congestive Heart Failure Cohort Study
ID 81X1300102
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Gerd Hasenfuß
Standort Göttingen
Projektart Klinische Studie
Fördersumme 1731738.90€ 1.731.738,90
Beginn 2013-08-0101.08.2013
Ende 2024-05-3030.05.2024
Projektdetails
heart failure, asymptomatic systolic dysfunction
This cohort study explores ways of predicting when decreased cardiac performance without symptoms will develop into a clinically manifest disease. In many patients, decreased cardiac performance is detected during routine examinations without the patient showing any of the typical symptoms, such as a reduction in exercise tolerance or shortness of breath. This ‘hidden’ heart failure can be caused by high blood pressure, myocardial infarction or diseases of the heart muscle. Some 1,500 such patients are to be examined and followed over a period of at least five years at the DZHK partner sites and at other clinics. Within the scope of the study, blood markers, results from imaging studies and genetic profiles will be analysed in relation to the patients’ state of health and development of clinical symptoms. The emerging patterns and regularities could be used in the future to help predict when symptoms of heart failure will appear. Then therapeutic measures could be taken to counter the development of symptoms. This is all the more important because heart failure generally progresses gradually and clinicians have so far not found a way to prevent further deterioration of the condition.

VAD-DZHK3: Biometrie
ID 81X1300103
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Tim Friede
Standort Göttingen
Projektart Klinische Studie
Fördersumme 114959.00€ 114.959,00
Beginn 2013-10-0101.10.2013
Ende 2024-09-3030.09.2024
Projektdetails
end-stage heart disease, ventricular assist device (VAD)
https://vad.dzhk.de/

TORCH-DZHK1: TranslatiOnal Registry for CardiomyopatHies
ID 81X1400102
Institution Universitätsmedizin Greifswald
Projektleiter Wolfgang Hoffmann
Standort Greifswald
Projektart Klinische Studie
Fördersumme 311748.62€ 311.748,62
Beginn 2013-08-0101.08.2013
Ende 2019-12-3131.12.2019
Projektdetails
hereditary cardiomyopathy, inflammatory cardiomyopathy, acute myocarditis
Data is to be collected from some 2,300 patients with heart muscle damage (cardiomyopathy) whose condition was not caused by myocardial infarction, i.e. narrowing of the arteries. Instead this study will include patients who have suffered heart muscle damage for other reasons, for instance, as a result of genetic disposition or inflammatory processes. Diseases of the heart muscle have myriad causes and clinical manifestations. Therefore, the researchers intend to carry out detailed clinical examinations including taking small tissue samples from the heart by means of myocardial biopsy. This is the first registry of its kind worldwide and by evaluating the data and biological material of a large number of patients over a long period of time researchers hope to find new evidence that will help them to identify the various causes of disease. Ultimately, earlier and more precise diagnosis of heart muscle diseases and better treatments could result.

TORCH-DZHK1: TranslatiOnal Registry for CardiomyopatHies
ID 81X1500101
Institution Universitätsklinikum Heidelberg
Projektleiter Hugo A. Katus
Standort Heidelberg/Mannheim
Projektart Klinische Studie
Fördersumme 785702.72€ 785.702,72
Beginn 2013-08-0101.08.2013
Ende 2019-12-3131.12.2019
Projektdetails
hereditary cardiomyopathy, inflammatory cardiomyopathy, acute myocarditis
Data is to be collected from some 2,300 patients with heart muscle damage (cardiomyopathy) whose condition was not caused by myocardial infarction, i.e. narrowing of the arteries. Instead this study will include patients who have suffered heart muscle damage for other reasons, for instance, as a result of genetic disposition or inflammatory processes. Diseases of the heart muscle have myriad causes and clinical manifestations. Therefore, the researchers intend to carry out detailed clinical examinations including taking small tissue samples from the heart by means of myocardial biopsy. This is the first registry of its kind worldwide and by evaluating the data and biological material of a large number of patients over a long period of time researchers hope to find new evidence that will help them to identify the various causes of disease. Ultimately, earlier and more precise diagnosis of heart muscle diseases and better treatments could result.

APPROACH-ACS-AF-DZHK7: Apixaban versus Phenprocoumon: Orale Antikoagulation plus antithrombozytäre Therapie bei Patienten mit akuten Koronarsyndrom und Vorhofflimmern
ID 81X1600203
Institution Klinikum der Universität München
Projektleiter Reza Wakili
Standort München
Projektart Klinische Studie
Fördersumme 474076.69€ 474.076,69
Beginn 2016-01-0101.01.2016
Ende 2021-06-3030.06.2021
Projektdetails
acute coronary syndrome, atrial fibrillation, triple therapy, oral anticoagulation, novel oral anticoagulants (NOAC)
https://approach.dzhk.de/

ISAR-REACT 5 - Prospektive, randomisierte, klinische Studie von Ticagrelor versus Prasugrel bei Patienten mit akutem Koronarsyndrom
ID 81X1600501
Institution Deutsches Herzzentrum München
Projektleiter Adnan Kastrati
Standort München
Projektart Klinische Studie
Fördersumme 1085319.68€ 1.085.319,68
Beginn 2014-08-1818.08.2014
Ende 2021-12-3131.12.2021
Projektdetails
ticagrelor, prasugrel, acute coronary syndrome, percutaneous coronary intervention
Cardiovascular diseases caused by a blockage or severe narrowing of the coronary artery fall into the category of acute coronary syndrome (ACS). ACS and the life-threatening disturbances of heart perfusion associated with it range from instable angina pectoris to myocardial infarction. Despite the fact that huge progress has been made in the treatment of ACS with the use of drugs that prevent blood clotting and targeted therapy, ACS-related morbidity and mortality remain high. In Germany, an estimated 350,000 new cases of ACS are diagnosed each year. This study compares two agents used to inhibit blood clotting - ticagrelor and prasugrel. It is designed to make a significant contribution to antithrombotic therapy in ACS patients so that clinical outcomes can be improved. The hypothesis that ticagrelor is superior to prasugrel for the treatment of patients with acute coronary syndrome will be examined in relation to clinical outcomes. This is based on: the possibility of pre-treatment independent of clinical presentation and coronary anatomy consistently positive results in the sub-group of patients with conservative treatment strategy potentially positive effects of ticagrelor as a result of its interaction with adenosine metabolism, which affects several genes To test this hypothesis 4,000 ACS patients are to receive either ticagrelor or prasugrel over a 12-month period and a comparative analysis of the two active agents will be performed.

ISAR-REACT 5 - Prospektive, randomisierte, klinische Studie von Ticagrelor versus Prasugrel bei Patienten mit akutem Koronarsyndrom - Bioatatistik
ID 81X1600601
Institution Klinikum rechts der Isar der Technischen Universität München
Projektleiter Kurt Ulm
Standort München
Projektart Klinische Studie
Fördersumme 13849.14€ 13.849,14
Beginn 2014-06-2727.06.2014
Ende 2021-10-3131.10.2021
Projektdetails
ticagrelor, prasugrel, acute coronary syndrome, percutaneous coronary intervention
Cardiovascular diseases caused by a blockage or severe narrowing of the coronary artery fall into the category of acute coronary syndrome (ACS). ACS and the life-threatening disturbances of heart perfusion associated with it range from instable angina pectoris to myocardial infarction. Despite the fact that huge progress has been made in the treatment of ACS with the use of drugs that prevent blood clotting and targeted therapy, ACS-related morbidity and mortality remain high. In Germany, an estimated 350,000 new cases of ACS are diagnosed each year. This study compares two agents used to inhibit blood clotting - ticagrelor and prasugrel. It is designed to make a significant contribution to antithrombotic therapy in ACS patients so that clinical outcomes can be improved. The hypothesis that ticagrelor is superior to prasugrel for the treatment of patients with acute coronary syndrome will be examined in relation to clinical outcomes. This is based on: the possibility of pre-treatment independent of clinical presentation and coronary anatomy consistently positive results in the sub-group of patients with conservative treatment strategy potentially positive effects of ticagrelor as a result of its interaction with adenosine metabolism, which affects several genes To test this hypothesis 4,000 ACS patients are to receive either ticagrelor or prasugrel over a 12-month period and a comparative analysis of the two active agents will be performed.

APPROACH-ACS-AF-DZHK7: Projektmanagement
ID 81X1600603
Institution Klinikum rechts der Isar der Technischen Universität München
Projektleiter Silvia Egert
Standort München
Projektart Klinische Studie
Fördersumme 246021.00€ 246.021,00
Beginn 2016-01-0101.01.2016
Ende 2021-06-3030.06.2021
Projektdetails
acute coronary syndrome, atrial fibrillation, triple therapy, oral anticoagulation, novel oral anticoagulants (NOAC)
https://approach.dzhk.de/

APPROACH-ACS-AF-DZHK7: Biometrie
ID 81X1600701
Institution Ludwig-Maximilians-Universität München
Projektleiter Ulrich Mansmann
Standort München
Projektart Klinische Studie
Fördersumme 54000.00€ 54.000,00
Beginn 2016-01-0101.01.2016
Ende 2021-06-3030.06.2021
Projektdetails
acute coronary syndrome, atrial fibrillation, triple therapy, oral anticoagulation, novel oral anticoagulants (NOAC)
https://approach.dzhk.de/

TOMAHAWK-DZHK4: Sofortige Koronarangiographie versus verzögerte Triage bei Überlebenden eines außerklinischen Herzstillstandes ohne ST-Hebung
ID 81X1700102
Institution Universität zu Lübeck
Projektleiter Steffen Desch
Standort Hamburg/Kiel/Lübeck
Projektart Klinische Studie
Fördersumme 1552988.84€ 1.552.988,84
Beginn 2015-11-0101.11.2015
Ende 2022-12-3131.12.2022
Projektdetails
out-of-hospital cardiac arrest, myocardial infarction, percutaneous coronary intervention
https://tomahawk.dzhk.de/

Generation of a Lmcd1-deficient mouse model using the CRISPR (Cas9 system)
ID 81X2100112
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Michael Bader
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 001)
Fördersumme 14000.00€ 14.000,00
Beginn 2014-09-0101.09.2014
Ende 2017-12-3131.12.2017
Projektdetails

Mechanical and electrical remodeling in the developing and diseased cardiomyocyte
ID 81X2100113
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Michael Gotthardt
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 018)
Fördersumme 7000.00€ 7.000,00
Beginn 2014-11-1515.11.2014
Ende 2016-01-3131.01.2016
Projektdetails

Analysis of circadian regulated gene expression in microvascular endothelial cells
ID 81X2100115
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Norbert Hübner
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 006)
Fördersumme 15970.80€ 15.970,80
Beginn 2015-02-1515.02.2015
Ende 2016-07-3131.07.2016
Projektdetails

Gewichtsentwicklung nach unter AT1Rezeptorblockade in MAS knock out Mäusen
ID 81X2100116
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Michael Bader
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 001)
Fördersumme 11100.00€ 11.100,00
Beginn 2015-02-0101.02.2015
Ende 2016-12-3131.12.2016
Projektdetails

Generation of exon1A-renin knockout rats as a new model to study cardiac failure
ID 81X2100117
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Michael Bader
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 001)
Fördersumme 24410.00€ 24.410,00
Beginn 2015-02-0101.02.2015
Ende 2016-01-3131.01.2016
Projektdetails

Generation of a MD-2 transgenic mouse model
ID 81X2100118
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Michael Bader
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 001)
Fördersumme 11644.92€ 11.644,92
Beginn 2015-02-0101.02.2015
Ende 2016-01-3131.01.2016
Projektdetails

Screening of MYBPC3 gene for genetic variations in a panel of control individuals without diastolic dysfunction
ID 81X2100121
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Norbert Hübner
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 006)
Fördersumme 31428.00€ 31.428,00
Beginn 2015-06-0101.06.2015
Ende 2016-05-3131.05.2016
Projektdetails

Elucidating the functions of evolutionary-conserved, cardiovascular-disease-related long noncording RNA
ID 81X2100122
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Wei Chen
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 006)
Fördersumme 29294.05€ 29.294,05
Beginn 2016-01-0101.01.2016
Ende 2017-06-3030.06.2017
Projektdetails

Proteomic analysis of the resolving macrophage in cardiovascular inflammation
ID 81X2100123
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Norbert Hübner
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 006)
Fördersumme 15000.00€ 15.000,00
Beginn 2015-09-0101.09.2015
Ende 2018-04-3030.04.2018
Projektdetails

Identification of ischemic heart disease-regulated T-cell IncRNAs
ID 81X2100124
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Wei Chen
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 006)
Fördersumme 54526.82€ 54.526,82
Beginn 2015-10-0101.10.2015
Ende 2017-12-3131.12.2017
Projektdetails

Spatial-temporal mathematical modeling of NCX function in ventricular myocytes
ID 81X2100125
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Martin Falcke
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 014)
Fördersumme 24079.38€ 24.079,38
Beginn 2015-11-1818.11.2015
Ende 2016-06-3030.06.2016
Projektdetails

The Role of serotonin in aortic calcification
ID 81X2100126
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Natalia Alenina
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 058)
Fördersumme 15000.00€ 15.000,00
Beginn 2016-01-0101.01.2016
Ende 2016-12-3131.12.2016
Projektdetails

Epigenetic factors in the pathogenesis of arterial hypertension
ID 81X2100127
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Natalia Alenina
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 139)
Fördersumme 12000.00€ 12.000,00
Beginn 2016-01-0101.01.2016
Ende 2016-12-3131.12.2016
Projektdetails

Defining individual amino acids mediating the interaction of basic leucine zipper and W2 domain (BZW2) protein and ß-catenin through peptide SPOT technology as a prerequisite for a novel approach towards the treatment of heart failure
ID 81X2100128
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Enno Klussmann
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 103)
Fördersumme 15500.00€ 15.500,00
Beginn 2016-01-0101.01.2016
Ende 2016-12-3131.12.2016
Projektdetails

Endothelial cell senescence and gene expression patterns promoting thrombosis
ID 81X2100129
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Norbert Hübner
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 006)
Fördersumme 11327.70€ 11.327,70
Beginn 2016-01-0101.01.2016
Ende 2017-06-3030.06.2017
Projektdetails

Role of the chemokine atypical receptor Darc in atherosclerosis
ID 81X2100130
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Michael Bader
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 049)
Fördersumme 14000.00€ 14.000,00
Beginn 2016-01-0101.01.2016
Ende 2016-12-3131.12.2016
Projektdetails

NF-kB signalling in microvascular endothelial cells of the blood-brain barrier
ID 81X2100131
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Norbert Hübner
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 006)
Fördersumme 15400.00€ 15.400,00
Beginn 2016-01-0101.01.2016
Ende 2016-12-3131.12.2016
Projektdetails

Genome-wide identification of estrogen receptor binding sites in rat cardiac fibroblasts from both sexes
ID 81X2100209
Institution Charité - Universitätsmedizin Berlin
Projektleiter Elke Dworatzek
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 101)
Fördersumme 7079.04€ 7.079,04
Beginn 2014-08-0101.08.2014
Ende 2016-12-3131.12.2016
Projektdetails

Blinded ECG analysis of the “HEart and BRain interfaces in Acute ischemic Stroke” (HEBRAS) Study
ID 81X2100212
Institution Charité - Universitätsmedizin Berlin
Projektleiter Karl Georg Häusler
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 078)
Fördersumme 1289.68€ 1.289,68
Beginn 2014-10-2020.10.2014
Ende 2016-12-3131.12.2016
Projektdetails

Specific contribution of vascular and macrophage cannabinoid receptor CB1 signaling to the cardiometabolic effects of endocannabinoids
ID 81X2100213
Institution Charité - Universitätsmedizin Berlin
Projektleiter Ulrich Kintscher
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 004)
Fördersumme 12158.93€ 12.158,93
Beginn 2015-01-0101.01.2015
Ende 2016-12-3131.12.2016
Projektdetails

Effects of oestrogen and Mylip on cardiac contractile function in zebrafish
ID 81X2100214
Institution Charité - Universitätsmedizin Berlin
Projektleiter Georgios Kararigas
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 034)
Fördersumme 9988.90€ 9.988,90
Beginn 2015-03-0101.03.2015
Ende 2017-12-3131.12.2017
Projektdetails

PRAS40/mTOR mediated signaling in smooth muscle cells – a potential therapeutic target in vascular disease
ID 81X2100215
Institution Charité - Universitätsmedizin Berlin
Projektleiter Till Althoff
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 117)
Fördersumme 13440.12€ 13.440,12
Beginn 2015-03-0101.03.2015
Ende 2016-09-3030.09.2016
Projektdetails

Effects of chronic dichloroacetate administration in the mouse heart
ID 81X2100216
Institution Charité - Universitätsmedizin Berlin
Projektleiter Georgios Kararigas
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 106)
Fördersumme 8245.33€ 8.245,33
Beginn 2015-03-0101.03.2015
Ende 2017-12-3131.12.2017
Projektdetails

The transcription factor TFEB mediates Ang II-induced pathological cardiac remodeling
ID 81X2100217
Institution Charité - Universitätsmedizin Berlin
Projektleiter Jens Fielitz
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 028)
Fördersumme 14037.92€ 14.037,92
Beginn 2015-03-0101.03.2015
Ende 2016-04-1414.04.2016
Projektdetails

Studies on combined cardiac/skeletal muscle inflammatory and metabolic status in patients with infective myocarditis
ID 81X2100218
Institution Charité - Universitätsmedizin Berlin
Projektleiter Wolfram Döhner
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 118)
Fördersumme 14637.36€ 14.637,36
Beginn 2015-05-0101.05.2015
Ende 2016-05-3131.05.2016
Projektdetails

NOVEL RNA-BASED CARDIOVASCULAR THERAPIES TARGETING IMMUNOREGULATORY LONG NONCODING RNAs
ID 81X2100219
Institution Charité - Universitätsmedizin Berlin
Projektleiter Ulf Landmesser
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 097)
Fördersumme 12790.89€ 12.790,89
Beginn 2015-05-0101.05.2015
Ende 2016-04-3030.04.2016
Projektdetails

Investigation of ventricular tachycardia using patient-specific induced pluripotent stem cells
ID 81X2100220
Institution Charité - Universitätsmedizin Berlin
Projektleiter Silke Rickert-Sperling
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 019)
Fördersumme 5840.00€ 5.840,00
Beginn 2015-05-0101.05.2015
Ende 2016-04-3030.04.2016
Projektdetails

mTOR modulation in atherosclerosis
ID 81X2100221
Institution Charité - Universitätsmedizin Berlin
Projektleiter Till Althoff
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 112)
Fördersumme 27570.00€ 27.570,00
Beginn 2015-05-0101.05.2015
Ende 2018-06-3030.06.2018
Projektdetails

In vivo Modulation of M-CSF in viral myocarditis using nanoparticle encapsulated siRNA.
ID 81X2100222
Institution Charité - Universitätsmedizin Berlin
Projektleiter Antje Voigt
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 121)
Fördersumme 23905.76€ 23.905,76
Beginn 2015-05-0101.05.2015
Ende 2016-12-3131.12.2016
Projektdetails

Proteome profiling of human umbilical vein endothelial cells from twin pairs of the opposite sex
ID 81X2100223
Institution Charité - Universitätsmedizin Berlin
Projektleiter Mario Lorenz
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 099)
Fördersumme 9512.00€ 9.512,00
Beginn 2016-01-0101.01.2016
Ende 2016-12-3131.12.2016
Projektdetails

Mapping endothelial to mesenchymal transition by stage-specific marker genes
ID 81X2100224
Institution Charité - Universitätsmedizin Berlin
Projektleiter Sabine Klaassen
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 136)
Fördersumme 12988.65€ 12.988,65
Beginn 2016-01-0101.01.2016
Ende 2018-06-3030.06.2018
Projektdetails

Skeletal energetic metabolic characteristics of patients with HFpEF and HFrEF. Pilot project
ID 81X2100225
Institution Charité - Universitätsmedizin Berlin
Projektleiter Nadja Scherbakov
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 118)
Fördersumme 13527.06€ 13.527,06
Beginn 2016-01-0101.01.2016
Ende 2017-07-3131.07.2017
Projektdetails

Identification of pro-proliferative and anti-apoptotic microRNAs in adult human cardiomyocytes using a functional high-throughput screening
ID 81X2100226
Institution Charité - Universitätsmedizin Berlin
Projektleiter Philipp Jakob
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 019)
Fördersumme 14157.71€ 14.157,71
Beginn 2016-01-0101.01.2016
Ende 2017-12-3131.12.2017
Projektdetails

Role of CaV3.2, CaV1.2, and TRPV channels in local elementary calcium signaling
ID 81X2100227
Institution Charité - Universitätsmedizin Berlin
Projektleiter Mario Kaßmann
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 129)
Fördersumme 11686.20€ 11.686,20
Beginn 2016-01-0101.01.2016
Ende 2017-03-3131.03.2017
Projektdetails

Functional characterization of psiPSC-CMs derived from patients with Tetralogy of Fallot in comparison to healthy controls
ID 81X2100228
Institution Charité - Universitätsmedizin Berlin
Projektleiter Silke Rickert-Sperling
Standort Berlin
Projektart Kooperation mit Externen
Fördersumme 16453.16€ 16.453,16
Beginn 2016-01-0101.01.2016
Ende 2017-12-3131.12.2017
Projektdetails

Analysis of PAR2 mouse mutants to specify the role of PAR2 in viral myocarditis
ID 81X2100229
Institution Charité - Universitätsmedizin Berlin
Projektleiter Antje Voigt
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 121)
Fördersumme 29402.11€ 29.402,11
Beginn 2016-01-0101.01.2016
Ende 2017-06-3030.06.2017
Projektdetails

Pediatric cardiomyopathy - screening for mutations and evaluation of their impact in iPSC-derived cardiomyocytes
ID 81X2100230
Institution Charité - Universitätsmedizin Berlin
Projektleiter Sabine Klaassen
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 136)
Fördersumme 12713.94€ 12.713,94
Beginn 2016-01-0101.01.2016
Ende 2017-12-3131.12.2017
Projektdetails

MPI imaging capability to visualize inflammatory atherosclerotic plaques
ID 81X2100231
Institution Charité - Universitätsmedizin Berlin
Projektleiter Antje Ludwig
Standort Berlin
Projektart Kooperation mit Externen
Fördersumme 7603.94€ 7.603,94
Beginn 2016-01-0101.01.2016
Ende 2016-12-3131.12.2016
Projektdetails

Role of Sirt3 in the anti-inflammatory effects of estrogen receptors signaling
ID 81X2100232
Institution Charité - Universitätsmedizin Berlin
Projektleiter Maria Luisa Barcena de Arellano
Standort Berlin
Projektart Kooperation mit Externen
Fördersumme 14992.31€ 14.992,31
Beginn 2016-02-0101.02.2016
Ende 2017-12-3131.12.2017
Projektdetails

Defining the optimal temporal and spatial resolution for cardiac magnetic resonance feature tracking
ID 81X2100303
Institution Deutsches Herzzentrum Berlin
Projektleiter Sebastian Kelle
Standort Berlin
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 120)
Fördersumme 14561.20€ 14.561,20
Beginn 2016-02-0101.02.2016
Ende 2017-12-3131.12.2017
Projektdetails

Determination of arginine derivatives in the EPIC cohort
ID 81X2100501
Institution Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke (DIfE)
Projektleiter Matthias Schulze
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 16450.95€ 16.450,95
Beginn 2014-09-1919.09.2014
Ende 2016-06-3030.06.2016
Projektdetails

Epigenetic Control of Endo-MT
ID 81X2200108
Institution Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III
Projektleiter Andreas Zeiher
Standort RheinMain
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 097)
Fördersumme 13333.97€ 13.333,97
Beginn 2014-06-0101.06.2014
Ende 2016-06-3030.06.2016
Projektdetails

Cardiac gene transfer of non-coding RNA
ID 81X2200112
Institution Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III
Projektleiter Andreas Zeiher
Standort RheinMain
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 042 und SE 047)
Fördersumme 15000.00€ 15.000,00
Beginn 2014-09-1010.09.2014
Ende 2018-06-3030.06.2018
Projektdetails

Mechanisms of gap junction remodelling in health and diseases
ID 81X2200119
Institution Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III
Projektleiter Andreas Zeiher
Standort RheinMain
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 100)
Fördersumme 11000.00€ 11.000,00
Beginn 2014-10-0101.10.2014
Ende 2016-03-3131.03.2016
Projektdetails

Assessment of lncRNA functions in human engineered heart tissue
ID 81X2200121
Institution Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III
Projektleiter Andreas Zeiher
Standort RheinMain
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 024)
Fördersumme 3999.92€ 3.999,92
Beginn 2015-03-0101.03.2015
Ende 2017-12-3131.12.2017
Projektdetails

Development of miR-92a inhibitors for the treatment of cardiovascular disease
ID 81X2200122
Institution Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III
Projektleiter Stefanie Dimmeler
Standort RheinMain
Projektart Translational Research Project
Fördersumme 2457576.20€ 2.457.576,20
Beginn 2015-02-0101.02.2015
Ende 2019-12-3131.12.2019
Projektdetails
Based on own preliminary works that show that miR-92a inhibitors can improve cardiac function after infarction, the safety and optimisation studies necessary for an application in human beings are to be carried out in the context of the application. For this, the composition of the microRNA inhibitors is to be optimised and the necessary pharmacological and toxicological examinations are to be performed.

NOVEL RNA-BASED CARDIOVASCULAR THERAPIES TARGETING IMMUNOREGULATORY LONG NONCODING RNAs
ID 81X2200126
Institution Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III
Projektleiter Andreas Zeiher
Standort RheinMain
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 097)
Fördersumme 15000.00€ 15.000,00
Beginn 2015-05-0101.05.2015
Ende 2016-04-3030.04.2016
Projektdetails

Elucidating the functions of evolutionary-conserved, cardiovascular-disease-related long non-coding RNA
ID 81X2200127
Institution Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III
Projektleiter Andreas Zeiher
Standort RheinMain
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 006)
Fördersumme 29985.26€ 29.985,26
Beginn 2016-01-0101.01.2016
Ende 2017-06-3030.06.2017
Projektdetails

Identification of ischemic heart disease-regulated T-cell lncRNAs
ID 81X2200128
Institution Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III
Projektleiter Andreas Zeiher
Standort RheinMain
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 006)
Fördersumme 5000.00€ 5.000,00
Beginn 2015-10-0101.10.2015
Ende 2017-12-3131.12.2017
Projektdetails

BioID and complexome-remodelling analysis of cMyBP-C
ID 81X2200129
Institution Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III
Projektleiter Andreas Zeiher
Standort RheinMain
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 137)
Fördersumme 23220.00€ 23.220,00
Beginn 2016-01-0101.01.2016
Ende 2017-12-3131.12.2017
Projektdetails

Investigation of a redox-phosphorylation crosstalk in human hypertrophic cardiomyopathy
ID 81X2200130
Institution Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III
Projektleiter Andreas Zeiher
Standort RheinMain
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 137)
Fördersumme 6999.16€ 6.999,16
Beginn 2016-01-0101.01.2016
Ende 2016-12-3131.12.2016
Projektdetails

Generation of mouse models for the characterization of the cardiomyopathy- associated gene SARAF by nuclease-based genome editing methods
ID 81X2200306
Institution Max-Planck-Institut für Herz- und Lungenforschung
Projektleiter Nina Wettschureck
Standort RheinMain
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 113)
Fördersumme 35130.73€ 35.130,73
Beginn 2015-04-0101.04.2015
Ende 2016-03-3131.03.2016
Projektdetails

Characterization of the role of Gq/11- and G12/13-mediated signaling cascades in the myogenic autoregulation of isolated murine mesenteric vessels
ID 81X2200307
Institution Max-Planck-Institut für Herz- und Lungenforschung
Projektleiter Stefan Offermanns
Standort RheinMain
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 119)
Fördersumme 12840.60€ 12.840,60
Beginn 2015-03-0101.03.2015
Ende 2016-03-3131.03.2016
Projektdetails

Von Shared Expertises zu Core Facilities – Kompetitiver Austausch von Fähigkeiten und Fachkenntnissen, die ein Alleinstellungsmerkmal eines Partners/Standortes darstellen - Vorhaben siehe Projektbeschreibungen
ID 81X2210102
Institution Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Projektleiter Thomas Münzel
Standort RheinMain
Projektart Shared Expertise (SE)
Fördersumme 68533.00€ 68.533,00
Beginn 2013-11-0101.11.2013
Ende 2016-03-3131.03.2016
Projektdetails

Analyses on the impact of the intestinal microbiota on atherosclerotic plaque development, plaque rupture and atherothrombosis
ID 81X2210106
Institution Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Projektleiter Christoph Reinhardt
Standort RheinMain
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 049)
Fördersumme 10000.00€ 10.000,00
Beginn 2014-10-2020.10.2014
Ende 2016-12-3131.12.2016
Projektdetails

Role of TLR4 signaling in platelet-induced thrombin generation and arterial platelet adhesion
ID 81X2210107
Institution Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Projektleiter Sven Jäckel
Standort RheinMain
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 104)
Fördersumme 10000.00€ 10.000,00
Beginn 2015-06-0101.06.2015
Ende 2016-09-3030.09.2016
Projektdetails

Comprehensive evaluation of functional iron deficiency: Prognostic value and genetic evaluation in the Gutenberg Health Study
ID 81X2210108
Institution Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Projektleiter Karl Lackner
Standort RheinMain
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 123)
Fördersumme 7876.79€ 7.876,79
Beginn 2015-09-0101.09.2015
Ende 2016-08-3131.08.2016
Projektdetails

Analysis of PAR2 mouse mutants to specify the role of PAR2 in viral myocarditis
ID 81X2210109
Institution Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Projektleiter Wolfram Ruf
Standort RheinMain
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 121)
Fördersumme 28294.22€ 28.294,22
Beginn 2015-12-0101.12.2015
Ende 2017-06-3030.06.2017
Projektdetails

Endothelial cell senescence and gene expression patterns promoting thrombosis
ID 81X2210110
Institution Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Projektleiter Katrin Schäfer
Standort RheinMain
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 006)
Fördersumme 12000.00€ 12.000,00
Beginn 2015-12-0101.12.2015
Ende 2017-06-3030.06.2017
Projektdetails

Importance of p63RhoGEF for the vascular response to injury
ID 81X2210111
Institution Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Projektleiter Katrin Schäfer
Standort RheinMain
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 094)
Fördersumme 12466.97€ 12.466,97
Beginn 2015-12-0101.12.2015
Ende 2018-01-3131.01.2018
Projektdetails

Von Shared Expertises zu Core Facilities – Kompetitiver Austausch von Fähigkeiten und Fachkenntnissen, die ein Alleinstellungsmerkmal eines Partners/Standortes darstellen.
ID 81X2300106
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Wolfram-Hubertus Zimmermann
Standort Göttingen
Projektart Shared Expertise (SE)
Fördersumme 152844.00€ 152.844,00
Beginn 2013-07-0101.07.2013
Ende 2016-06-3030.06.2016
Projektdetails

Differentiation of human MEF2 reporter-iPS cells to cardiomyocytes
ID 81X2300111
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Wolfram-Hubertus Zimmermann
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 019)
Fördersumme 7498.46€ 7.498,46
Beginn 2014-10-0101.10.2014
Ende 2017-03-3131.03.2017
Projektdetails

Cardiomyocytes derived from patient-specific induced pluripotent stem cells as a model system for individualized medicine
ID 81X2300112
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Kaomei Guan
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 019)
Fördersumme 15078.72€ 15.078,72
Beginn 2014-10-1515.10.2014
Ende 2016-01-1414.01.2016
Projektdetails

Role of HCN channels for sinoatrial network synchronization and stable heart beat
ID 81X2300114
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Wolfram-Hubertus Zimmermann
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 017)
Fördersumme 10000.00€ 10.000,00
Beginn 2014-10-1313.10.2014
Ende 2016-10-3131.10.2016
Projektdetails

Blinded ECG analysis of the “HEart and BRain interfaces in Acute ischemic Stroke” (HEBRAS) Study
ID 81X2300116
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Wolfram-Hubertus Zimmermann
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 078)
Fördersumme 15999.99€ 15.999,99
Beginn 2014-10-1313.10.2014
Ende 2016-12-3131.12.2016
Projektdetails

Mechanical and electrical remodeling in the developing and diseased cardiomyocyte
ID 81X2300119
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Stephan Lehnart
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 018)
Fördersumme 26321.51€ 26.321,51
Beginn 2014-11-1515.11.2014
Ende 2016-01-3131.01.2016
Projektdetails

Generation and transcriptional analysis of iPS-derived engineered heart muscle from patients with genetic cardiac disease and healthy donors
ID 81X2300122
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Katrin Streckfuß-Bömeke
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 031)
Fördersumme 9375.00€ 9.375,00
Beginn 2015-03-0101.03.2015
Ende 2016-05-3131.05.2016
Projektdetails

Characterization of the role of BZW2 in adult heart homoeostasis
ID 81X2300123
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Laura Zelarayán
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 028)
Fördersumme 7650.00€ 7.650,00
Beginn 2015-03-0101.03.2015
Ende 2016-08-3131.08.2016
Projektdetails

Effects of chronic dichloroacetate administration in the mouse heart
ID 81X2300124
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Laura Zelarayán
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 106)
Fördersumme 22498.69€ 22.498,69
Beginn 2015-01-0101.01.2015
Ende 2017-12-3131.12.2017
Projektdetails

Studies on combined cardiac/skeletal muscle inflammatory and metabolic status in patients with infective myocarditis
ID 81X2300129
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Jochen Springer
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 118)
Fördersumme 14621.54€ 14.621,54
Beginn 2015-03-0101.03.2015
Ende 2016-09-3030.09.2016
Projektdetails

Investigation of ventricular tachycardia using patient-specific induced pluripotent stem cells
ID 81X2300130
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Kaomei Guan
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 019)
Fördersumme 23990.66€ 23.990,66
Beginn 2015-05-0101.05.2015
Ende 2016-04-3030.04.2016
Projektdetails

Accomplishment of a split-ubiquitin yeast-two-hybrid screen to identify novel interaction partners of Junctophilin-1 and Junctophilin-2
ID 81X2300131
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Stephan Lehnart
Standort Göttingen
Projektart Kooperation mit Externen
Fördersumme 7850.00€ 7.850,00
Beginn 2015-06-0101.06.2015
Ende 2016-08-3131.08.2016
Projektdetails

Role of Ca/Calmodulin-dependent protein kinase II in isolated cardiac fibroblasts
ID 81X2300132
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Samuel Sossalla
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 092)
Fördersumme 3998.97€ 3.998,97
Beginn 2015-06-0101.06.2015
Ende 2016-02-2929.02.2016
Projektdetails

New vascular keys to EndMT and cardiac fibrosis
ID 81X2300133
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Elisabeth Zeisberg
Standort Göttingen
Projektart Kooperation mit Externen
Fördersumme 11450.00€ 11.450,00
Beginn 2015-07-0101.07.2015
Ende 2016-04-3030.04.2016
Projektdetails

Targeting T. cruzi-specific STAT1 serine phosphatase in the treatment of chagasic cardiomyopathy
ID 81X2300134
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Christoph Herrmann-Lingen
Standort Göttingen
Projektart Kooperation mit Externen
Fördersumme 9550.00€ 9.550,00
Beginn 2015-07-0101.07.2015
Ende 2016-06-3030.06.2016
Projektdetails

Role of caspases and NADPH oxidases in hypoxia induced pulmonary hypertension
ID 81X2300135
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Jochen Springer
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 118)
Fördersumme 13662.69€ 13.662,69
Beginn 2015-07-1515.07.2015
Ende 2018-01-3131.01.2018
Projektdetails

Comprehensive evaluation of myocardial mechanics using cardiovascular magnetic resonance feature tracking in patients with myocardial infarction
ID 81X2300136
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Andreas Schuster
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 120)
Fördersumme 15970.43€ 15.970,43
Beginn 2015-09-0101.09.2015
Ende 2017-01-3131.01.2017
Projektdetails

Characterization of SCF-type Cullin-RING E3 ubiquitin ligases in cardiac hypertrophy
ID 81X2300137
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Michael Didié
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 108)
Fördersumme 0.00€ 0,00
Beginn 2015-10-0101.10.2015
Ende 2017-12-3131.12.2017
Projektdetails

AAV9-mediated rescue of TBX5KO mouse hearts from ventricular arrhythmias
ID 81X2300138
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Maria Patapia Zafeiriou
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 028)
Fördersumme 7613.49€ 7.613,49
Beginn 2015-09-0101.09.2015
Ende 2017-03-3131.03.2017
Projektdetails

Role of killer cell immunoglobulin-like receptors in killing of induced pluripotent stem cell-derived cardiomyocytes
ID 81X2300139
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Ralf Dressel
Standort Göttingen
Projektart Kooperation mit Externen
Fördersumme 18650.00€ 18.650,00
Beginn 2016-01-0101.01.2016
Ende 2018-01-3131.01.2018
Projektdetails

Role of protein phosphatases in human cardiac pathology
ID 81X2300140
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Samuel Sossalla
Standort Göttingen
Projektart Kooperation mit Externen
Fördersumme 9000.00€ 9.000,00
Beginn 2015-11-0101.11.2015
Ende 2016-12-3131.12.2016
Projektdetails

Mapping endothelial to mesenchymal transition by stage-specific marker genes
ID 81X2300141
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Elisabeth Zeisberg
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 136)
Fördersumme 15000.00€ 15.000,00
Beginn 2016-01-0101.01.2016
Ende 2018-06-3030.06.2018
Projektdetails

Skeletal energetic metabolic characteristics of patients with HFpEF and HFrEF. Pilot project
ID 81X2300142
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Jochen Springer
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 118)
Fördersumme 14332.88€ 14.332,88
Beginn 2016-01-0101.01.2016
Ende 2017-07-3131.07.2017
Projektdetails

Identification of pro-proliferative and anti-apoptotic microRNAs in adult human cardiomyocytes using a functional high-throughput screening
ID 81X2300143
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Katrin Streckfuß-Bömeke
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 019)
Fördersumme 14442.96€ 14.442,96
Beginn 2016-01-0101.01.2016
Ende 2017-12-3131.12.2017
Projektdetails

Role of IGFBP5 in cardiac stress induced by pressure overload
ID 81X2300144
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Claudia Noack
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 028)
Fördersumme 15800.00€ 15.800,00
Beginn 2016-01-0101.01.2016
Ende 2016-12-3131.12.2016
Projektdetails

Investigation of the role of long intergenic non-coding RNAs (lincRNAs) in the transition of human hypertrophy to heart failure using AAV mediated overexpression in human iPS cell--derived cardiomyocytes
ID 81X2300145
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Sara Khadjeh
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 028)
Fördersumme 16660.94€ 16.660,94
Beginn 2016-01-0101.01.2016
Ende 2018-03-3131.03.2018
Projektdetails

Defining individual amino acids mediating the interaction of basic leucine zipper and W2 domain (BZW2) protein and ß-catenin through peptide SPOT technology as a prerequisite for a novel approach towards the treatment of heart failure
ID 81X2300146
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Laura Zelarayán
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 103)
Fördersumme 13869.32€ 13.869,32
Beginn 2016-01-0101.01.2016
Ende 2016-12-3131.12.2016
Projektdetails

Functional and molecular analysis of NADPH-oxidases in iPSC-derived cardiomyocytes from anthacycline-induced cardiotoxicity patients
ID 81X2300147
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Katrin Streckfuß-Bömeke
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 040)
Fördersumme 15234.00€ 15.234,00
Beginn 2016-01-0101.01.2016
Ende 2017-09-3030.09.2017
Projektdetails

Importance of p63RhoGEF for the vascular response to injury
ID 81X2300148
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Susanne Lutz
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 094)
Fördersumme 9512.05€ 9.512,05
Beginn 2015-11-0101.11.2015
Ende 2018-01-3131.01.2018
Projektdetails

Defining the optimal temporal and spatial resolution for cardiac magnetic resonance feature tracking
ID 81X2300149
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Andreas Schuster
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 120)
Fördersumme 11300.54€ 11.300,54
Beginn 2016-02-0101.02.2016
Ende 2017-12-3131.12.2017
Projektdetails

RNA-guided gene de-methylation by Cas9-based methylcytosine dioxygenase
ID 81X2300150
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Elisabeth Zeisberg
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 028)
Fördersumme 15268.29€ 15.268,29
Beginn 2016-02-0101.02.2016
Ende 2017-12-3131.12.2017
Projektdetails

Inotropy and Chronotropy Screens in Engineered Human Myocardium by Optical Analysis in Real Time
ID 81X2300151
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Wolfram-Hubertus Zimmermann
Standort Göttingen
Projektart Kooperation mit Externen
Fördersumme 25774.80€ 25.774,80
Beginn 2016-02-0101.02.2016
Ende 2016-09-3030.09.2016
Projektdetails

LEAP termination of ventricular arrhythmias in a porcine myocard infarct model in vitro
ID 81X2300401
Institution Max-Planck-Institut für Dynamik und Selbstorganisation
Projektleiter Stefan Luther
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 048)
Fördersumme 13320.86€ 13.320,86
Beginn 2015-03-1515.03.2015
Ende 2016-12-3131.12.2016
Projektdetails

Spatial-temporal mathematical modeling of NCX function in ventricular myocytes
ID 81X2300402
Institution Max-Planck-Institut für Dynamik und Selbstorganisation
Projektleiter Stefan Luther
Standort Göttingen
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 014)
Fördersumme 6042.24€ 6.042,24
Beginn 2016-01-0101.01.2016
Ende 2016-06-3030.06.2016
Projektdetails

Low-Energy Termination off Ventricular Fibrillation in a Porcine Heart Failure Model
ID 81X2300403
Institution Max-Planck-Institut für Dynamik und Selbstorganisation
Projektleiter Stefan Luther
Standort Göttingen
Projektart Translational Research Project
Fördersumme 590585.86€ 590.585,86
Beginn 2016-01-0101.01.2016
Ende 2019-09-3030.09.2019
Projektdetails
In previous studies run by the working group led by Stefan Luther it was shown that the energy applied in cardiac arrhythmias could be reduced by 80 to 90 percent compared to conventional defibrillations. In order to translate these results successfully into clinical application, the necessary proof of efficacy in an animal model is to be produced in the scope of this project: the termination of ventricular fibrillation by means of a novel defibrillator compared to conventional defibrillation will be examined in pigs used as an animal model for heart failure. The results will constitute the foundation for preparing a study for a first-in-human application.

Generation of a MD-2 transgenic mouse model
ID 81X2400107
Institution Universitätsmedizin Greifswald
Projektleiter Stephan B. Felix
Standort Greifswald
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 001)
Fördersumme 8967.37€ 8.967,37
Beginn 2015-02-0101.02.2015
Ende 2016-01-3131.01.2016
Projektdetails

To investigate the role for S1P and its receptor subtypes in vascular thrombosis
ID 81X2400108
Institution Universitätsmedizin Greifswald
Projektleiter Bernhard Rauch
Standort Greifswald
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 104)
Fördersumme 13225.20€ 13.225,20
Beginn 2015-02-0101.02.2015
Ende 2016-01-3131.01.2016
Projektdetails

The role of myeloid differentiation factor-2 (MD-2) during inflammatory processes in human monocytes and human cardiac fibroblasts
ID 81X2400109
Institution Universitätsmedizin Greifswald
Projektleiter Stephan B. Felix
Standort Greifswald
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 092)
Fördersumme 10752.98€ 10.752,98
Beginn 2015-02-0101.02.2015
Ende 2016-03-3131.03.2016
Projektdetails

Generation of exon1A-renin knockout rats as a new model to study cardiac failure
ID 81X2400110
Institution Universitätsmedizin Greifswald
Projektleiter Jörg Peters
Standort Greifswald
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 001)
Fördersumme 9300.78€ 9.300,78
Beginn 2015-02-0101.02.2015
Ende 2016-01-3131.01.2016
Projektdetails

Determination of S1P in the SHIP-TREND and GANI_MED cohorts
ID 81X2400111
Institution Universitätsmedizin Greifswald
Projektleiter Marcus Dörr
Standort Greifswald
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 057)
Fördersumme 4391.44€ 4.391,44
Beginn 2015-02-0101.02.2015
Ende 2017-01-3131.01.2017
Projektdetails

Single molecule force spectroscopy of the ß1 adrenergic receptor and autoantibodies
ID 81X2400112
Institution Universitätsmedizin Greifswald
Projektleiter Ricardo Pires
Standort Greifswald
Projektart Kooperation mit Externen
Fördersumme 19137.22€ 19.137,22
Beginn 2015-05-0101.05.2015
Ende 2016-12-3030.12.2016
Projektdetails

Promotion of positive images of ageing in elderly patients after myocardial infarction
ID 81X2400113
Institution Universitätsmedizin Greifswald
Projektleiter Sabina Ulbricht
Standort Greifswald
Projektart Kooperation mit Externen
Fördersumme 11253.80€ 11.253,80
Beginn 2015-06-0101.06.2015
Ende 2016-01-3131.01.2016
Projektdetails

Role of TLR4 signaling in platelet-induced thrombin generation and arterial platelet adhesion
ID 81X2400114
Institution Universitätsmedizin Greifswald
Projektleiter Bernhard Rauch
Standort Greifswald
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 104)
Fördersumme 10585.24€ 10.585,24
Beginn 2015-06-0101.06.2015
Ende 2016-09-3030.09.2016
Projektdetails

Development of dietary intervention tools supported by motivational interviewing techniques
ID 81X2400115
Institution Universitätsmedizin Greifswald
Projektleiter Jennis Freyer-Adam
Standort Greifswald
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 109)
Fördersumme 4921.56€ 4.921,56
Beginn 2015-07-1616.07.2015
Ende 2016-02-1515.02.2016
Projektdetails

European Meta-Analysis of Genome-Wide Association Studies of the Early Repolarization Pattern
ID 81X2400116
Institution Universitätsmedizin Greifswald
Projektleiter Alexander Teumer
Standort Greifswald
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 081)
Fördersumme 14976.35€ 14.976,35
Beginn 2015-07-1515.07.2015
Ende 2018-02-2828.02.2018
Projektdetails

Human Atrial Tissue Proteomics, Pilot Analysis
ID 81X2400118
Institution Universitätsmedizin Greifswald
Projektleiter Uwe Völker
Standort Greifswald
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 099)
Fördersumme 20080.00€ 20.080,00
Beginn 2015-09-0101.09.2015
Ende 2016-08-3131.08.2016
Projektdetails

Proteome profiling of human umbilical vein endothelial cells from twin pairs of the opposite sex
ID 81X2400119
Institution Universitätsmedizin Greifswald
Projektleiter Uwe Völker
Standort Greifswald
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 099)
Fördersumme 20488.00€ 20.488,00
Beginn 2016-01-0101.01.2016
Ende 2016-12-3131.12.2016
Projektdetails

Is autophagy flux altered in a mouse model of heart failure?
ID 81X2400120
Institution Universitätsmedizin Greifswald
Projektleiter Stephanie Könemann
Standort Greifswald
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 102)
Fördersumme 13235.68€ 13.235,68
Beginn 2016-01-0101.01.2016
Ende 2017-06-3030.06.2017
Projektdetails

Charakterisierung der Lmcd1/Dyxin Knockout Maus - die Bedeutung der Inflammation
ID 81X2500101
Institution Universitätsklinikum Heidelberg
Projektleiter Hugo A. Katus
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
Fördersumme 14907.52€ 14.907,52
Beginn 2012-10-0808.10.2012
Ende 2016-05-3131.05.2016
Projektdetails

Epigenetic Control of Endo-MT
ID 81X2500114
Institution Universitätsklinikum Heidelberg
Projektleiter David Hassel
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 097)
Fördersumme 14628.94€ 14.628,94
Beginn 2014-06-0101.06.2014
Ende 2016-06-3030.06.2016
Projektdetails

Mapping the cardiac methylome - towards new epigenetic diagnostics
ID 81X2500117
Institution Universitätsklinikum Heidelberg
Projektleiter Johannes Backs
Standort Heidelberg/Mannheim
Projektart Kooperation mit Externen
Fördersumme 37500.00€ 37.500,00
Beginn 2014-08-1414.08.2014
Ende 2016-12-3131.12.2016
Projektdetails

Beta2 Integrin Activation of T cells in Atherosclerosis
ID 81X2500118
Institution Universitätsklinikum Heidelberg
Projektleiter Mathias Konstandin
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 020)
Fördersumme 18720.91€ 18.720,91
Beginn 2014-09-0404.09.2014
Ende 2016-06-3030.06.2016
Projektdetails

Differentiation of human MEF2 reporter-iPS cells to cardiomyocytes
ID 81X2500122
Institution Universitätsklinikum Heidelberg
Projektleiter Johannes Backs
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 019)
Fördersumme 7406.29€ 7.406,29
Beginn 2014-10-0101.10.2014
Ende 2017-03-3131.03.2017
Projektdetails

Generation and transcriptional analysis of iPS-derived engineered heart muscle from patients with genetic cardiac disease and healthy donors
ID 81X2500125
Institution Universitätsklinikum Heidelberg
Projektleiter Benjamin Meder
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 031)
Fördersumme 12371.31€ 12.371,31
Beginn 2015-04-0101.04.2015
Ende 2016-05-3131.05.2016
Projektdetails

Characterization of the role of BZW2 in adult heart homoeostasis
ID 81X2500126
Institution Universitätsklinikum Heidelberg
Projektleiter Oliver Müller
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 028)
Fördersumme 12254.58€ 12.254,58
Beginn 2015-03-0101.03.2015
Ende 2016-08-3131.08.2016
Projektdetails

Effects of oestrogen and Mylip on cardiac contractile function in zebrafish
ID 81X2500127
Institution Universitätsklinikum Heidelberg
Projektleiter David Hassel
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 034)
Fördersumme 17637.90€ 17.637,90
Beginn 2015-02-0101.02.2015
Ende 2017-12-3131.12.2017
Projektdetails

PRAS40/mTOR mediated signaling in smooth muscle cells – a potential therapeutic target in vascular disease
ID 81X2500128
Institution Universitätsklinikum Heidelberg
Projektleiter Johannes Backs
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 117)
Fördersumme 14713.48€ 14.713,48
Beginn 2015-02-0101.02.2015
Ende 2016-09-3030.09.2016
Projektdetails

The transcription factor TFEB mediates Ang II-induced pathological cardiac remodeling
ID 81X2500129
Institution Universitätsklinikum Heidelberg
Projektleiter Oliver Müller
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 028)
Fördersumme 14966.66€ 14.966,66
Beginn 2015-03-0101.03.2015
Ende 2016-02-2929.02.2016
Projektdetails

Generation of mouse models for the characterization of the cardiomyopathy- associated gene SARAF by nuclease-based genome editing methods
ID 81X2500130
Institution Universitätsklinikum Heidelberg
Projektleiter Marc Freichel
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 113)
Fördersumme 33955.61€ 33.955,61
Beginn 2015-04-0101.04.2015
Ende 2016-04-0101.04.2016
Projektdetails

Regulation of lncRNAs in cardiac tissue from heart failure patients
ID 81X2500131
Institution Universitätsklinikum Heidelberg
Projektleiter Benjamin Meder
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 031)
Fördersumme 7927.57€ 7.927,57
Beginn 2015-04-0101.04.2015
Ende 2016-01-3131.01.2016
Projektdetails

Characterization of the role of Gq/11- and G12/13-mediated signaling cascades in the myogenic autoregulation of isolated murine mesenteric vessels
ID 81X2500132
Institution Universitätsklinikum Heidelberg
Projektleiter Marc Freichel
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 119)
Fördersumme 31409.33€ 31.409,33
Beginn 2015-04-0101.04.2015
Ende 2016-03-3131.03.2016
Projektdetails

Modeling the genetic and molecular basis of cardiac arrhythmias with patient-specific iPS cells
ID 81X2500133
Institution Universitätsklinikum Heidelberg
Projektleiter Sandra Hoffmann
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 043)
Fördersumme 18491.82€ 18.491,82
Beginn 2015-05-0101.05.2015
Ende 2017-12-3131.12.2017
Projektdetails

mTOR modulation in atherosclerosis
ID 81X2500135
Institution Universitätsklinikum Heidelberg
Projektleiter Mirko Völkers
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 112)
Fördersumme 29917.66€ 29.917,66
Beginn 2015-05-0101.05.2015
Ende 2018-06-3030.06.2018
Projektdetails

In vivo Modulation of M-CSF in viral myocarditis using nanoparticle encapsulated siRNA.
ID 81X2500136
Institution Universitätsklinikum Heidelberg
Projektleiter Florian Leuschner
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 121)
Fördersumme 20522.00€ 20.522,00
Beginn 2015-05-0101.05.2015
Ende 2016-12-3131.12.2016
Projektdetails

Gene therapy of pathological hypertrophy by targeted downregulation of PPIA
ID 81X2500137
Institution Universitätsklinikum Heidelberg
Projektleiter Müller
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 022)
Fördersumme 24803.26€ 24.803,26
Beginn 2015-08-0101.08.2015
Ende 2016-12-3131.12.2016
Projektdetails

Characterization and neurohumoral regulation of the newly identified membrane protein TRPML-like 2 in cardiomyocytes
ID 81X2500138
Institution Universitätsklinikum Heidelberg
Projektleiter Marc Freichel
Standort Heidelberg/Mannheim
Projektart Kooperation mit Externen
Fördersumme 37477.28€ 37.477,28
Beginn 2015-07-0101.07.2015
Ende 2016-07-3131.07.2016
Projektdetails

Identification and detailed characterization of candidate miRNAs involved in cardiac development
ID 81X2500139
Institution Universitätsklinikum Heidelberg
Projektleiter David Hassel
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 034)
Fördersumme 14718.61€ 14.718,61
Beginn 2015-08-0101.08.2015
Ende 2017-12-3131.12.2017
Projektdetails

AAV9-mediated rescue of TBX5KO mouse hearts from ventricular arrhythmias
ID 81X2500140
Institution Universitätsklinikum Heidelberg
Projektleiter Oliver Müller
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 028)
Fördersumme 12811.02€ 12.811,02
Beginn 2015-09-0101.09.2015
Ende 2017-03-3131.03.2017
Projektdetails

Generation and characterization of two adult knockout zebrafish models using the CRISPR/Cas9 technique
ID 81X2500141
Institution Universitätsklinikum Heidelberg
Projektleiter David Hassel
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 034)
Fördersumme 19700.25€ 19.700,25
Beginn 2015-10-0101.10.2015
Ende 2017-12-3131.12.2017
Projektdetails

Role of miRNA-regulated lncRNAs in endothelial cells during atherosclerosis
ID 81X2500142
Institution Universitätsklinikum Heidelberg
Projektleiter Benjamin Meder
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 031)
Fördersumme 23490.04€ 23.490,04
Beginn 2015-10-0101.10.2015
Ende 2016-03-3131.03.2016
Projektdetails

Generation and initial characterization of the adeno-associated virus (AAV) vector for the dominant negative Gs -protein GS226A
ID 81X2500143
Institution Universitätsklinikum Heidelberg
Projektleiter Oliver Müller
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 028)
Fördersumme 20965.24€ 20.965,24
Beginn 2016-01-0101.01.2016
Ende 2016-12-3131.12.2016
Projektdetails

Role of IGFBP5 in cardiac stress induced by pressure overload
ID 81X2500144
Institution Universitätsklinikum Heidelberg
Projektleiter Oliver Müller
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 028)
Fördersumme 15157.51€ 15.157,51
Beginn 2016-01-0101.01.2016
Ende 2016-12-3131.12.2016
Projektdetails

Investigation of the role of long intergenic non-coding RNAs (lincRNAs) in the transition of human hypertrophy to heart failure using AAV mediated overexpression in human iPS cell--derived cardiomyocytes
ID 81X2500145
Institution Universitätsklinikum Heidelberg
Projektleiter Oliver Müller
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 028)
Fördersumme 17185.39€ 17.185,39
Beginn 2016-01-0101.01.2016
Ende 2018-03-3131.03.2018
Projektdetails

Role of CaV3.2, CaV1.2, and TRPV channels in local elementary calcium signaling
ID 81X2500203
Institution Ruprecht-Karls-Universität Heidelberg
Projektleiter Rudolf Schubert
Standort Heidelberg/Mannheim
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 129)
Fördersumme 16062.63€ 16.062,63
Beginn 2016-01-0101.01.2016
Ende 2017-03-3131.03.2017
Projektdetails

Genome-wide identification of estrogen receptor binding sites in rat cardiac fibroblasts from both sexes
ID 81X2600105
Institution Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Projektleiter Nina Henriette Uhlenhaut
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 101)
Fördersumme 21500.00€ 21.500,00
Beginn 2014-08-0101.08.2014
Ende 2016-12-3131.12.2016
Projektdetails

Evaluation of potential atrial calcium handling abnormalities contributing to the atrial arrhythmogenic substrate in a porcine model of ischemic heart failure
ID 81X2600216
Institution Klinikum der Universität München
Projektleiter Stefan Kääb
Standort München
Projektart Kooperation mit Externen
Fördersumme 8130.07€ 8.130,07
Beginn 2014-10-0101.10.2014
Ende 2017-05-3131.05.2017
Projektdetails

Organotypic slice cultures of human failing myocardium for mechanistic assessment of diastolic dysfunction
ID 81X2600217
Institution Klinikum der Universität München
Projektleiter Ulrich Pohl
Standort München
Projektart Kooperation mit Externen
Fördersumme 9790.41€ 9.790,41
Beginn 2014-10-0101.10.2014
Ende 2016-12-3131.12.2016
Projektdetails

Non-coding RNAs in human atherosclerotic lesions
ID 81X2600218
Institution Klinikum der Universität München
Projektleiter Christian Weber
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 105)
Fördersumme 59400.56€ 59.400,56
Beginn 2014-09-1515.09.2014
Ende 2016-03-3131.03.2016
Projektdetails

Role of HCN channels for sinoatrial network synchronization and stable heart beat
ID 81X2600219
Institution Klinikum der Universität München
Projektleiter Christian Kupatt
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 017)
Fördersumme 8704.76€ 8.704,76
Beginn 2014-05-2222.05.2014
Ende 2016-10-3131.10.2016
Projektdetails

Analyses on the impact of the intestinal microbiota on atherosclerotic plaque development, plaque rupture and atherothrombosis
ID 81X2600220
Institution Klinikum der Universität München
Projektleiter Christian Weber
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 049)
Fördersumme 10000.00€ 10.000,00
Beginn 2014-10-1515.10.2014
Ende 2016-12-3131.12.2016
Projektdetails

The TROPICAL-ACS SPARTAN Substudy
ID 81X2600221
Institution Klinikum der Universität München
Projektleiter Steffen Massberg
Standort München
Projektart Kooperation mit Externen
Fördersumme 10000.00€ 10.000,00
Beginn 2014-09-0101.09.2014
Ende 2016-08-3131.08.2016
Projektdetails

Specific contribution of vascular and macrophage cannabinoid receptor CB1 signaling to the cardiometabolic effects of endocannabinoids
ID 81X2600222
Institution Klinikum der Universität München
Projektleiter Sabine Steffens
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 004)
Fördersumme 14995.01€ 14.995,01
Beginn 2015-01-0101.01.2015
Ende 2016-12-3131.12.2016
Projektdetails

AFNET-EORP Register für Vorhofflimmern. Langzeitregister für Patienten mit Vorhofflimmern in Deutschland
ID 81X2600223
Institution Klinikum der Universität München
Projektleiter Michael Näbauer
Standort Extern
Projektart Kompetenznetze
Fördersumme 249394.50€ 249.394,50
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails

Annexin A1 prevents arterial leukocyte recruitment – mechanistic insights
ID 81X2600224
Institution Klinikum der Universität München
Projektleiter Oliver Söhnlein
Standort München
Projektart Kooperation mit Externen
Fördersumme 9992.91€ 9.992,91
Beginn 2015-06-0101.06.2015
Ende 2016-06-3030.06.2016
Projektdetails

Role of miRNA-regulated lncRNAs in endothelial cells during atherosclerosis
ID 81X2600225
Institution Klinikum der Universität München
Projektleiter Andreas Schober
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 031)
Fördersumme 6249.99€ 6.249,99
Beginn 2015-09-0101.09.2015
Ende 2016-03-3131.03.2016
Projektdetails

Proteomic analysis of the resolving macrophage in cardiovascular inflammation
ID 81X2600226
Institution Klinikum der Universität München
Projektleiter Oliver Söhnlein
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 006)
Fördersumme 15000.00€ 15.000,00
Beginn 2015-10-0101.10.2015
Ende 2018-04-3030.04.2018
Projektdetails

Investigation of vascular function in endothelial cell-specific Txnrd2-deficient mice in vivo
ID 81X2600227
Institution Klinikum der Universität München
Projektleiter Ulrich Pohl
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 100)
Fördersumme 9712.44€ 9.712,44
Beginn 2015-10-0101.10.2015
Ende 2017-09-3030.09.2017
Projektdetails

Non-invasive Renal Volume and Lipid Quantification as Biomarkers in Patients with Cardiovascular Disease
ID 81X2600228
Institution Klinikum der Universität München
Projektleiter Maximilian Reiser
Standort München
Projektart Kooperation mit Externen
Fördersumme 9917.10€ 9.917,10
Beginn 2015-10-0101.10.2015
Ende 2016-12-3131.12.2016
Projektdetails

Role of the chemokine atypical receptor Darc in atherosclerosis
ID 81X2600229
Institution Klinikum der Universität München
Projektleiter Christian Weber
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 049)
Fördersumme 15999.88€ 15.999,88
Beginn 2016-01-0101.01.2016
Ende 2016-12-3131.12.2016
Projektdetails

The Role of CD40 in Endothelial and Smooth Muscle Cell on Atherogenesis
ID 81X2600230
Institution Klinikum der Universität München
Projektleiter Christian Weber
Standort München
Projektart Kooperation mit Externen
Fördersumme 9999.00€ 9.999,00
Beginn 2016-01-0101.01.2016
Ende 2017-12-3131.12.2017
Projektdetails

Identification of hypertrophy-modulating Cullin-RING E3 ubiquitin ligases in primary cardiomyocytes
ID 81X2600402
Institution Technische Universität München
Projektleiter Stefan Engelhardt
Standort München
Projektart Shared Expertise (SE)
Fördersumme 10000.00€ 10.000,00
Beginn 2012-11-0101.11.2012
Ende 2017-12-3131.12.2017
Projektdetails

Von Shared Expertises zu Core Facilities
ID 81X2600404
Institution Technische Universität München
Projektleiter Stefan Engelhardt
Standort München
Projektart Shared Expertise (SE)
Fördersumme 21896.00€ 21.896,00
Beginn 2013-09-0101.09.2013
Ende 2016-03-3131.03.2016
Projektdetails

Cardiac gene transfer of non-coding RNA
ID 81X2600405
Institution Technische Universität München
Projektleiter Stefan Engelhardt
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 042 und SE 047)
Fördersumme 34975.54€ 34.975,54
Beginn 2014-08-2121.08.2014
Ende 2018-06-3030.06.2018
Projektdetails

Cardiomyocytes derived from patient-specific induced pluripotent stem cells as a model system for individualized medicine
ID 81X2600406
Institution Technische Universität München
Projektleiter Stefan Engelhardt
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 019)
Fördersumme 14876.00€ 14.876,00
Beginn 2014-10-1515.10.2014
Ende 2016-01-1414.01.2016
Projektdetails

Characterization of SCF-type Cullin-RING E3 ubiquitin ligases in cardiac hypertrophy
ID 81X2600408
Institution Technische Universität München
Projektleiter Stefan Engelhardt
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 108)
Fördersumme 15000.00€ 15.000,00
Beginn 2015-10-0101.10.2015
Ende 2017-12-3131.12.2017
Projektdetails

Generation of viral vectors for the functional characterization of long non-coding RNA in vivo
ID 81X2600409
Institution Technische Universität München
Projektleiter Stefan Engelhardt
Standort München
Projektart Kooperation mit Externen
Fördersumme 9966.40€ 9.966,40
Beginn 2015-12-0101.12.2015
Ende 2016-09-3030.09.2016
Projektdetails

Determination of miR-29 subtypes in myocardial cell types and their regulation
ID 81X2600410
Institution Technische Universität München
Projektleiter Stefan Engelhardt
Standort München
Projektart Kooperation mit Externen
Fördersumme 10000.00€ 10.000,00
Beginn 2015-11-0101.11.2015
Ende 2017-05-1414.05.2017
Projektdetails

Role of NADPH oxidases in cardiac miRNA expression under normoxia and hypoxia
ID 81X2600507
Institution Deutsches Herzzentrum München
Projektleiter Agnes Görlach
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 063)
Fördersumme 12350.00€ 12.350,00
Beginn 2015-05-0101.05.2015
Ende 2017-08-3131.08.2017
Projektdetails

Epigenetic Profile of Cardiac Progenitor Cells – Global DNA Methylome
ID 81X2600508
Institution Deutsches Herzzentrum München
Projektleiter Heribert Schunkert
Standort München
Projektart Kooperation mit Externen
Fördersumme 8168.48€ 8.168,48
Beginn 2015-07-0101.07.2015
Ende 2016-04-3030.04.2016
Projektdetails

Identification and detailed characterization of candidate miRNAs involved in cardiac development
ID 81X2600509
Institution Deutsches Herzzentrum München
Projektleiter Heribert Schunkert
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 034)
Fördersumme 14590.00€ 14.590,00
Beginn 2015-07-1515.07.2015
Ende 2017-12-3131.12.2017
Projektdetails

Role of caspases and NADPH oxidases in hypoxia induced pulmonary hypertension
ID 81X2600510
Institution Deutsches Herzzentrum München
Projektleiter Andreas Petry
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 118)
Fördersumme 13700.00€ 13.700,00
Beginn 2015-07-1515.07.2015
Ende 2018-01-3131.01.2018
Projektdetails

European Meta-Analysis of Genome-Wide Association Studies of the Early Repolarization Pattern
ID 81X2600511
Institution Deutsches Herzzentrum München
Projektleiter Heribert Schunkert
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 081)
Fördersumme 14400.00€ 14.400,00
Beginn 2015-07-1515.07.2015
Ende 2018-02-2828.02.2018
Projektdetails

Functional and molecular analysis of NADPH-oxidases in iPSC-derived cardiomyocytes from anthacycline-induced cardiotoxicity patients
ID 81X2600512
Institution Deutsches Herzzentrum München
Projektleiter Andreas Petry
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 040)
Fördersumme 14551.17€ 14.551,17
Beginn 2016-01-0101.01.2016
Ende 2017-09-3030.09.2017
Projektdetails

Functional role of ZC3HC1 in neointima formation
ID 81X2600513
Institution Deutsches Herzzentrum München
Projektleiter Thorsten Kessler
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 140)
Fördersumme 17926.17€ 17.926,17
Beginn 2016-01-0101.01.2016
Ende 2017-12-3131.12.2017
Projektdetails

Adipokines as biomarkers for dysfunction of retinal microvasculature
ID 81X2600604
Institution Klinikum rechts der Isar der Technischen Universität München
Projektleiter Martin Halle
Standort München
Projektart Kooperation mit Externen
Fördersumme 10126.50€ 10.126,50
Beginn 2014-09-0101.09.2014
Ende 2016-03-3131.03.2016
Projektdetails

LEAP termination of ventricular arrhythmias in a porcine myocard infarct model in vitro
ID 81X2600606
Institution Klinikum rechts der Isar der Technischen Universität München
Projektleiter Christian Kupatt
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 048)
Fördersumme 14997.92€ 14.997,92
Beginn 2015-03-1515.03.2015
Ende 2016-12-3131.12.2016
Projektdetails

Modeling the genetic and molecular basis of cardiac arrhythmias with patient-specific iPS cells
ID 81X2600607
Institution Klinikum rechts der Isar der Technischen Universität München
Projektleiter Alessandra Moretti
Standort München
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 043)
Fördersumme 31485.88€ 31.485,88
Beginn 2015-05-0101.05.2015
Ende 2017-12-3131.12.2017
Projektdetails

Optical action potential recordings for high-­-throughput cardiomyocytes subtype identification.
ID 81X2600608
Institution Klinikum rechts der Isar der Technischen Universität München
Projektleiter Alessandra Moretti
Standort München
Projektart Kooperation mit Externen
Fördersumme 10000.00€ 10.000,00
Beginn 2015-09-0101.09.2015
Ende 2016-08-3131.08.2016
Projektdetails

Low-Energy Termination of Ventricular Fibrillation in a Porcine Heart Failure Model
ID 81X2600609
Institution Klinikum rechts der Isar der Technischen Universität München
Projektleiter Christian Kupatt
Standort München
Projektart Translational Research Project
Fördersumme 430505.66€ 430.505,66
Beginn 2016-01-0101.01.2016
Ende 2019-09-3030.09.2019
Projektdetails

Mechanisms of gap junction remodelling in health and diseases
ID 81X2700108
Institution Universität zu Lübeck
Projektleiter Cor de Wit
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 100)
Fördersumme 15124.62€ 15.124,62
Beginn 2014-10-0101.10.2014
Ende 2016-03-3131.03.2016
Projektdetails

Gewichtsentwicklung nach unter AT1Rezeptorblockade in MAS knock out Mäusen
ID 81X2700110
Institution Universität zu Lübeck
Projektleiter Walter Raasch
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 001)
Fördersumme 10917.43€ 10.917,43
Beginn 2015-03-0101.03.2015
Ende 2016-12-3131.12.2016
Projektdetails

Analysis of circadian regulated gene expression in microvascular endothelial cells
ID 81X2700111
Institution Universität zu Lübeck
Projektleiter Markus Schwaninger
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 006)
Fördersumme 1951.71€ 1.951,71
Beginn 2015-03-0101.03.2015
Ende 2016-07-3131.07.2016
Projektdetails

Role of NADPH oxidases in cardiac miRNA Expression under normoxia and hypoxia
ID 81X2700112
Institution Universität zu Lübeck
Projektleiter Zouhair Aherrahrou
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 063)
Fördersumme 10559.39€ 10.559,39
Beginn 2015-05-0101.05.2015
Ende 2017-08-3131.08.2017
Projektdetails

Generation and characterization of a novel zebrafish atherosclerotic model by overexpression of the humanized ApoE3-leiden protein
ID 81X2700113
Institution Universität zu Lübeck
Projektleiter Aherrahrou
Standort Hamburg/Kiel/Lübeck
Projektart Kooperation mit Externen
Fördersumme 0.00€ 0,00
Beginn 2015-07-0101.07.2015
Ende 2016-09-3030.09.2016
Projektdetails

Comprehensive evaluation of myocardial mechanics using cardiovascular magnetic resonance feature tracking in patients with myocardial infarction
ID 81X2700114
Institution Universität zu Lübeck
Projektleiter Holger Thiele
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 120)
Fördersumme 16000.00€ 16.000,00
Beginn 2015-08-0101.08.2015
Ende 2016-12-3131.12.2016
Projektdetails

Investigation of vascular function in endothelial cell-specific Txnrd2-deficient mice in vivo
ID 81X2700115
Institution Universität zu Lübeck
Projektleiter Cor de Wit
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 100)
Fördersumme 14296.31€ 14.296,31
Beginn 2015-10-0101.10.2015
Ende 2017-09-3030.09.2017
Projektdetails

The Role of serotonin in aortic calcification
ID 81X2700116
Institution Universität zu Lübeck
Projektleiter Zouhair Aherrahrou
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 058)
Fördersumme 15000.00€ 15.000,00
Beginn 2016-01-0101.01.2016
Ende 2016-12-3131.12.2016
Projektdetails

Epigenetic factors in the pathogenesis of arterial hypertension
ID 81X2700117
Institution Universität zu Lübeck
Projektleiter Zouhair Aherrahrou
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 139)
Fördersumme 18000.00€ 18.000,00
Beginn 2016-01-0101.01.2016
Ende 2016-12-3131.12.2016
Projektdetails

Cerebral blood flow changes after stroke in brain endothelial thrombomodulin knockout mice
ID 81X2700118
Institution Universität zu Lübeck
Projektleiter Markus Schwaninger
Standort Hamburg/Kiel/Lübeck
Projektart Kooperation mit Externen
Fördersumme 3381.26€ 3.381,26
Beginn 2015-12-0101.12.2015
Ende 2016-05-3131.05.2016
Projektdetails

NF-kB signalling in microvascular endothelial cells of the blood-brain barrier
ID 81X2700120
Institution Universität zu Lübeck
Projektleiter Markus Schwaninger
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 006)
Fördersumme 11246.12€ 11.246,12
Beginn 2016-04-0101.04.2016
Ende 2016-12-3131.12.2016
Projektdetails

Treatment of mice with an AT1-receptor blocker reduces hypothalamic lipids which
ID 81X2700119
Institution Universität zu Lübeck
Projektleiter Walter Raasch
Standort Hamburg/Kiel/Lübeck
Projektart Kooperation mit Externen
Fördersumme 13800.00€ 13.800,00
Beginn 2016-02-0101.02.2016
Ende 2018-08-3131.08.2018
Projektdetails

Functional role of ZC3HC1 in neointima formation
ID 81X2700121
Institution Universität zu Lübeck
Projektleiter Zouhair Aherrarhou
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 140)
Fördersumme 13543.22€ 13.543,22
Beginn 2016-01-0101.01.2016
Ende 2017-12-3131.12.2017
Projektdetails

Charakterisierung der Lmcd1/Dyxin Knockout Maus - die Bedeutung der Inflammation
ID 81X2700201
Institution Universitätsklinikum Schleswig-Holstein
Projektleiter Norbert Frey
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
Fördersumme 14551.94€ 14.551,94
Beginn 2013-01-0101.01.2013
Ende 2016-05-3131.05.2016
Projektdetails

Generation of a Lmcd1-deficient mouse model using the CRISPR (Cas9 system)
ID 81X2700206
Institution Universitätsklinikum Schleswig-Holstein
Projektleiter Derk Frank
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 001)
Fördersumme 13976.55€ 13.976,55
Beginn 2014-09-2929.09.2014
Ende 2017-12-3131.12.2017
Projektdetails

Gene therapy of pathological hypertrophy by targeted downregulation of PPIA
ID 81X2700207
Institution Universitätsklinikum Schleswig-Holstein
Projektleiter Frey
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 022)
Fördersumme 24993.78€ 24.993,78
Beginn 2015-09-0101.09.2015
Ende 2016-12-3131.12.2016
Projektdetails

Generation and characterization of two adult knockout zebrafish models using the CRISPR/Cas9 technique
ID 81X2700208
Institution Universitätsklinikum Schleswig-Holstein
Projektleiter Derk Frank
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 034)
Fördersumme 20492.23€ 20.492,23
Beginn 2015-10-0101.10.2015
Ende 2017-12-3131.12.2017
Projektdetails

Von Shared Expertises zu Core Facilities – Kompetitiver Austausch von Fähigkeiten und Fachkenntnissen, die ein Alleinstellungsmerkmal eines Partners/Standortes darstellen
ID 81X2710105
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Thomas Eschenhagen
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
Fördersumme 91738.92€ 91.738,92
Beginn 2013-01-0101.01.2013
Ende 2016-12-3131.12.2016
Projektdetails

Von Shared Expertises zu Core Facilities – Beauftragung Externer Shared Expertises
ID 81X2710106
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Thomas Eschenhagen
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
Fördersumme 30529.50€ 30.529,50
Beginn 2013-01-0101.01.2013
Ende 2016-03-3131.03.2016
Projektdetails

Identification of hypertrophy-modulating Cullin-RING E3 ubiquitin ligases in primary cardiomyocytes
ID 81X2710107
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Thomas Eschenhagen
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
Fördersumme 9928.33€ 9.928,33
Beginn 2013-11-0101.11.2013
Ende 2017-12-3131.12.2017
Projektdetails

Determination of arginine derivatives in the EPIC cohort
ID 81X2710108
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Edzard Schwedhelm
Standort Hamburg/Kiel/Lübeck
Projektart Kooperation mit Externen
Fördersumme 28316.87€ 28.316,87
Beginn 2014-09-0101.09.2014
Ende 2016-06-3030.06.2016
Projektdetails

Beta2 Integrin Activation of T cells in Atherosclerosis
ID 81X2710109
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Thomas Eschenhagen
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 020)
Fördersumme 19055.16€ 19.055,16
Beginn 2014-08-2727.08.2014
Ende 2016-06-3030.06.2016
Projektdetails

To investigate the role for S1P and its receptor subtypes in vascular thrombosis
ID 81X2710115
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Edzard Schwedhelm
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 104)
Fördersumme 2738.58€ 2.738,58
Beginn 2015-01-0101.01.2015
Ende 2016-01-3131.01.2016
Projektdetails

Assessment of lncRNA functions in human engineered heart tissue
ID 81X2710116
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Arne Hansen
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 024)
Fördersumme 15727.99€ 15.727,99
Beginn 2015-03-0101.03.2015
Ende 2017-12-3131.12.2017
Projektdetails

The role of myeloid differentiation factor-2 (MD-2) during inflammatory processes in human monocytes and human cardiac fibroblasts
ID 81X2710117
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Dirk Westermann
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 092)
Fördersumme 21000.04€ 21.000,04
Beginn 2015-02-0101.02.2015
Ende 2016-03-3131.03.2016
Projektdetails

Determination of S1P in the SHIP-TREND and GANI_MED cohorts
ID 81X2710121
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Edzard Schwedhelm
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 057)
Fördersumme 29789.16€ 29.789,16
Beginn 2015-02-0101.02.2015
Ende 2017-01-3131.01.2017
Projektdetails

Role of Ca/Calmodulin-dependent protein kinase II in isolated cardiac fibroblasts
ID 81X2710124
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Dirk Westermann
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 092)
Fördersumme 15932.00€ 15.932,00
Beginn 2015-06-0101.06.2015
Ende 2016-02-2929.02.2016
Projektdetails

Screening of MYBPC3 gene for genetic variations in a panel of control individuals without diastolic dysfunction
ID 81X2710125
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Lucie Carrier
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 006)
Fördersumme 6909.59€ 6.909,59
Beginn 2015-06-0101.06.2015
Ende 2016-05-3131.05.2016
Projektdetails

Development of dietary intervention tools supported by motivational interviewing techniques
ID 81X2710126
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Birgit-Christiane Zyriax
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 109)
Fördersumme 4665.00€ 4.665,00
Beginn 2015-07-1616.07.2015
Ende 2016-02-1515.02.2016
Projektdetails

Autophagy screening platform
ID 81X2710127
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Lucie Carrier
Standort Hamburg/Kiel/Lübeck
Projektart Kooperation mit Externen
Fördersumme 3667.74€ 3.667,74
Beginn 2015-07-0101.07.2015
Ende 2016-06-3030.06.2016
Projektdetails

Human Atrial Tissue Proteomics, Pilot Analysis
ID 81X2710129
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Tanja Zeller
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 099)
Fördersumme 9966.64€ 9.966,64
Beginn 2015-09-0101.09.2015
Ende 2016-08-3131.08.2016
Projektdetails

Comprehensive evaluation of functional iron deficiency: Prognostic value and genetic evaluation in the Gutenberg Health Study
ID 81X2710130
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Mahir Karakas
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 123)
Fördersumme 1952.94€ 1.952,94
Beginn 2015-10-0101.10.2015
Ende 2016-08-3131.08.2016
Projektdetails

Identification of differentially expressed proteins in the cardiac tissue of CRTC1 deficient mice and their wild-type littermates
ID 81X2710131
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Elke Oetjen
Standort Hamburg/Kiel/Lübeck
Projektart Kooperation mit Externen
Fördersumme 3242.92€ 3.242,92
Beginn 2015-11-0101.11.2015
Ende 2016-12-3131.12.2016
Projektdetails

Role for microRNAs in calcineurin-mediated immunosuppression after solid organ transplantation
ID 81X2710132
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Sonja Schrepfer
Standort Hamburg/Kiel/Lübeck
Projektart Kooperation mit Externen
Fördersumme 8999.93€ 8.999,93
Beginn 2015-11-0101.11.2015
Ende 2016-12-3131.12.2016
Projektdetails

Generation and initial characterization of the adeno-associated virus (AAV) vector for the dominant negative Gs -protein GS226A
ID 81X2710133
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Viacheslav Nicolaev
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 028)
Fördersumme 5180.43€ 5.180,43
Beginn 2016-01-0101.01.2016
Ende 2016-12-3131.12.2016
Projektdetails

BioID and complexome-remodelling analysis of cMyBP-C
ID 81X2710134
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Friederike Cuello
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 137)
Fördersumme 10200.00€ 10.200,00
Beginn 2016-01-0101.01.2016
Ende 2017-12-3131.12.2017
Projektdetails

Pediatric cardiomyopathy - screening for mutations and evaluation of their impact in iPSC-derived cardiomyocytes
ID 81X2710135
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Giulia Mearini
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 136)
Fördersumme 17991.36€ 17.991,36
Beginn 2016-01-0101.01.2016
Ende 2017-12-3131.12.2017
Projektdetails

Is autophagy flux altered in a mouse model of heart failure?
ID 81X2710136
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Lucie Carrier
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Anbieter  (SE 102)
Fördersumme 19033.78€ 19.033,78
Beginn 2016-01-0101.01.2016
Ende 2017-06-3030.06.2017
Projektdetails

Investigation of a redox-phosphorylation crosstalk in human hypertrophic cardiomyopathy
ID 81X2710137
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Friederike Cuello
Standort Hamburg/Kiel/Lübeck
Projektart Shared Expertise (SE)
SE-Merkmal SE-Partner  (SE 137)
Fördersumme 2885.38€ 2.885,38
Beginn 2016-01-0101.01.2016
Ende 2016-12-3131.12.2016
Projektdetails

Mapping the cardiac methylome - towards new epigenetic diagnostics
ID 81X2800105
Institution Albert-Ludwigs-Universität Freiburg
Projektleiter Lutz Hein
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 41667.00€ 41.667,00
Beginn 2014-09-1616.09.2014
Ende 2016-12-3131.12.2016
Projektdetails

Organotypic slice cultures of human failing myocardium for mechanistic assessment of diastolic dysfunction
ID 81X2800106
Institution Ruhr-Universität Bochum Universitätsklinik Herz- und Diabeteszentrum Nordrhein-Westfalen
Projektleiter Hendrik Milting
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 10000.00€ 10.000,00
Beginn 2014-10-0101.10.2014
Ende 2016-12-3131.12.2016
Projektdetails

Evaluation of potential atrial calcium handling abnormalities contributing to the atrial arrhythmogenic substrate in a porcine model of ischemic heart failure
ID 81X2800108
Institution Universitätsklinikum Essen
Projektleiter Dobromir Dobrev
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 10990.00€ 10.990,00
Beginn 2014-11-1313.11.2014
Ende 2017-05-3131.05.2017
Projektdetails

The role of myeloid differentiation factor-2 (MD-2) in infectious inflammatory and non-infectious cardiomyopathy
ID 81X2800109
Institution Eberhard Karls Universität Tübingen
Projektleiter Karin Klingel
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 32640.82€ 32.640,82
Beginn 2014-10-0101.10.2014
Ende 2017-01-3131.01.2017
Projektdetails

Klinische Studien des Kompetenznetzes Vorhofflimmern e.V.
ID 81X2800110
Institution Kompetenznetz Vorhofflimmern e. V.
Projektleiter Günter Breithardt
Standort Extern
Projektart Kompetenznetze
Fördersumme 1273976.94€ 1.273.976,94
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails

Nationales Register für angeborene Herzfehler mit Biomaterialbank
ID 81X2800111
Institution Nationales Register für angeborene Herzfehler e.V.
Projektleiter Ulrike Bauer
Standort Extern
Projektart Kompetenznetze
Fördersumme 3013196.01€ 3.013.196,01
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails

Geschäftstelle des Kompetenznetzes AHF e. V.
ID 81X2800112
Institution Kompetenznetz Angeborene Herzfehler e. V.
Projektleiter Ulrike Bauer
Standort Extern
Projektart Kompetenznetze
Fördersumme 754578.72€ 754.578,72
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails

Kompetenznetz Herzinsuffizienz
ID 81X2800113
Institution Universitätsklinikum Würzburg
Projektleiter Stefan Störk
Standort Extern
Projektart Kompetenznetze
Fördersumme 820627.65€ 820.627,65
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails

Adipokines as biomarkers for dysfunction of retinal microvasculature
ID 81X2800114
Institution Universitätsklinikum Ulm
Projektleiter Wolfgang Koenig
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 9796.80€ 9.796,80
Beginn 2014-12-0101.12.2014
Ende 2016-03-3131.03.2016
Projektdetails

The TROPICAL-ACS SPARTAN Substudy
ID 81X2800115
Institution Eberhard Karls Universität Tübingen
Projektleiter Tobias Geisler
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 10000.00€ 10.000,00
Beginn 2014-11-0101.11.2014
Ende 2016-08-3131.08.2016
Projektdetails

Single molecule force spectroscopy of the ß1 adrenergic receptor and autoantibodies
ID 81X2800117
Institution Heinrich-Heine-Universität Düsseldorf
Projektleiter Friedrich Boege
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 16999.39€ 16.999,39
Beginn 2015-05-0101.05.2015
Ende 2016-12-3030.12.2016
Projektdetails

Annexin A1 prevents arterial leukocyte recruitment – mechanistic insights
ID 81X2800118
Institution Westfälische Wilhelms-Universität Münster
Projektleiter Alexander Zarbock
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 9692.43€ 9.692,43
Beginn 2015-05-0101.05.2015
Ende 2016-04-3030.04.2016
Projektdetails

Zentrales Management der Kohortenstudie des Kompetenznetzes Herzinsuffizienz (KN HI) durch das Deutsche Zentrum für Herz-Kreislauf-Forschung e.V. (DZHK)
ID 81X2800119
Institution Universität Leipzig
Projektleiter Markus Löffler
Standort Extern
Projektart Kompetenznetze
Fördersumme 567036.88€ 567.036,88
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails

Accomplishment of a split-ubiquitin yeast-two-hybrid screen to identify novel interaction partners of Junctophilin-1 and Junctophilin-2
ID 81X2800120
Institution Universität Bielefeld
Projektleiter Michael Schwake
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 15305.43€ 15.305,43
Beginn 2015-06-0101.06.2015
Ende 2016-08-3131.08.2016
Projektdetails

Promotion of positive images of ageing in elderly patients after myocardial infarction
ID 81X2800121
Institution Friedrich-Alexander-Universität Erlangen-Nürnberg
Projektleiter Susanne Wurm
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 10953.29€ 10.953,29
Beginn 2015-06-0101.06.2015
Ende 2016-01-3131.01.2016
Projektdetails

Generation and characterization of a novel zebrafish atherosclerotic model by overexpression of the humanized ApoE3-leiden protein
ID 81X2800122
Institution Universität Potsdam
Projektleiter Salim Seyfried
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 10740.00€ 10.740,00
Beginn 2015-09-0101.09.2015
Ende 2016-08-3131.08.2016
Projektdetails

New vascular keys to EndMT and cardiac fibrosis
ID 81X2800123
Institution Medizinische Hochschule Hannover - Zentrum Innere Medizin - Klinik für Nieren- und Hochdruckerkrankungen
Projektleiter Sibylle von Vietinghoff
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 14423.68€ 14.423,68
Beginn 2015-07-0101.07.2015
Ende 2016-04-3030.04.2016
Projektdetails

Targeting T. cruzi-specific STAT1 serine phosphatase in the treatment of chagasic cardiomyopathy
ID 81X2800124
Institution Philipps-Universität Marburg
Projektleiter Ralph T. Schwarz
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 2237.79€ 2.237,79
Beginn 2015-08-0101.08.2015
Ende 2016-06-3030.06.2016
Projektdetails

Epigenetic Profile of Cardiac Progenitor Cells – Global DNA Methylome
ID 81X2800125
Institution Albert-Ludwigs-Universität Freiburg
Projektleiter Lutz Hein
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 9900.00€ 9.900,00
Beginn 2015-08-0101.08.2015
Ende 2016-04-3030.04.2016
Projektdetails

Autophagy screening platform
ID 81X2800126
Institution Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
Projektleiter Ole Pleß
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 12785.22€ 12.785,22
Beginn 2015-08-0101.08.2015
Ende 2016-06-3030.06.2016
Projektdetails

Optical action potential recordings for high---throughput cardiomyocytes subtype identification.
ID 81X2800127
Institution Universität des Saarlandes
Projektleiter Peter Lipp
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 8818.57€ 8.818,57
Beginn 2015-09-0101.09.2015
Ende 2016-08-3131.08.2016
Projektdetails

Characterization and neurohumoral regulation of the newly identified membrane protein TRPML-like 2 in cardiomyocytes
ID 81X2800128
Institution Universität des Saarlandes
Projektleiter Peter Lipp
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 33395.79€ 33.395,79
Beginn 2015-08-0101.08.2015
Ende 2016-07-3131.07.2016
Projektdetails

Non-invasive Renal Volume and Lipid Quantification as Biomarkers in Patients with Cardiovascular Disease
ID 81X2800129
Institution Universitätsklinikum Tübingen
Projektleiter Mike Notohamiprodjo
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 8688.90€ 8.688,90
Beginn 2015-10-0101.10.2015
Ende 2016-12-3131.12.2016
Projektdetails

Generation of viral vectors for the functional characterization of long non-coding RNA in vivo
ID 81X2800130
Institution Medizinische Hochschule Hannover
Projektleiter Thomas Thum
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 10000.00€ 10.000,00
Beginn 2015-10-0101.10.2015
Ende 2016-07-3030.07.2016
Projektdetails

ldentification of differentially expressed proteins in the cardiac tissue of CRTC1 deficient mice and their wildtype littermates
ID 81X2800131
Institution Universität zu Köln
Projektleiter Elke Oetjen
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 7149.98€ 7.149,98
Beginn 2015-11-0101.11.2015
Ende 2016-12-3131.12.2016
Projektdetails

Role for microRNAs in calcineurin-mediated immunosuppression after solid organ transplantation
ID 81X2800132
Institution Universität zu Köln
Projektleiter Matti Adam
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 9880.27€ 9.880,27
Beginn 2015-11-0101.11.2015
Ende 2016-12-3131.12.2016
Projektdetails

Role of killer cell immunoglobulin-like receptors in killing of induced pluripotent stem cell-derived cardiomyocytes
ID 81X2800133
Institution Heinrich-Heine-Universität Düsseldorf
Projektleiter Markus Uhrberg
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 11629.03€ 11.629,03
Beginn 2016-01-0101.01.2016
Ende 2018-01-3131.01.2018
Projektdetails

Role of protein phosphatases in human cardiac pathology
ID 81X2800134
Institution Technische Universität Dresden
Projektleiter Ali El-Armouche
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 13999.99€ 13.999,99
Beginn 2015-11-0101.11.2015
Ende 2016-12-3131.12.2016
Projektdetails

Determination of miR-29 subtypes in myocardial cell types and their regulation
ID 81X2800135
Institution Medizinische Hochschule Hannover
Projektleiter Thomas Thum
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 10000.00€ 10.000,00
Beginn 2015-11-0101.11.2015
Ende 2017-05-1414.05.2017
Projektdetails

Functional characterization of psiPSC-CMs derived from patients with Tetralogy of Fallot in comparison to healthy controls.
ID 81X2800136
Institution Universitätsklinikum Essen
Projektleiter Dobromir Dobrev
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 12475.07€ 12.475,07
Beginn 2016-01-0101.01.2016
Ende 2017-12-3131.12.2017
Projektdetails

Cerebral blood flow changes after stroke in brain endothelial thrombomodulin knockout mice
ID 81X2800137
Institution Medizinisches Laserzentrum Lübeck GmbH
Projektleiter Gereon Hüttmann
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 15975.00€ 15.975,00
Beginn 2016-01-0101.01.2016
Ende 2016-05-3131.05.2016
Projektdetails

The Role of CD40 in Endothelial and Smooth Muscle Cell on Atherogenesis
ID 81X2800139
Institution Albert-Ludwigs-Universität Freiburg - Medizinische Fakultät
Projektleiter Andreas Zirlik
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 10000.00€ 10.000,00
Beginn 2016-01-0101.01.2016
Ende 2017-12-3131.12.2017
Projektdetails

Role of Sirt3 in the anti-inflammatory effects of estrogen receptors signaling
ID 81X2800140
Institution Justus-Liebig-Universität Gießen
Projektleiter Dursun Gündüz
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 13550.74€ 13.550,74
Beginn 2016-01-0101.01.2016
Ende 2017-12-3131.12.2017
Projektdetails

Inotropy and Chronotropy Screens in Engineered Human Myocardium by Optical Analysis in Real Time. Teilvorhaben der HOCHSCHULE DARMSTADT
ID 81X2800141
Institution Hochschule Darmstadt
Projektleiter Ralf Blendowske
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 4702.76€ 4.702,76
Beginn 2016-01-0101.01.2016
Ende 2016-09-3030.09.2016
Projektdetails

Research Grant: Molecular aspects of the antiviral activity of ISG15 in CVB3-induced myocarditis
ID 81X3100202
Institution Charité - Universitätsmedizin Berlin
Projektleiter Nadine Althof
Standort Berlin
Projektart Exzellenzprogramm
Fördersumme 30761.12€ 30.761,12
Beginn 2015-07-0101.07.2015
Ende 2017-06-2121.06.2017
Projektdetails

Rotation Grant: Heart failure in children and adolescents
ID 81X3100302
Institution Deutsches Herzzentrum Berlin
Projektleiter Nadya Al-Wakeel
Standort Berlin
Projektart Exzellenzprogramm
Fördersumme 85635.56€ 85.635,56
Beginn 2015-08-0101.08.2015
Ende 2018-09-3030.09.2018
Projektdetails

Postdoc Start-up Grant: The regulatory role of Reg3ß on neutrophil persistence and functionality after the onset myocardial infarction
ID 81X3200301
Institution Max-Planck-Institut für Herz- und Lungenforschung
Projektleiter Holger Lörchner
Standort RheinMain
Projektart Exzellenzprogramm
Fördersumme 58624.31€ 58.624,31
Beginn 2015-10-0101.10.2015
Ende 2016-11-3030.11.2016
Projektdetails

Postdoc Start-up Grant: The role of sympathetic and parasympathetic innervation in heart development and regeneration
ID 81X3200302
Institution Max-Planck-Institut für Herz- und Lungenforschung
Projektleiter Ryota Matsuoka
Standort RheinMain
Projektart Exzellenzprogramm
Fördersumme 60000.00€ 60.000,00
Beginn 2015-10-0101.10.2015
Ende 2016-09-3030.09.2016
Projektdetails

Rotation Grant: Catheter ablation for atrial fibrillation in hearth failure with preserved ejection fraction
ID 81X3500106
Institution Universitätsklinikum Heidelberg
Projektleiter Maura Magdalena Zylla
Standort Heidelberg/Mannheim
Projektart Exzellenzprogramm
Fördersumme 85468.57€ 85.468,57
Beginn 2015-07-0101.07.2015
Ende 2016-12-3131.12.2016
Projektdetails

Rotation Grant: Efficacy of ticagrelor after cardiopulmonary resuscitation in hypothermic patients with a myocardial infarction
ID 81X3500108
Institution Universitätsklinikum Heidelberg
Projektleiter Lisa Tilemann
Standort Heidelberg/Mannheim
Projektart Exzellenzprogramm
Fördersumme 76778.00€ 76.778,00
Beginn 2015-07-0101.07.2015
Ende 2016-08-3131.08.2016
Projektdetails

Postdoc Start-up Grant: Role of miR-147 in macrophages in atherosclerosis
ID 81X3600203
Institution Klinikum der Universität München
Projektleiter Maliheh Nazari-Jahantigh
Standort München
Projektart Exzellenzprogramm
Fördersumme 59981.00€ 59.981,00
Beginn 2015-12-0101.12.2015
Ende 2017-03-3131.03.2017
Projektdetails

Rotation Grant: Functional characterization of risk factor gene ADAMTS7 in vascular smooth muscle cells
ID 81X3600502
Institution Deutsches Herzzentrum München
Projektleiter Thorsten Kessler
Standort München
Projektart Exzellenzprogramm
Fördersumme 94000.00€ 94.000,00
Beginn 2015-07-0101.07.2015
Ende 2016-09-3030.09.2016
Projektdetails

Rotation Grant: Characterization of long noncoding RNAs as novel modulators of cardiac hypertrophy
ID 81X3700202
Institution Universitätsklinikum Schleswig-Holstein
Projektleiter Constantin Kühl
Standort Hamburg/Kiel/Lübeck
Projektart Exzellenzprogramm
Fördersumme 89513.69€ 89.513,69
Beginn 2015-08-0101.08.2015
Ende 2016-08-3131.08.2016
Projektdetails

Rotation Grant: Pressure-volume analysis in structural heart disease
ID 81X3710105
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Michael Schwarzl
Standort Hamburg/Kiel/Lübeck
Projektart Exzellenzprogramm
Fördersumme 87074.50€ 87.074,50
Beginn 2015-11-0101.11.2015
Ende 2017-01-3131.01.2017
Projektdetails

Microbiome and cardiovascular disease
ID 81Z1100101
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Dominik Müller
Standort Berlin
Projektart Standortprojekt
Topic inflammation/vascular inflammation
Fördersumme 262364.36€ 262.364,36
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
microbiome, CVD
The microbiome includes a diverse community of bacteria in our gut and its impact on health has spawned the Human Microbiome Project. This immensely rich bacterial community, which is known to respond to fluctuations in lifestyle and diet, is increasingly recognized as an important factor that influences host health and disease. Several diseases have been shown to be influenced by gut microbiota, such as obesity, diabetes mellitus, inflammatory bowel disease and autoimmune disease. Even though the importance of the gut microbiome has been recognized, the role of environmental factors like high salt on the gut microbiome as well as the role for the gut microbiota in hypertension-induced target organ damage is not known. The project addresses these isuues.

Metabolic control of vascular diseases (Stammzellplattform)
ID 81Z1100102
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Sebastian Diecke
Standort Berlin
Projektart Standortprojekt
Topic iPSC
Fördersumme 701111.28€ 701.111,28
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
Stem cells, Genome editing, differentiation, reprogramming, disease modeling, screening
The Stem Cell platform of the DZHK in Berlin was established to provide stem cell specific services to scientists of the DZHK to overcome technical obstacles in a field of reprogramming, differentiation and genome editing rapidly growing and full of spectacular innovations.The stem cell platform already established feeder free cultivation system of hiPSC using homemade chemical defined media and different endothelial and cardiac, differentiation protocols in cooperation with the DZHK affiliated groups of Prof. Willnow, Hübner, Sperling, Gerhardt. The stem cell platform also performed genome engineering experiments using Crispr/Cas9 or TALEN mediated gene targeting and derived different disease and non- disease specific patient iPSC lines using different reprogramming techniques.

Heart prevention study
ID 81Z1100103
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Tobias Pischon
Standort Berlin
Projektart Standortprojekt
Topic arteriosclerosis
Fördersumme 250836.75€ 250.836,75
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
myocardial infarction, diet, nutrition, physical activity, patients
Current guidelines recommend a healthy diet and physical activity of at least moderate intensity for management of cardiovascular risk. Recent studies suggest that a Mediterranean diet reduces the risk of major cardiovascular events among persons at high cardiovascular risk. However, it is unclear whether in non-Mediterranean countries, diets similar to the Mediterranean diet have comparable effects. Further, preliminary evidence indicates that interval-based vigorous physical activity may be at least as beneficial as moderate activity. The aim of this project is therefore to study in a German population the association of diet, physical activity, lifestyle, and metabolic factors with prognosis of patients with history of myocardial infarction.

Endothelial cell dynamics in vascular remodelling
ID 81Z1100104
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Holger Gerhardt
Standort Berlin
Projektart Standortprojekt
Topic vascular remodelling/altering
Fördersumme 2301504.32€ 2.301.504,32
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
angiogenesis, imaging, blood flow, mouse, zebrafish
Our recent work on endothelial cell specification, competition, dynamic rearrangements, Notch signalling synchronization, and vessel regression established key principles in vascular patterning and malformations. Challenges ahead lie in the multiscale and multiphysics nature of vascular remodelling. Our project bridges across scales and disciplines to establish mechanisms of dynamic cell polarity establishment and regulation of endothelial cell shape in vascular remodelling, as well as transmission and integration of physical forces with signalling to influence shape and polarity of individual cells. We then ask how collective cell behaviour under the influence of the above-mentioned principles is coordinated with blood flow and tissue responses to achieve functional remodelling.

Development of microRNA therapeutics for vascular diseases
ID 81Z1100112
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Nikolaus Rajewski
Standort Berlin
Projektart Standortprojekt
Fördersumme 330046.67€ 330.046,67
Beginn 2012-01-0101.01.2012
Ende 2018-12-3131.12.2018
Projektdetails

Metabolic control in cerebrovascular disease – Role of extracellu- lar matrix and junctional proteins for post-stroke regeneration
ID 81Z1100201
Institution Charité - Universitätsmedizin Berlin
Projektleiter Ulrich Dirnagl
Standort Berlin
Projektart Standortprojekt
Topic angiogenesis
Fördersumme 473143.09€ 473.143,09
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
Ischemic stroke is a vascular disease affecting neuronal function. The ‘bimodal response’ of the neurovascular unit (NVU) to brain ischemia is characterized by an early blood-brain-barrier disruption followed later by vascular remodelling and, hence, a switch from brain injury to repair and recovery. The aim of this project is to target extracellular matrix (ECM) components essential for NVU integrity to protect from stroke and to identify novel biomarkers to translate these findings into clinical practice. Using a model of transient focal brain ischemia and a genetically modified mice, we investigate the role of key ECM components for stroke outcome and their potential use as biomarkers for the switch from injury to recovery.

RNA Therapeutics 1_5
ID 81Z1200101
Institution Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III
Projektleiter Stefanie Dimmeler
Standort RheinMain
Projektart Standortprojekt
Topic miRNAS/IncRNA
Fördersumme 1404260.50€ 1.404.260,50
Beginn 2014-09-1010.09.2014
Ende 2018-12-3131.12.2018
Projektdetails
cardiovascular, RNA, miRNA, lncRNA, RNA therapeutics
In the last years, it has become evident that the majority of the genome is transcribed, while only about 2% codes for proteins. These so-called non-coding RNAs (ncRNAs) comprise microRNAs, long ncRNAs (>200 nt) and circular RNAs (circRNAs). The research groups of Prof. Dimmeler, Prof. Fleming and Prof. Brandes at RheinMain have extensive expertise in non-coding RNA research including the development of microRNA inhibitors in angiogenesis, cardiac aging and aneurysm formation as well as the characterization of the long non-coding RNAs in endothelial cell functions in vitro and in vivo. In frame of this common project we will join efforts to better understand the function of lncRNAs and circRNAs in the cardiovascular system in order to identify putative novel therapeutic targets.

Cell Therapy
ID 81Z1200102
Institution Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III
Projektleiter Andreas Zeiher
Standort RheinMain
Projektart Standortprojekt
Topic stem cells/cardiac regeneration
Fördersumme 239980.90€ 239.980,90
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
acute myocardial infarction, heart failure, stem cell therapy
Intracoronary therapy using autologous bone-marrow derived  cells (BMCs) has been shown to moderately improve left ventricular function in patients with acute myocardial infarction and chronic heart failure. One of the key factors influencing the efficacy of the application is certainly the heterogeneity of the cell products which varies depending on the genetic determinants and risk factors of the individual patients. Focus of this project is the establishment of fast and easy-to-perform in vitro methods to analyze the functionality of BMCs already before the re-application in the patient. Identification of factors determining the functionality of the applied cellular product might also enable ex-vivo modification by drugs or small molecules in order to further enhance the efficacy of cell therapy in patients with cardiovascular diseases.

Biomarker Research
ID 81Z1200201
Institution Kerckhoff-Klinik, Gesellschaft mit beschränkter Haftung
Projektleiter Christian Hamm
Standort RheinMain
Projektart Standortprojekt
Fördersumme 897561.16€ 897.561,16
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
biomarker, heart failure, microRNA
The Biomarker Research Group aims to identify and validate of cardiac biomarkers, which is the central area of clinical and basic research in this Project in order to improve diagnosis, decision on therapeutic strategies and prognosis of cardiovascular disease. Only a few Biomarkers (e.g. Troponin, CKMB) have made into daily clinical practice and are routinely measured in patients in a limited number of clinical settings (exclusion of myocardial infarction). Thus, there is an essential need for a broader range of biomarkers not only in the context of myocardial infarction but also for other cardiac and vascular diseases like heart failure (diastolic/systolic dysfunction), right/left ventricular insufficiency and for cardiac ischemia. Furthermore, new concepts of (bio)-markers (e.g. circulating micro-RNAs and molecular signature of circulating mononuclear cells) are investigated for their potential to act as therapeutic or prognostic indicators of cardiac pathologies.

Metabolic Response to Pharmacological and Non-pharmacological Interventions
ID 81Z1400101
Institution Universitätsmedizin Greifswald
Projektleiter Raila Busch
Standort Greifswald
Projektart Standortprojekt
Topic endothelial cells/vascular function
Fördersumme 560749.31€ 560.749,31
Beginn 2014-08-1818.08.2014
Ende 2018-12-3131.12.2018
Projektdetails
exercise, lipid-lowering medication, interactive effects, endothelial function, animal models, cell culture and flow-chamber experiments
This project investigates the interaction between pharmacological therapies and life-style changes as non-pharmacological intervention. The current guidelines recommend a combination of pharmacological and non-pharmacological approaches. However, little is known at the current state e.g. how life-style interventions like exercise training and medication interact. For primary and secondary prevention interactions between exercise training and lipid lowering medication is of high interest. Up to now it is still unclear if the positive effects of exercise training or lipid lowering medication alone act additively/synergisticly or counteractively when applied in combination as recommended by the guidelines. The major aim of this project is to investigate the effects of lipid lowering medication on endothelial/vascular function in cell culture models. Furthermore animal models shall provide insights into the interaction of exercise training and lipid lowering medication on cardiopulmonary capacity, vascular and heart function.

Vascular Regeneration/Remodelling
ID 81Z1600211
Institution Klinikum der Universität München
Projektleiter Ulrich Pohl
Standort München
Projektart Standortprojekt
Topic vascular remodelling/altering
Fördersumme 718832.52€ 718.832,52
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails
smooth muscle, AMPK, connexins, cell migration, cytoskelton, podosomes, mitochnodrial impairment
In this project we study the role of vascular connexins in remodelling processes. Using genetic connexin mutations their effect on of vascular on cell growth and migration and heterocellular communication are analyzed. We further study the role endothelial mitochondrial impairment, cytoskeletal reorganization and altered smooth muscle calcium homeostasis on cellular migration in isolated cultured microvessels and a model of arteriogenesis. One of the targets is the AMP-activated kinase (AMPK) which establishes a close link to metabolic and inflammatory diseases and microvascular remodelling

Immunotherapy of Vascular Disease
ID 81Z1600212
Institution Klinikum der Universität München
Projektleiter Christian Weber
Standort München
Projektart Standortprojekt
Topic inflammation/vascular inflammation
Fördersumme 1849181.03€ 1.849.181,03
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails
chemokine, heteromer, neutrophil, platelet, inflammation, recruitment
The newly established research group headed by the DZHK-Professor Oliver Soehnlein shall develop and pursue novel concepts for target identification and therapeutic exploitation in the context of the chemokine-interactome, leukocytic granule proteins, and costimulatory molecules for the treatment of inflammatory aspects of cardiovascular diseases. These are based on detailed structure-function analyses, modelling of molecular interactions, and synthetic peptide chemistry for generation of interceptors, which shall be validated and optimized for safety and efficacy during atherogenic immune cell recruitment. It is the aim to generate peptides for use in clinical studies which shall be realized in subsequent funding periods.

Clinical CHD - Clinical Platelet Therapy Research
ID 81Z1600214
Institution Klinikum der Universität München
Projektleiter Steffen Massberg
Standort München
Projektart Standortprojekt
Topic platelet function/thrombosis mechanisms
Fördersumme 1567485.72€ 1.567.485,72
Beginn 2013-05-0101.05.2013
Ende 2018-12-3131.12.2018
Projektdetails
platelet, thrombosis, immune cells, coagulation
Platelets are central mediators of arterial thrombosis and the main target of treatment as well as prophylaxis of coronary heart disease. However, despite improvements in antiplatelet therapy thrombotic disorders a still a leading cause of mortality worldwide. Therefore, the central aim of this project is to pave the way for innovative therapeutic approaches targeting the prothrombotic functions of platelets. This is based on an improved understanding of the interactions of platelets with the coagulation as well as the immune system using state-of-the-art basic science approaches and reaching to clinical evaluation. The results of this project will provide valuable insight into the mechanisms of thrombotic disorders and will break new ground for the treatment of coronary heart disease.

Gender Medicine
ID 81Z1600215
Institution Klinikum der Universität München
Projektleiter Julinda Mehilli
Standort München
Projektart Standortprojekt
Fördersumme 573929.98€ 573.929,98
Beginn 2012-01-0101.01.2012
Ende 2018-12-3131.12.2018
Projektdetails
gender, women, TAVI, TAVR, AS,HTx, heart transplantation,CAD, BRS, scaffold
gender-related analyses from different registries and ongoing randomized trials focused on clinical outcomes after trans-catheter aortic valve repair, after heart transplantation as well as after implantation of bioresorbable vascular scaffolds

Cell Adhesion in CHD
ID 81Z1600313
Institution Max-Planck-Institut für Biochemie
Projektleiter Reinhard Fässler
Standort München
Projektart Standortprojekt
Topic endothelial cells/vascular function
Fördersumme 775111.00€ 775.111,00
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails
cell adhesion signaling, knock-out mice, parvin, integrin, cardiomyocytes, vascular smooth muscle cells, hypertrophy, proteomics
The project „cell adhesion in coronary heart diseases“ makes use of genetically modified mouse lines to analyze the role of integrin-mediated adhesion of vascular smooth muscle cell and cardiomyocyte to the extracellular matrix (cell-matrix adhesion) and neighboring cells (cell-cell adhesion) in vivo. We aim to characterize ?-Parvin and ?-Parvin-regulated signal pathways that control vascular and cardiomyocyte function and the progression of CHDs (such as aneurysms, hypertonia or hypertrophy) by a combination of genetic experiments in mice, cell biology and proteomic analysis. A second aim is the development of therapeutic strategies for the treatment of CHDs using synthetic peptides that bind to and inactivate cell adhesion proteins.

Experimental and integrative analysis of CAD
ID 81Z1600512
Institution Deutsches Herzzentrum München
Projektleiter Heribert Schunkert
Standort München
Projektart Standortprojekt
Topic genetics of cardiovascular diseases
Fördersumme 831297.87€ 831.297,87
Beginn 2013-01-0101.01.2013
Ende 2018-12-3131.12.2018
Projektdetails
animal models, genome-wide association studies, coronary artery disease, myocardial infarction
Our group has significantly contributed to the discovery and functional analysis of a large number of genomic variants which were identified to be genome-wide significantly associated with coronary artery disease. Hence, several transgenic animal models as well as novel bioinformatics strategies have been established to enable the analysis of networks and signaling pathways. In the project “Experimental and integrative analysis of CAD” we aim to experimentally explore these tools of functional gene analysis. Furthermore, using OMICS datasets and animal models, which are based on the genome-wide significant coronary artery disease loci, we aim to improve the understanding of the molecular consequences of the identified variants for the development of coronary artery disease and myocardial infarction.

Clinical CHD Therapy - Early Clinical Trial Unit
ID 81Z1600514
Institution Deutsches Herzzentrum München
Projektleiter Adnan Kastrati
Standort München
Projektart Standortprojekt
Fördersumme 1262041.09€ 1.262.041,09
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails
Coronary artery disease, thrombosis, restenosis, platelet, aggregation, stent, women,antiproliferative drug, antiplatelet drug, clinical trial, phase II
The objective is 2 fold: evaluation of new therapeutic concepts for the prevention of stent thrombosis and restenosis. A new substance, a glycoproten VI inhibitor, Revacept, which prevents the adhesion of platelets to the vessel wall injury site, is expected to protect against thrombosis without impacting significantly on bleeding. Preclinical and phase I studies have shown promise that Revacept might be an effective and safe drug for prevention of thrombotic events after percutaneous coronary intervention. This substance will be assessed in a phase II clinical trial. The second objective is the development of safer and effective drug-eluting stents. RGD peptide and novel fully resorbable polymers will be subject of pre-clinical and first-in-man studies. We are establishing an early clinical trial unit for the conductance of these studies.

From GWAS hits to novel treatment targets
ID 81Z1700101
Institution Universität zu Lübeck
Projektleiter Jeanette Erdmann
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Topic genetics of cardiovascular diseases
Fördersumme 1840985.79€ 1.840.985,79
Beginn 2014-11-0505.11.2014
Ende 2018-12-3131.12.2018
Projektdetails
myocardial infarction, coronary artery disease, genetics, GWAS, animal models, SNPs, NGS
The project aims to systematically explore the human genome in cardiovascular disease, as well as to study the functional consequences of genomic variations in human cell and animal models. We wish to enhance diagnostic and therapeutic options particularly in the context of atherosclerosis and myocardial infarction. We systematically explored genome-wide association as well as genome-wide sequencing data and contributed to the identification of most currently known alleles affecting risk of the disease. Transgenic animal models (mice), also based on these newly identified genes, are about to further refine the mechanistic understanding of these processes. We aim to utilize these resources for the benefit of patients in terms of improved risk prediction and individualized medical treatment.

Phenotypic evaluation of MI genes in mouse models
ID 81Z1700102
Institution Universität zu Lübeck
Projektleiter Cor de Wit
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Topic genetics of cardiovascular diseases
Fördersumme 309685.98€ 309.685,98
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
endothelium, microcirculation, knockout-models
This project is aimed to analyse mouse models that carry identified CAD/MI genes with respect to flow regulation in the microcirculation, neointima formation in carotid artery, and platelet aggregation in arterioles. Flow regulation is studied by measuring arteriolar diameter changes in the in vivo setting before and after stimulation using vasoactive agents. Neointima formation is an in vivo model of atherosclerosis that induces a switch in smooth muscle phenotype. Thrombus formation is initiated in vivo in arterioles by mechanical or excitation of light-sensitive dyes to induce platelet activation. By these means we aim to obtain insight into pathophysiological mechanisms that are initiated by such genes of risk which ultimately may cause or promote CAD/MI.

Genetic epidemiology and clinical studies
ID 81Z1700103
Institution Universität zu Lübeck
Projektleiter Inke R. König
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Topic genetics of cardiovascular diseases
Fördersumme 165000.00€ 165.000,00
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
biomarker, simulation, interaction, study design, randomise all, biomarker stratified, subgroup analysis
The first aim is to derive practical recommendations for identifying interactions between predictive biomarkers and treatments in different study designs via simulations based on distinct regression models. The first step is to design simulation scenarios based on effects and effect combinations described in literature. Next, transformations are developed to define equivalent effects in different regression models resulting in subsequent simulation runs. The second aim is to give recommendations how to analyse subgroup designs defined by multiple biomarkers. The first step here is again to design simulation scenarios by literature search. Practical recommendations arise from simulations based on these scenarios, and unbiased estimators for treatment and biomarker effects will be developed.

Functional investigationof mutations in cardiovascular disease
ID 81Z1700104
Institution Universität zu Lübeck
Projektleiter Frank Kaiser
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Topic genetics of cardiovascular diseases
Fördersumme 182046.40€ 182.046,40
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
chromatin, SNP, transcription, mutation
To characterize genetic variants associated with cardiovascular disease two different analytic pipelines are used. The first one is focusing on variants affecting protein coding regions of the genome by a broad spectrum of different technologies (two hybrid assays, immunoprecipitation or ChIP) to investigate exchanges of selected amino acids on protein complex formation or protein DNA interaction. The second part of this project is focusing on variants within the non-coding part of the genome. Based on public or own databases variants are rated and listed regarding their predicted functional relevance. Selected variants will be analyzed by cellular in-vitro systems and chromatin conformation capture assays to investigate their effect on chromatin structure and gene expression.

Vascular end organ damage
ID 81Z1700105
Institution Universität zu Lübeck
Projektleiter Markus Schwaninger
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Topic endothelial cells/vascular function
Fördersumme 248630.83€ 248.630,83
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
optical coherence tomography, diabetic complications, diabetic microvascular pathology, incontinentia pigmenti, small vessel diseases, NF-kB, gene therapy
Our project investigates vascular pruning and remodeling in mouse models of disease. We focus on (i) diabetes and (ii) incontinentia pigmenti, a genetic disease that leads to vascular pathology in the brain. Although diverse in etiology, the two conditions share an involvement of the proinflammatory transcription factor NF-?B. To explore whether interfering with NF-?B signaling offers therapeutic opportunities, we employ classical small-molecule pharmacology as well as gene therapy approaches. Optical coherence tomography and various physiological or morphological techniques are used to evaluate the vasculature.

Omics-based approaches in cardiovascular disease
ID 81Z1710101
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Tanja Zeller
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Topic genetics of cardiovascular diseases
Fördersumme 1368872.73€ 1.368.872,73
Beginn 2014-10-2929.10.2014
Ende 2018-12-3131.12.2018
Projektdetails
OMICS, cardiovascular genetics, genomics, gene expression, candidate genes, translation, clinical application, systems medicine
Systems medince approaches to characterize candidate genes and networks of cardiovascular diseases such as myocardial infarction, heart failure and atrial fibrillation. As resources we use large-scale omics and phenotypic data sets as well as comprehensive biobanks of population-based and disease cohorts. Candidate genes are investigated at the molecular and cellular levels. Findings are translated into clinical disease models and tested for clinical application.

Modulation of the AGAT/homoarginine pathway in cardio - vascular diseases
ID 81Z1710102
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Edzard Schwedhelm
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Fördersumme 368000.00€ 368.000,00
Beginn 2014-10-2929.10.2014
Ende 2018-12-3131.12.2018
Projektdetails
AGAT, CRTC1, homoarginine
L-arginine:glycine amidinotransferase (AGAT) is involved in creatine as well as homoarginine (hArg) synthesis. hArg is an amino acid identified as risk marker in cardiovascular (CV) and cerebrovascular diseases. Cardiac phenotyping of AGAT deficient, Mybpc3-targeted knock-in, and CREB-regulated transcription coactivator 1 deficient mice is part of the project for a better understanding of processes in CV diseases. The aim of the project is to investigate the potential relevance of the AGAT/hArg pathway as a new therapeutic approach in CV diseases, e.g. atrial fibrillation, stroke/transient ischemic attack, heart failure, and hypertrophic cardiomyopathy with AGAT modulators, identified by high throughput screening, and homoarginine supplementation in healthy and diseased patients.

Examination of novel risk markers for atrial fibrillation
ID 81Z1710103
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Renate B. Schnabel
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Topic other arrhythmias
Fördersumme 208086.86€ 208.086,86
Beginn 2014-10-2929.10.2014
Ende 2018-12-3131.12.2018
Projektdetails
atrial fibrillation, risk prediction, outcome, epidemiology
At University Heart Centre Hamburg we have established obserational cohorts to investigate incidence and outcome of atrial fibrillation. Cohorts range from population-based individuals to patients at risk of developing atrial fibrillation, lone atrial fibrillation, and postoperative new-onset disease. In the DZHK project we perform epidemiological analyses that examine classical risk factors and novel risk markers for atrial fibrillation. Our aim is to improve the understanding of the disease pathophysiology and its natural history. In pre-defined subgroups we try to improve risk prediction beyond existing risk algorithms. In addition, by our well-characterized cohorts we provide a clinical-epidemiological basis for a fast translation of basic research findings into the clinical setting.

Integration of transcriptional and posttranscriptional regulation in dilated cardiomyopathy
ID 81Z2100101
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Norbert Hübner
Standort Berlin
Projektart Standortprojekt
Topic genetics of cardiovascular diseases
Fördersumme 189185.95€ 189.185,95
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
Genetic variation, transcriptional and translational regulation
We investigate the molecular basis of cardiovascular diseases with a main focus on dilated cardiomyopathy (DCM), a major cause of congestive heart failure. Genetic factors are known to play an important role in disease etiology but the molecular mechanisms are largely unknown. In order to elucidate the impact of pathogenic variation, we perform RNA-seq and ribosome profiling of cardiac disease tissue. Ribosome profiling is a powerful and novel methodology to obtain qualitative and quantitative information about translation on a genome-wide scale. This technology provides a way to thoroughly investigate translational regulation and to significantly improve the estimate of protein levels compared to traditional gene expression approaches.

Alternatives Spleißen als therapeutisches Target für Erkrankungen des Herzens
ID 81Z2100102
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Michael Gotthardt
Standort Berlin
Projektart Standortprojekt
Topic cardiomyocyte function
Fördersumme 357275.80€ 357.275,80
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
RNA, splicing, therapy
The project „alternative splicing as a therapeutic target for cardiac diseases“ builds on our identification of RBM20 as a splice factor with substrates related to sarcomere function and calcium homeostasis. We will study the regulation of RBM20 expression and function, as well as its interaction with other proteins to identify potential therapeutic targets. Through the coordinated interference with cardiac isoform expression, we will adapt the elastic and electrical properties of the heart.

Sex-specific use of estrogen pathway modulation in human heart failure
ID 81Z2100201
Institution Charité - Universitätsmedizin Berlin
Projektleiter Vera Regitz-Zagrosek
Standort Berlin
Projektart Standortprojekt
Topic cardiac hypertrophy/remodeling
Fördersumme 887303.04€ 887.303,04
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
calcium, fibrosis, hormone, mitochondria, receptor
There are major sex differences in heart failure. The overall hypothesis is that female sex or sex hormones lead to better maintenance of mitochondrial function, calcium handling and reduced fibrosis and apoptosis under stress. To investigate these processes, we use animal models and tissues from male and female patients undergoing cardiac surgery in the following objectives: 1) sex-specific role of ER? and ER? on mitochondrial energy production in the human heart; 2) sex-specific role of ER? and ER? effects in cardiac fibrosis; 3) role of mitochondrial cAMP-signaling in the cardioprotective effects of ER; 4) sex differences in calcium-dependent cardiomyocyte death in heart failure; 5) integrative model of sex differences in cardiomyocyte function and testing of targets.

Translationale Studien zur Rolle der non-coding RNA (miR und long ncRNA) für die kardievaskuläre Repair- und Immunmodulationsprozesse beim akuten Koronarsyndrom
ID 81Z2100202
Institution Charité - Universitätsmedizin Berlin
Projektleiter Ulf Landmesser
Standort Berlin
Projektart Standortprojekt
Topic inflammation/vascular inflammation
Fördersumme 755163.91€ 755.163,91
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
non-coding RNA, inflammation, vascular, endothelium, repair, monocytes, mircoRNA
The project aims to better define mechanisms regulating vascular and cardiac immune and repair responses in cardiovascular diseases. We combine flow cytometric sorting of human monocyte populations and the characterization of their coding and non-coding RNA profiles in relation to monocyte functions. Furthermore, we assess the functional impact of each of the known 2000+ miR species for monocyte-endothelial cell interaction and for cardiomyocyte proliferation. Another sub-project investigates microvesicles and their miR cargo for the interaction between blood leukocyte populations and the endothelium in patients with acute and stable cardiovascular diseases. Finally, we assess the role of lipoproteins for the interaction between cells of the innate immunity and cells of the vascular wall.

Präventionsstudie/Risikomanagement
ID 81Z2100501
Institution Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke (DIfE)
Projektleiter Matthias Schulze
Standort Berlin
Projektart Standortprojekt
Fördersumme 255239.29€ 255.239,29
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
Beobachtungsstudie, Ernährung, körperliche Aktivität, Mortalität, koronare Herzkrankheit
In einer Beobachtungsstudie werden Ernährung und körperliche Aktivität als Risikofaktoren für die Prognose und Mortalität von Patienten mit stabiler koronarer Herzkrankheit untersucht.")

W2 RNA Biology
ID 81Z2200101
Institution Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III
Projektleiter Stefanie Dimmeler
Standort RheinMain
Projektart Standortprojekt
Topic miRNAS/IncRNA
Fördersumme 1000001.20€ 1.000.001,20
Beginn 2015-05-0101.05.2015
Ende 2019-01-3131.01.2019
Projektdetails
cardiovascular, RNA therapeutics, bioinformatics, biomarker
In frame of this project we would like to strengthen our extensive expertise in non-coding RNA research by appointing two new W2 professorships “RNA Therapeutics” and “Bioinformatics in Cardiovascular Disease” at the university hospital in Frankfurt. Dr. Reinier Boon has recently been appointed as professor in RNA Therapeutics and is mainly focusing on the establishment of in vitro and in vivo systems to unravel the role of newly discovered non-coding RNAs, especially lincRNAs, in cardiovascular diseases. The W2 professorship in “Bioinformatics in Cardiovascular Disease” will provide strong expertise in bioinformatics to support the analysis of large datasets (e.g. microarrays, ChIP and NGS) for the identification of new biomarker and to generate databases mainly focusing on the non-coding Genome.

MyoVasc-Kohortenstudie
ID 81Z2210101
Institution Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Projektleiter Philipp Wild
Standort RheinMain
Projektart Standortprojekt
Fördersumme 2431414.02€ 2.431.414,02
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
Heart Failure, vascular function, Biodatabanking, phenomics, cohort study
The Myovasc Study is a prospective cohort study investigating heart failure and its interactions with vascular disease. From January 2013 to January 2017 approximately 3000 participants with asymptomatic and symptomatic heart failure are eligible for the study. The primary outcome of interest is worsening of heart failure, defined as transition of cardiac dysfunction to symptomatic heart failure or cardiac death in asymptomatic individuals and hospitalization or cardiac death in symptomatic heart failure. Study participants start with a 5-hour baseline examination including comprehensive cardiovascular diagnostics. A follow up with the same examination program is performed after 2 and 4 years. A computer-assisted telephone interview with assessment of outcome is conducted yearly.

Genotyp/Phänotyp Analysen in 2D und 3D iPS-Modellen
ID 81Z2300121
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Gerd Hasenfuß
Standort Göttingen
Projektart Standortprojekt
Fördersumme 838625.00€ 838.625,00
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails

Personalized Medicine: Molecular Stratification of DCM patients
ID 81Z2400121
Institution Universitätsmedizin Greifswald
Projektleiter Stephan B. Felix
Standort Greifswald
Projektart Standortprojekt
Topic Inflammatory heart diseases
Fördersumme 557511.98€ 557.511,98
Beginn 2012-01-0101.01.2012
Ende 2018-12-3131.12.2018
Projektdetails
dilated cardiomyopathy, risk profiles, biomarker, inflammatory processes, animal models, cell culture
The discovery of inflammatory processes involved in the development of cardiomyopathies has lead to the development of new therapies. The aim of this project is to use existing patient cohorts with dilated cardiomyopathy to investigate individual inflammatory risk profiles. Biomaterials will be investigated regarding new factors indicating an individual predisposition for developing the disease or factors influencing the progression of the disease. Generated hypotheses shall be further explored in experimental settings e.g. cell cultures or animal models. The major aim is to create new insights into the pathegenesis of DCM and to develop new diagnostic tools for dilated cardiomyopathy which may be also relevant for new therapeutic approaches.

Genomische und epigenomische Ursachen von Kardiomyopathien und ihre klinische Relevanz
ID 81Z2500101
Institution Universitätsklinikum Heidelberg
Projektleiter Benjamin Meder
Standort Heidelberg/Mannheim
Projektart Standortprojekt
Fördersumme 2361099.02€ 2.361.099,02
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
cardiomyopathy, genetics, epigenetics
The project investigates the genetic and epigenetic mechanisms involved in the pathogenesis of cardiomyopathies. It further studies the connection of genetics and inflammatory heart disease on the clinical and molecular level.

Hereditäre und Inflammatorische Kardiomyophatien
ID 81Z2500102
Institution Universitätsklinikum Heidelberg
Projektleiter Hugo A. Katus
Standort Heidelberg/Mannheim
Projektart Standortprojekt
Fördersumme 768615.15€ 768.615,15
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails

Molekulare und epigenetische Regulationsmechanismen bei dem pathologischen kardialen Remodeling
ID 81Z2500103
Institution Universitätsklinikum Heidelberg
Projektleiter Hugo A. Katus
Standort Heidelberg/Mannheim
Projektart Standortprojekt
Fördersumme 1812188.44€ 1.812.188,44
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails

Translational therapeutics: Therapeutic endpoints and diagnostic biomarker for advanced therapy medicinal products (ATMP) against heart failure
ID 81Z2500104
Institution Universitätsklinikum Heidelberg
Projektleiter Patrick Most
Standort Heidelberg/Mannheim
Projektart Standortprojekt
Topic DNA/RNA based, protein based therapy
Fördersumme 525688.20€ 525.688,20
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
Heart failure gene therapy efficacy parameter & biomarker, Disease- & ligand-controlled expression systems
To enable the design of meaningful clinical trial protocols for future heart failure gene therapy programs, this project aims to determine optimized parameters of therapeutic efficacy (work package 1), viral vectors (work package 2) and predictive biomarkers (work package 3) for DNA-based therapeutic targets/ATMP against chronic heart failure such as S100A1 and others. In addition, this project seeks development of disease- (work package 4) and ligand-controlled (work package 5) gene expression systems suitable for the human-sized heart to overcome limitations of currently used constitutive systems.

Pre-clinical evaluation of novel targets against cardiomyopathies
ID 81Z2500105
Institution Universitätsklinikum Heidelberg
Projektleiter Patrick Most
Standort Heidelberg/Mannheim
Projektart Standortprojekt
Topic DNA/RNA based, protein based therapy
Fördersumme 555342.14€ 555.342,14
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
Peptide- and mRNA-based therapeutic molecules, heart failure, Cor pulmonale
Unmet clinical needs such as heart failure or Cor pulmonale fuel our interest in pharmacological strategies that improve cardiac performance by bypassing cAMP signaling and extend to the mitigation of tachyarrhythmia susceptibility, energy defects and adverse remodeling. To this end, this project seeks to determine therapeutic efficacy and safety/toxicology of S100A1 synthetic peptide- (working package 1a/b) and in vitro transcribed mRNA-based (working package 2a/b) experimental therapies against disorders of the left and right ventricular chambers in in vitro and in vivo models.

From channelopathies to clinical arrhythmias
ID 81Z2500201
Institution Ruprecht-Karls-Universität Heidelberg
Projektleiter Martin Borggrefe
Standort Heidelberg/Mannheim
Projektart Standortprojekt
Topic iPSC
Fördersumme 554176.29€ 554.176,29
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
iPS, arrhythmias, Patch-clamp
Investigation of underlying mechanisms and identification of new therapeutic targets: hiPSC-CMs possess characteristics similar to that of native human cardiomyocytes and can model the main features of some heart diseases. They provide a new platform to study the disease pathology and screen drugs. The aim of our study is to use the hiPSC-CMs modeling the arrhythmogenic heart diseases (SQTs, LQTs, Brugada syndrome, ARVC, HCM and DCM) for studying the underlying mechanisms and identifying new therapeutic targets for the treatment of the diseases. In addition, we will test effects of drugs on the “diseased” hiPSC-CMs and design better drug treatments for the diseases

Multimodal Image Fusion
ID 81Z2500202
Institution Ruprecht-Karls-Universität Heidelberg
Projektleiter Martin Borggrefe
Standort Heidelberg/Mannheim
Projektart Standortprojekt
Topic imaging
Fördersumme 250319.60€ 250.319,60
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
Detection of fibrosis, epicardial adipose tissue, Na+-Imaging
Detection of fibrosis using CMR: In patients with cardiomyopathies we want to investigate the diagnostic value of T1 mapping in comparision to late gadolinium enhancement imaging for the evaluation of fibrosis. Epicardial adipose tissue: In patients with cardiomyopathies we want to correlate changes in epicardial adipose tissue to morphological and functional parameters as well as outcome. Na+-Imaging: In cooperation with the Institute of Computer Assisted Clinical Medicine (Prof. Dr. rer. Nat L. Schad) we aime to examine the feasibility of 23Na+ heart imaging with a double-resonant 23Na-1H surface RF coil at 3 T.

Translational diagnostics of cardiomyopathies
ID 81Z2500203
Institution Ruprecht-Karls-Universität Heidelberg
Projektleiter Martin Borggrefe
Standort Heidelberg/Mannheim
Projektart Standortprojekt
Topic imaging
Fördersumme 105710.16€ 105.710,16
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
outcome, CMR imaging, ICD implantation, benefits, risks
Identification of prognostic relevant risk factors In patients with cardiomyopathies and arrhythmias we aim to improve prognosis through clinical interventions. Therefore the identification of outcome-relevant parameters is crucial. In patients who underwent CMR-imaging prior to primary or secondary ICD implantation we aim to investigate which patient-specific and CMR parameters are relevant for reaching a primary or secondary endpoint. Besides, we want to find out in which patients the benefits of the lifesaving ICD implantations outweigh the risk of device associated complications.

Registry for primary electrical disease
ID 81Z2500204
Institution Ruprecht-Karls-Universität Heidelberg
Projektleiter Martin Borggrefe
Standort Heidelberg/Mannheim
Projektart Standortprojekt
Topic other arrhythmias
Fördersumme 241543.78€ 241.543,78
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
primary electrical disease of the heart, channelopathies, risk stratification
Registry for primary electrical disease of the heart: Channelopathies are a heterogeneous group of disorders resulting from the dysfunction of ion channels located in the membranes of all cells. Channelopathies are diseases that develop because of defects in ion channels caused by either genetic or acquired factors . In patients with inherited channelopathies phenotype, individual disease course and mechanisms of arrhythmogenesis are quite different among individual patients. While in some patients causes and genetic background of ventricular fibrillation are better understood, others will develop ventricular fibrillation of unknown cause. The clinical phenotype might be influenced by unknown genetic mutations, epigenetic modifiers, gender or other still unkown risk factors. Therefore, the aim of our registry for primary electrical disease of the heart, is to identify genetic and epigenetic factors which may cause lethal arrhythmias as a result of dysfunctioning cardiac ion channels.

Identification and Validation of Novel Inotropy-Enhancing Molecular Targets
ID 81Z2500205
Institution Ruprecht-Karls-Universität Heidelberg
Projektleiter Thomas Wieland
Standort Heidelberg/Mannheim
Projektart Standortprojekt
Topic cardiomyocyte function
Fördersumme 609514.92€ 609.514,92
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
cardiac contractiliy,muscarinic receptors, RhoGTPases, RhoGTPase-activating proteins, RhoGTPase guanine nucleotide exchange factors,
In this project molecular targets in a novel positive inotropic pathway coupling M2 muscarinic receptors to RhoA/Rho-kinase in heart failure are characterized and validated. The so far identified targets are the Regulator of G-protein signaling RGS3, the RhoGTPase-actvating protein p190RhoGAP and the guanine nucleotide exchange factor Tiam1. Depending on the expression level of RGS3 this proteins allow for a switch of the coupling of M2 muscarinic receptors to a Rho-kinase dependent positive inotropic response in cardiac myocytes. Therefore, all three proteins are putative molecular targets for novel therapies in heart failure.

Experimental evaluation of cause specific personalized treatment options
ID 81Z2500206
Institution Ruprecht-Karls-Universität Heidelberg
Projektleiter Jochen Utikal
Standort Heidelberg/Mannheim
Projektart Standortprojekt
Topic iPSC
Fördersumme 201473.50€ 201.473,50
Beginn 2015-01-0101.01.2015
Ende 2018-05-3131.05.2018
Projektdetails
iPSC, repogramming, skin, fibroblast, cardiomyocyte
Generation of induced pluripotent stem cells (iPSCs) from patients with heart diseases, their differentiation in cardiomyocytes and their use in functional protocols

Kardiale Zelltyp- und Risikofaktor-spezifische DNA-Methylierung (DKFZ-PL-1)
ID 81Z2500301
Institution Deutsches Krebsforschungszentrum (DKFZ)
Projektleiter Christoph Plass
Standort Heidelberg/Mannheim
Projektart Standortprojekt
Fördersumme 263917.41€ 263.917,41
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails

Kardiale Zelltyp- und Risikofaktor-spezifische Histonmodifikationen
ID 81Z2500401
Institution Europäisches Laboratorium für Molekularbiologie (EMBL)
Projektleiter Eileen Furlong
Standort Heidelberg/Mannheim
Projektart Standortprojekt
Fördersumme 125505.72€ 125.505,72
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails

Functional role of nexilin in dilated cardiomyopathy
ID 81Z2700101
Institution Universität zu Lübeck
Projektleiter Zouhair Aherrahrou
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Topic genetics of cardiovascular diseases
Fördersumme 270000.00€ 270.000,00
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
Nexilin, Cardiomyopathy, Cardiomyocytes, iPS cells
Nexilin is one of the key genes, which have recently been identified by our group to play a critical role in cardiomyopathy. Our research interest is the evaluation of the functional role of nexilin in dilated cardiomyopathy (DCM) using constitutive and conditional mouse models as well as cardiomyocytes differentiated from human induced pluripotent stem cells (iPS cells).

The role of nexilin in dilated cardiomyopathy
ID 81Z2700121
Institution Universität zu Lübeck
Projektleiter Jeanette Erdmann
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Fördersumme 355455.45€ 355.455,45
Beginn 2011-10-1515.10.2011
Ende 2016-03-3131.03.2016
Projektdetails

Non-coding RNAs in cardiac remodeling
ID 81Z2700201
Institution Universitätsklinikum Schleswig-Holstein
Projektleiter Norbert Frey
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Topic cardiac hypertrophy/remodeling
Fördersumme 1231634.31€ 1.231.634,31
Beginn 2014-11-0101.11.2014
Ende 2018-12-3131.12.2018
Projektdetails
non-coding RNAs, lncRNA, MicroRNA
Non-coding RNAs, including micro-RNAs and lncRNAs, have been shown to play a critical role in the regulation of gene expression. It is estimated that about 4.000 lncRNAs exist, yet little is known about the role of lncRNAs in cardiac remodeling and heart failure. We thus hypothesize that lncRNAs may significantly contribute to the pathogenesis and progression of heart failure. Specifically, we aim to identify differentially regulated lncRNAs in animal models as well as human heart failure. These data will be bioinformatically analyzed and correlated with cDNA and miRNA expression. In addition, we plan a comprehensive functional characterization of novel cardiac lncRNAs utilizing adenoviruses encoding for lncRNAs and inhibitors, respectively, as well as generation of transgenic animal models. Finally, we aim to explore novel therapeutic options via experimental manipulation of specific lncRNAs in vitro and in vivo

Molecular Mechnanismus of Hypoplastic Left Heart Syndrome (HLHS)
ID 81Z2700202
Institution Universitätsklinikum Schleswig-Holstein
Projektleiter Hans-Heiner Kramer
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Fördersumme 445266.19€ 445.266,19
Beginn 2014-11-0101.11.2014
Ende 2018-12-3131.12.2018
Projektdetails
hypoplastic left heart syndrome, DNA methylation, whole exome sequencing, zebrafish
Hypoplastic left heart syndrome (HLHS) displays one of the most severe cardiac malformations that encompasses a spectrum of structural defects characterized by atresia or stenosis of the aortic and mitral valve, as well as a hypoplasia of the left ventricle and aorta. In order to analyze genetic and transcriptomic changes potentially involved in the pathogenesis of HLHS, whole exome sequencing and RNA sequencing is performed on heart tissue samples from independent cases. To evaluate epigenetic alterations, DNA methylation profiles are being analyzed. Identified candidate genes are characterized using zebrafish model organism and furthermore, patient-specific inducible pluripotent stem cells are analyzed to provide a contribution for a better understanding of the etiology of HLHS.

Minimally invasive valve resection and replacement: polycarbonateurethane valved stent implantation
ID 81Z2700203
Institution Universitätsklinikum Schleswig-Holstein
Projektleiter Georg Lutter
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Topic stem cells/cardiac regeneration
Fördersumme 280000.00€ 280.000,00
Beginn 2014-11-0101.11.2014
Ende 2018-12-3131.12.2018
Projektdetails
tissue engineering, endothelial progenitor cells, cell seeding, polymeric scaffolds
Tissue engineering is an upcoming technique for heart valve replacement, providing a living valve, capable of growth and biological integration. Heart valves made of synthetic polymers such as polyurethanes exhibit biocompatibility, bioresorbability and excellent mechanical properties with high durability. Endothelial progenitor cells (EPCs) are ideal candidates for vascular regenerative therapy, as they participate in blood vessel formation and incorporate into damaged vascular structure. In this project, the optimal conditions for administration of EPCs on polymeric scaffolds will be improved. Functionality, biocompatibility, inflammatory capacity and biological integrity of these engineered valved stents will be analysed in vivo (sheep model) for human cardiovascular application.

Cardiac tissue engineering
ID 81Z2710101
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Arne Hansen
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Topic stem cells/cardiac regeneration
Fördersumme 1556334.48€ 1.556.334,48
Beginn 2014-10-2929.10.2014
Ende 2019-02-2828.02.2019
Projektdetails
Engineered heart tissue, guinea pig kryo injury model, cardiac repair
The project aims to unravel mechanisms of human engineered heart tissue (EHT) mediated cardiac repair. The project is based on a guinea pig kryo injury EHT transplant model and addresses coupling, EHT morphology after tranplantation, cardiomyocyte proliferation among others.

Hypertrophic cardiomyopathy: from gene identification to individualized therapy
ID 81Z2710102
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Lucie Carrier
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Topic genetics of cardiovascular diseases
Fördersumme 692627.97€ 692.627,97
Beginn 2014-10-2929.10.2014
Ende 2018-12-3131.12.2018
Projektdetails
Cardiomyopathy, Hypertrophy, iPSC, CRISPR/Cas9, disease modeling
Goals of this project are : i) to search for mutations in patients with HCM and to evaluate the molecular pathways in several human samples (blood, septal myectomies, skin biopsy); ii) to model HCM in the dish in both 2D culture of cardiac myocytes and 3D engineered heart tissues (EHT) obtained from iPSC-derived from HCM patients’ skin biopsy. Evaluation of contractile function and electrophysiological properties. iii) to evaluate different molecular therapies in human cardiac myocytes and EHT. Therefore, we also plan to use the CRISPR-Cas9 technology to remove the mutation in iPSC, which will be then used as controls for disease phenotype and molecular therapy.

Reverse cardiac remodeling
ID 81Z2710103
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Heimo Ehmke
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Topic cardiomyocyte function
Fördersumme 307489.08€ 307.489,08
Beginn 2014-10-2929.10.2014
Ende 2018-12-3131.12.2018
Projektdetails
acute mechanical unloading, Ca2+ cycling, phospholamban, Ca2+ channel, cardiac arrhythmias, SERCA2, heart transplantation
Cardiac mechanical unloading is associated with an increased risk of ventricular arrhythmias. Underlying pathophysiological mechanisms are still poorly understood. Recent studies indicate that unloading causes a remodeling of Ca2+ homeostasis in ventricular cardiomyocytes leading to a reduced contribution of sarcoplasmic reticulum (SR) Ca2+ release to the systolic Ca2+ transient. Using pharmacological and genetic interventions in a rodent model of cardiac unloading, this project tests the hypothesis that reestablishing the dominance of SR Ca2+ release will stabilize cardiac repolarization and therefore reduce the occurrence of arrhythmias.

Inflammation in atrial fibrillation
ID 81Z2710104
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Stephan Willems
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Topic other arrhythmias
Fördersumme 386990.40€ 386.990,40
Beginn 2014-10-2929.10.2014
Ende 2018-12-3131.12.2018
Projektdetails
arrythmias, atrial fibrillation, Hypertension, Left ventricular hypertrophy, cardiac nervous system
The development of cardiac fibrosis and a higher susceptibility of atrial fibrillation (AF) have been shown in an animal model of long-term hypertension. However, the causal relationship between hypertension, fibrosis and AF remains unclear. Using Angiotensin II, we have established a long-term hypertension model in sheep in order to elucidate structural and electrophysiological changes as a prerequisite for AF. Since the intrinsic cardiac nervous system (ICANS) is known affect AF and other arrhythmias and might present a potential target for catheter-based interventions, we additionally characterise the role of the ICANS in arrhythmias using our sheep model.

Immunobiology of pluripotent stem cells
ID 81Z2710105
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Sonja Schrepfer
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Topic stem cells/cardiac regeneration
Fördersumme 320582.89€ 320.582,89
Beginn 2014-10-2929.10.2014
Ende 2018-12-3131.12.2018
Projektdetails
cardiac regeneration; islet cell regeneration; regenerative medicine; immunobiology of pluripotent stem cells; stem cell rejection
Due to ethical concerns, the derivation of induced pluripotent stem (iPS) cells seems to be a novel, promising tool. However, the generation, validation, differentiation and puri-fication of iPS cells takes weeks to months and therefore, patient-specific iPS cells will not be readily available for acute diseases such as myocardial infarction or stroke. For this purpose, off-the-shelf cell products (e.g., iPS cell-derived cardiac and neuronal cells) will be required to be administered in a timely fashion. These cells, however, would not be patient-specific, but allogeneic. Since systemic immunosuppression for iPS cell recipients is not justifiable and feasible for cell therapy, we are aiming to understand their immune rejection and subsequent generate hypo-immunogenic cells that allow universal allogeneic transplantation without inducing immune activation, thereby evading rejection.

Oxidative post-translational modifications in cardiovascular disease
ID 81Z2710106
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Friederike Cuello
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Topic cardiomyocyte function
Fördersumme 340241.71€ 340.241,71
Beginn 2014-10-2929.10.2014
Ende 2018-12-3131.12.2018
Projektdetails
Signalling pathways in cardiovascular disease, Protein kinase, Redox regulation
The group‘s research aims to increase the understanding of the molecular mechanisms of heart failure. In particular, we study how signals from the sympathetic nervous system are transduced into the cardiac myocyte, which processes are subsequently triggered and what molecular alterations occur during heart failure development. Over the past years, we have concentrated our attention on the redox-regulation of protein kinase signalling and the effect on posttranslational regulation of kinases and their substrates. Through this, we have recently established disease-specific posttranslational fingerprints of the myofilament proteome in human heart failure tissue by combining interdisciplinary techniques such as molecular biology and redox-proteomics analyses.

Molecular mechanisms of HF
ID 81Z2710107
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Dirk Westermann
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Topic cardiac hypertrophy/remodeling
Fördersumme 292596.06€ 292.596,06
Beginn 2014-10-2929.10.2014
Ende 2018-12-3131.12.2018
Projektdetails
Heart failure, extracellular matrix, inflammation
Our goal is to describe molecular mechanisms involved in heart failure pathology. Therefore, our research is focused on the extracellular matrix remodelling and the regulation of cardiac inflammation in different types of heart failure. Different animal models were used to induce heart failure. Furthermore, we combine in vivo animal models with in vitro cell culture experiments as well as the analysis of human samples to describe molecular mechanisms involved in heart failure pathology. Special focus will be on cardiac remodeling and changes in the extracellular matrix.

Modulation of cAMP microdomains to treat heart failure
ID 81Z2710108
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Viacheslav Nicolaev
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Topic cardiac hypertrophy/remodeling
Fördersumme 491801.84€ 491.801,84
Beginn 2014-10-2929.10.2014
Ende 2018-12-3131.12.2018
Projektdetails
cAMP, microdomains, hypertrophy, beta-blocker, AAV, genetherapy
The ubiquitous second messenger cAMP plays central roles in the regulation of cardiac function and diseases such as hypertrophy and heart failure. Especially the stimulation of cardiomyocyte ?-adrenoceptors leads to strong contractile response and disease progression, while other membrane receptors coupled to the stimulatory G-protein (Gs) play less prominent role. Beta-blockers are therefore central to the therapy but lead to non-cardiac side-effects which limit patient compliance. This project will test the hypothesis that cardiomyocyte-specific delivery of a dominant negative Gs mutant should provide beneficial antihypertrophic effect without systemic side-effects. This mutant will be studied in mouse diseased models and introduced into AAV for gene therapy studies.

Systolic and diastolic heart failure - Collagen regulation
ID 81Z3100231
Institution Charité - Universitätsmedizin Berlin
Projektleiter Carsten Tschöpe
Standort Berlin
Projektart Standortprojekt
Topic Inflammatory heart diseases
Fördersumme 397144.32€ 397.144,32
Beginn 2014-01-0101.01.2014
Ende 2018-12-3131.12.2018
Projektdetails
collagen, LoxL-2
Left ventricular stiffness and diastolic dysfunction are besides a raise in collagen/matrix also due to an increased crosslinking of the matrix. Lysyloxidases (LOX) are a family of extracellular matrix crosslinking enzymes and critical contributors to the development of cardiac fibrosis. Besides LOX1, particularly LOX-like (LOXL)-2 is an important target since inhibition of LOXL2 has been shown to result in a marked reduction in activated fibroblasts (myofibroblasts), decreased production of cytokines, and decreased TGF-? pathway signaling. Furthermore, higher serum LOXL2 levels have been shown to be associated with increased risk for idiopatic pulmonary fibrosis disease progression. Importantly, LOXL2 is besides the heart expressed in the spleen and the thymus. Given the importance of the cardiosplenic axis in heart failure, linking inflammation with cardiac fibrosis on the one hand, and the expression of LOXL2 in the spleen/thymus and their antifibrotic features on the other hand, a role of LOXL2 in the inflammation and fibrosis process in heart failure is suggested. This project is focused at evaluating the role of LOXL2 in heart failure with preserved ejection fraction (HFpEF). Therefore, cardiac expression of LOXL2 will be evaluated in HFpEF and heart failure with reduced ejection fraction (HFrEF) patients and the effect of LOXL2 on TGF-ß signaling in cardiac fibroblasts from HFpEF and HFrEF patients analyzed. There will be evaluated whether serum LOXL2 levels are a predictive biomarker for cardiac LOXL2 expression and HFpEF, and whether LOXL2 inhibition may abrograte the progression of cardiac fibrosis.

Systolic heart failure and diastolic heart failure
ID 81Z3100331
Institution Deutsches Herzzentrum Berlin
Projektleiter Volkmar Falk
Standort Berlin
Projektart Standortprojekt
Fördersumme 2194941.80€ 2.194.941,80
Beginn 2011-10-0101.10.2011
Ende 2020-12-3131.12.2020
Projektdetails

Mechanisms of heart failure in congenital heart disease
ID 81Z3100333
Institution Deutsches Herzzentrum Berlin
Projektleiter Felix Berger
Standort Berlin
Projektart Standortprojekt
Topic genetics of cardiovascular diseases
Fördersumme 681214.79€ 681.214,79
Beginn 2013-01-0101.01.2013
Ende 2018-12-3131.12.2018
Projektdetails
cardiomyopathy, heart failure, MRI, genetic analysis, disease mechanisms
Pediatric cardiomyopathies are genetically heterogeneous and information on the epidemiology and outcomes of cardiomyopathy in children is limited by disease diversity and small case series. In order to specifically identify patients that would profit from early intervention such as an implantable cardioverter defibrillator (ICD) or specific pharmacologic treatment for heart failure we study individuals <= 18 years and their first-degree relatives with the following phenotypes: Hypertrophic cardiomyopathy (HCM), Dilated cardiomyopathy (DCM), Left ventricular noncompaction cardiomyopathy (LVNC), and Arrhythmogenic right ventricular cardiomyopathy (ARVC). Detailed phenotyping including MRI and genotyping with a Next Generation Sequencing Panel of 170 candidate genes is performed.

Herzinsuffizienz - Transition GOE MD 1 UMG
ID 81Z3300131
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Stefan Anker
Standort Göttingen
Projektart Standortprojekt
Fördersumme 2448242.69€ 2.448.242,69
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails

Herzinsuffizienz - Regeneration
ID 81Z3300132
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Wolfram-Hubertus Zimmermann
Standort Göttingen
Projektart Standortprojekt
Fördersumme 1255543.47€ 1.255.543,47
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails

Herzinsuffizienz – Regeneration
ID 81Z3300232
Institution Deutsches Primatenzentrum Gesellschaft mit beschränkter Haftung - Leibniz-Institut für Primatenforschung
Projektleiter Rüdiger Behr
Standort Göttingen
Projektart Standortprojekt
Fördersumme 1629344.24€ 1.629.344,24
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails

Risk factor patterns associated with systolic and diastolic left ventricular dysfunction
ID 81Z3400131
Institution Universitätsmedizin Greifswald
Projektleiter Marcus Dörr
Standort Greifswald
Projektart Standortprojekt
Topic cardiomyocyte function
Fördersumme 1475849.35€ 1.475.849,35
Beginn 2012-01-0101.01.2012
Ende 2018-12-3131.12.2018
Projektdetails
heart failure, HFrEF, HFpEF, risk profiles biomarker, animal models, TAC, cell culture
The aim of this project is to identify risk profiles which are associated with the development of systolic and diastolic left ventricular dysfunction (HFrEF/ HFpEF). Based on populations-based data new knowledge should be generated regarding the general population. Furthermore patient cohorts (GANI_MED) in an early asymptomatic disease stage shall be investigated to identify factors and mechanisms which indicate or lead to the transition to symptomatic heart failure. Generated hypotheses will be validated and further investigated by cell and animal model based experimental approaches. The major aim is to identify new targets and mechanisms that can be tackled in new prevention and therapeutic approaches in early stages of heart failure to inhibit disease progression.

Myocardial RNA Therapy
ID 81Z3600431
Institution Technische Universität München
Projektleiter Stefan Engelhardt
Standort München
Projektart Standortprojekt
Topic DNA/RNA based, protein based therapy
Fördersumme 2107648.12€ 2.107.648,12
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails
miRNA-based therapy, microRNA, AntagomiR, anti-miR, AAV
This project aims to develop RNA-based therapeutics that interfere with myocardial damage. For this purpose several cardiovascular microRNAs have been identified and functionally characterized with regard to their capacity to regulate key cellular signaling pathways. A subset of these miRNAs are being validated in mouse models of disease and approaches for their therapeutic manipulation are being developed. This involves studies that aim to optimize the pharmacokinetics and pharmacodynamics of miRNA inhibitor molecules.

Arrhythmia Modelling
ID 81Z4300141
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Stephan Lehnart
Standort Göttingen
Projektart Standortprojekt
Fördersumme 1445283.03€ 1.445.283,03
Beginn 2012-01-0101.01.2012
Ende 2018-12-3131.12.2018
Projektdetails

Arrhythmia Modelling
ID 81Z4300441
Institution Max-Planck-Institut für Dynamik und Selbstorganisation
Projektleiter Stefan Luther
Standort Göttingen
Projektart Standortprojekt
Fördersumme 1582022.06€ 1.582.022,06
Beginn 2012-01-0101.01.2012
Ende 2018-12-3131.12.2018
Projektdetails

Early Clinical Trials with Focus Arrhythmia
ID 81Z4600241
Institution Klinikum der Universität München
Projektleiter Stefan Kääb
Standort München
Projektart Standortprojekt
Fördersumme 632804.55€ 632.804,55
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails

Metabolic mechanisms of cardiovascular disease and the German Prevention Study
ID 81Z5100251
Institution Charité - Universitätsmedizin Berlin
Projektleiter Joachim Spranger
Standort Berlin
Projektart Standortprojekt
Topic arteriosclerosis
Fördersumme 1206113.23€ 1.206.113,23
Beginn 2012-01-0101.01.2012
Ende 2018-12-3131.12.2018
Projektdetails
Metabolism, brain-heart axis, diabetes, NAFLD, prevention
We aim to identify novel and further elucidate known endogenous metabolic modifiers of cardiovascular health. We analyze the interrelation between environment, novel metabolic targets and CVD in relation to age and pre-existing CVD to finally translate those findings into preventive practice. We use established mouse models of metabolic disease (obesity, insulin resistance, NAFLD) and analyse the role of specific molecular targets in rodents. We particularly test selected interventional strategies (incl. pharmacology). This is combined with clinical studies in cohorts with impaired metabolism and increased cardiovascular risk (e.g. obesity, diabetes, insulin resistance)

Nutritional Pharmacology
ID 81Z5100254
Institution Charité - Universitätsmedizin Berlin
Projektleiter Ulrich Kintscher
Standort Berlin
Projektart Standortprojekt
Topic cardiac hypertrophy/remodeling
Fördersumme 554977.80€ 554.977,80
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
lipids, metabolism, heart failure
This study aims to investigate the preventive actions of new lipid mediators on myocardial hypertrophy and heart failure. We could recently show that palmitoleic acid (C16:1n7) promotes the development of physiological cardiac remodeling (Foryst-Ludwig A, J Biol Chem 2015). In continuation of this, we are now focusing on new ?-3 fatty acids. We will test the anti-hypertrophic/ anti-fibrotic potential of anti-inflammatory lipid mediators such as resolvins, protectins und maresins in different disease models such as TAC or isoprenalin injection.

Psychosoziale und Verhaltens-Interventionen
ID 81Z5300151
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Christoph Herrmann-Lingen
Standort Göttingen
Projektart Standortprojekt
Fördersumme 474744.45€ 474.744,45
Beginn 2012-01-0101.01.2012
Ende 2018-12-3131.12.2018
Projektdetails

Establishment of a Cardiovascular Examination Centre
ID 81Z5400151
Institution Universitätsmedizin Greifswald
Projektleiter Marcus Dörr
Standort Greifswald
Projektart Standortprojekt
Topic Inflammatory heart diseases
Fördersumme 2430579.10€ 2.430.579,10
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails
deep phenotyping, standarized phenotyping, examination centre, exercise training centre
This project aims to create a new infrastructure for conducting clinical trials by establishing a cardiovascular examination and training centre. This centre will carry out the standardized and quality controlled phenotyping of probands and patients. This includes algorithms for standardized data export and analysis. Methods for phenotyping include: standardized interviews and questionnaires, anthropometry, digital ECG, echocardiography, resting and 24 h blood pressure measurement, bodyplethysmography, spiroergometry, IMT measurements, peripheral endothelial function (FMD, EndoPAT), ankle-brachial-index measurements, pulse wave measurements (Vascular Explorer). Furthermore, training facilities will be established for conductiong cardiovascular prevention studies with life-style intervention programmes e.g. exercise.

Development of individualized intervention tools for primary prevention programmes
ID 81Z5400152
Institution Universitätsmedizin Greifswald
Projektleiter Ulrich John
Standort Greifswald
Projektart Standortprojekt
Topic Inflammatory heart diseases
Fördersumme 1344543.01€ 1.344.543,01
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails
expert feedback systems, behavioural changes, primary prevention, physical activity, motivation, adherence life-style changes
The aim of this project is to investigate how to reach relevant patient groups for primary prevention of cardiovascular diseases. Furthermore, automated intervention tools and feedback systems shall be developed which can be easily used in CVD prevention studies to increase motivation and adherence to life-style changes. Additionally, pilot studies and RCTs will be conducted to reduce sedentary behaviour as one major cardiovascular risk factor and to increase daily physical activity. A W2 professorship will be established to provide profound knowledge for prevention and behavioural change approaches e.g. exercise training and to support the other partner side projects especially those dealing with heart failure and coronary heart disease.

Individualized Tools for Life style Intervention in Patients with Chronic Heart Failure [Secondary Prevention]
ID 81Z5400153
Institution Universitätsmedizin Greifswald
Projektleiter Marcus Dörr
Standort Greifswald
Projektart Standortprojekt
Topic Inflammatory heart diseases
Fördersumme 1317560.22€ 1.317.560,22
Beginn 2012-01-0101.01.2012
Ende 2018-12-3131.12.2018
Projektdetails
exercise training, secondary prevention, biomarker profiles, heart failure, molecular cardiology
This projects aims to develop new life-style intervention approaches for secondary prevention of heart failure (HFrEF/HFpEF) and coronary heart disease. Pilotstudies will investigate the effects of life-style changes mainly exercise training on cardiovascular surrogate parameters and disease progression. Additionally, intervention-related biomarkers shall be investigated using transcriptomics, proteomics and metabolomics (urine, plasma, whole blood) which can be used as monitoring factors during intervention or as predictive factors for disease progression. The major aim is to find suitable surrogate paramters which can be easily implemented into large prevention RCTs and can be used to amplify the positive effects of life-style changes by increasing motivation and therapy complience and adherence. A W2 professorship for molecular cardiology will be established to support the investigation of prevention approaches and to interact with and support the other partner site projects.

Cardiovascular Population Studies
ID 81Z5600151
Institution Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Projektleiter Annette Peters
Standort München
Projektart Standortprojekt
Topic arteriosclerosis
Fördersumme 895595.21€ 895.595,21
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails
changes in cardiovascular risk factors, epigenetics, environmental factors, system biology
The aim of the DZHK project Cardiovascular Population Studies (MHA 5.1) is to identify novel risk factors to improve individual risk prediction. The last years showed that especially epigenetics and metabolic processes have great potential to elicit so far unknown pathomechanisms. The focus is on short-term triggers of myocardial infarction as well as long-term risk factors that influence arteriosclerosis. A junior research group was established to integrate life-style factors, environmental factors, epigenetic markers and blood biomarkers from the KORA study. Their relative impact are investigated using innovative methods. All data is available via KORA.PASST. Tasks: 1. Risk factors for coronary heart disease – which changes occurred in the last 30 years? 2. OMICs and novel methods from system medicine to investigate the etiology of coronary heart disease. 3. Environmental factors and coronary heart disease.

Zelluläre Netzwerke bei kardiovaskulären Erkrankungen
ID 81Z5600153
Institution Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Projektleiter Thomas Meitinger
Standort München
Projektart Standortprojekt
Fördersumme 621714.66€ 621.714,66
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails

Clinical genomics, risk prediction
ID 81Z5600551
Institution Deutsches Herzzentrum München
Projektleiter Heribert Schunkert
Standort München
Projektart Standortprojekt
Topic genetics of cardiovascular diseases
Fördersumme 882711.61€ 882.711,61
Beginn 2013-01-0101.01.2013
Ende 2018-12-3131.12.2018
Projektdetails
coronary artery disease, myocardial infarction, networks, pathway analysis, risk prediction
Our group has substantially contributed to the discovery of numerous genomic variants, which increase the risk of coronary artery disease. Based on these variants, we were able to evaluate the prospective value of a genetic risk score in a large sample set. Using novel bioinformatics techniques, we identified novel networks and pathways influencing the pathophysiology of coronary artery disease and myocardial infarction. The goal of the project “Clinical genomics, risk prediction“ is to explore the interaction of known and yet to be identified coronary artery disease risk loci as well as the interaction of coronary artery disease risk loci with environmental factors to ultimately improve risk prediction.

Development of novel methodology and technology for cardiovascular MR
ID 81Z6100161
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Thoralf Niendorf
Standort Berlin
Projektart Standortprojekt
Topic imaging
Fördersumme 261522.15€ 261.522,15
Beginn 2014-01-0101.01.2014
Ende 2018-12-3131.12.2018
Projektdetails
ultrhahigh field MRI, human studies
This project builds on the achievements of our previous GCCR project. It focuses on the development of enabling radiofrequency (RF) antenna technology tailored for high spatial resolution cardiac magnetic resonance imaging (MRI) at a magnetic field strength of 7.0 Tesla. To meet this objective multi-channel transmission RF antenna arrays will be designed. For this purpose novel dipole antenna building blocks will be developed, implemented and validated. The clinical feasibility of the novel technology will be evaluated in a volunteer study at 7.0 Tesla with the ultimate goal to enable sub-millimeter spatial resolution cardiac MR imaging that supports visualization of subtle cardiac anatomy, high fidelity cardiac chamber quantification and imaging based myocardial tissue characterization.

Noninvasive characterization of myocardial tissue
ID 81Z6100162
Institution Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Projektleiter Thoralf Niendorf
Standort Berlin
Projektart Standortprojekt
Topic imaging
Fördersumme 188439.49€ 188.439,49
Beginn 2014-01-0101.01.2014
Ende 2018-12-3131.12.2018
Projektdetails
CMR imaging, experimental and human studies
CMR has the capability to differentiate myocardial injury applying different techniques. There are increasing numbers of quantitative approaches but an integrative quantitative covering various pathologies is missing. A a non-rigid registration method to superimpose focal images and diffuse fibrosis imaging allowing for pixel-wise comparison could already be developed. Further efforts are focusing on the integration of other pathologies in fused images. The project is based on theoretical phantoms, in vitro phantoms leading to human studies.

Clinical imaging
ID 81Z6200161
Institution Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III
Projektleiter Eike Nagel
Standort RheinMain
Projektart Standortprojekt
Topic imaging
Fördersumme 2765542.01€ 2.765.542,01
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails
magnetic resonance, computed tomography, myocardial ischaemia, heart failure, inflammation, fibrosis
The Imaging Project at the University Hospital Frankfurt (Rhein-Main) is represented by a DZHK-Professor for Cardiovascular Imaging and equipped with a state-of-the art 3T MR scanner dedicated for cardiovascular research since May 2016. In October 2016 a state-of-the art CT scanner dedicated for cardiovascular research will be installed. The projects focus on the main areas of cardiovascular disease, such as ischaemia, inflammation, fibrosis and heart failure as well as the prediction and substrate for arrhythmia. Novel diagnostic strategies (such as real time imaging, fully quantitative perfusion imaging and tissue characterisation) are developed, validated for accuracy, reproducibility, transferability, outcome and reversibility the effects of therapeutic interventions are assessed.

Echtzeit MRI
ID 81Z6300161
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Joachim Lotz
Standort Göttingen
Projektart Standortprojekt
Fördersumme 1101795.14€ 1.101.795,14
Beginn 2012-01-0101.01.2012
Ende 2018-12-3131.12.2018
Projektdetails

Nanopathologie
ID 81Z6300162
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Stephan Lehnart
Standort Göttingen
Projektart Standortprojekt
Fördersumme 712655.25€ 712.655,25
Beginn 2012-01-0101.01.2012
Ende 2018-12-3131.12.2018
Projektdetails

Echtzeit-MRT
ID 81Z6300561
Institution Max-Planck-Institut für Biophysikalische Chemie
Projektleiter Jens Frahm
Standort Göttingen
Projektart Standortprojekt
Fördersumme 605859.47€ 605.859,47
Beginn 2012-01-0101.01.2012
Ende 2018-12-3131.12.2018
Projektdetails

Live-Nanopathology
ID 81Z6300562
Institution Max-Planck-Institut für Biophysikalische Chemie
Projektleiter Stefan W. Hell
Standort Göttingen
Projektart Standortprojekt
Fördersumme 822288.33€ 822.288,33
Beginn 2012-01-0101.01.2012
Ende 2018-12-3131.12.2018
Projektdetails

Biomarker Imaging
ID 81Z6600262
Institution Klinikum der Universität München
Projektleiter Reiser
Standort München
Projektart Standortprojekt
Topic imaging
Fördersumme 655059.11€ 655.059,11
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails
MRI, CT, 4D-flow MRI, T1-mapping, large vessel vasculitis, 3D-Blackblood, OSAS, TAVI
Biomarker Imaging develops diagnostic, prognostic and predictive CT and MRI biomarkers for heart disease and establishes them in clinical routine. This includes: • Validation and standardization of recording and evaluation techniques of 4D flow MRI in children • Characterization of diffuse myocardial fibrosis in hereditary cardiomyopathy using pre- and post-contrast T1-mapping • Contrast dose optimization in CT angiography for determining the size of the aortic annulus before TAVI • Evaluation of non-invasive imaging methods without radiation exposure for primary diagnostic imaging and assessment of large vessel vasculitis • Evaluation of the effect of obstructive sleep apnea syndrome (OSAS) on cardiac function as determined by MRI

Multimodal Cardiovascular Imaging
ID 81Z6600661
Institution Klinikum rechts der Isar der Technischen Universität München
Projektleiter Markus Schwaiger
Standort München
Projektart Standortprojekt
Topic imaging
Fördersumme 392617.58€ 392.617,58
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails
imaging atherosclerotic plaques, macrophage infiltration, Tilmanocept plaque inflammation, tracer development, CXCR4, Ga-68-pentixafor, acute myocardial infarction, post-ischemic inflammation, FDG-PET/MRI
The aim of this project is to develop multimodal imaging strategies with a focus on inflammatory processes in atherosclerosis and in the sub-acute phase after myocardial infarction. For this purpose tracers targeting inflammatory processes (such as activated macrophages) are being developed. One such example is the tracer “Tilmanocept” which binds specifically to mannose-receptors on the surface of macrophages. “Tilmanocept” has originally been developed to image sentinel lymph nodes and was therefore labeled with radionuclides ideal for conventional gamma cameras. In our research group “Tilmanocept” is being modified so that positron emitting radionuclides, particularly Gallium-68, can be attached to “Tilmanocept”. Furthermore, the structure of “Tilmanocept” is being adapted to improve the affinity and biodistribution of this tracer. First biodistribution data in Apo-E-mice demonstrated an increased uptake in atherosclerotic plaques. Another focus of our research is the evaluation of Ga-68-pentixafor – a PET-tracer binding with nanomolar affinity to the chemokine receptor 4 (CXCR4). CXCR4 is known to be overexpressed on activated, hypoxic macrophages – therefor CXCR4 seems to be a very promising target to image inflammatory processes in atherosclerosis. In a rabbit model of atherosclerosis this approach has already been evaluated. New Zealand White rabbits fed with a high cholesterol diet received an endothelial abrasion of the right carotid artery and of the abdominal aorta to induce atherosclerotic plaque formation. Studies were performed using Ga-68-pentixafor (for imaging studies) and I-125-pentixafor (for biodistribution studies). We were able to demonstrate that tracer uptake was increased in atherosclerotic lesions and could be blocked efficiently by AMD3100 – a CXCR4-inhibitor. CXCR4-immunohistochemistry staining showed a high correlation with tracer uptake in autoradiography. These results are the basis for a DZHK-funded project with the aim to evaluate Ga-68-pentixafor in humans with carotid plaques in comparison to F-18-FDG. Besides these experiments to study inflammatory processes in atherosclerotic plaques, a large number of clinical studies to investigate the post-ischemic inflammatory response after myocardial infarction have been conducted. Patients were imaged in the first few days after myocardial infarction on an integrated PET/MR scanner using F-18-FDG as radiotracer. Patients had to fast for >12 hours and received heparin before tracer injection in order to suppress physiological F-18 FDG uptake in remote myocardium. The area of F-18 FDG uptake showed a high correlation with the area at risk and was significantly larger than the infarcted area (the latter was determined by late gadolinium enhancement MRI). Interestingly, the intensity of F-18 FDG uptake – as a measure of post-ischemic inflammation – correlated inversely with left ventricular function after 6 months, i.e. the higher the inflammatory signal the more likely an increase in endsystolic/end-diastolic volume and a decrease in ejection fraction was observed. While preclinical rodent studies clearly suggest that the F-18 FDG uptake reflects the invasion of inflammatory cells into the post-ischemic myocardium, no large animal study has proven this hypothesis. That is the reason why our group initiated first large animal studies with the aim to further breakdown this novel biosignal.

Establishment DZHK Core Facility
ID 81Z7100201
Institution Charité - Universitätsmedizin Berlin
Projektleiter Vera Regitz-Zagrosek
Standort Berlin
Projektart Standortprojekt
Topic cardiac hypertrophy/remodeling
Fördersumme 407195.97€ 407.195,97
Beginn 2014-08-0101.08.2014
Ende 2018-12-3131.12.2018
Projektdetails
mouse models, echocardiography (mice, rats), training
Establishment of DZHK-core facility for imaging, telemetric and metabolic measurements of rodents

Experimental Core Facility
ID 81Z7200101
Institution Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III
Projektleiter Ralf Brandes
Standort RheinMain
Projektart Standortprojekt
Topic Mechanisms in ischemia/reperfusion
Fördersumme 1129114.89€ 1.129.114,89
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
mouse imaging, mouse Phenotyping
The core facility provides a platform for animal phenotyping within the DZHK. SOPs for angiogenesis assays, animal imaging, myocardial infarct models are provided and novel Assays are developed such as virtual histology and xenograph angiogenesis models.

IT: Novel statistical tools (FFM I.5)
ID 81Z7200175
Institution Johann Wolfgang Goethe-Universität Frankfurt am Main - Klinikum - Medizinische Klinik III
Projektleiter Eva Herrmann
Standort RheinMain
Projektart Standortprojekt
Fördersumme 104966.38€ 104.966,38
Beginn 2012-01-0101.01.2012
Ende 2018-12-3131.12.2018
Projektdetails
biostatistics, mathematical modelling, survival analysis, sample size calculation
The aim of this project is the development of new statistical tools, especially in form of easy to use R package with a graphical user interface. These tools should especially comprise sample size calculation tools, survival analysis tools and graphical illustrations of the analysis of longitudinal data which directly refer to needs of basic science and clinical projects in the DZHK. These packages will be available under the GNU licence for open software products.

Proteomics
ID 81Z7200301
Institution Max-Planck-Institut für Herz- und Lungenforschung
Projektleiter Thomas Braun
Standort RheinMain
Projektart Standortprojekt
Fördersumme 1943239.54€ 1.943.239,54
Beginn 2015-01-0101.01.2015
Ende 2018-12-3131.12.2018
Projektdetails
cardiovascular research, mass spectrometry-based proteomics, protein quantification, post-translational modificationv
Biomolecular mass spectrometry facility in Bad Nauheim provides service in state-of-the-art liquid chromatography and tandem mass spectrometry for all members of the DZHK. Cardiovascular diseases are multicausal and result from altered cellular processes. Therefore, changes within the proteome or incorrect signaling pathways need to be characterized to understand the molecular mechanisms of heart failure. Our facility enables proteomic approaches to identify and quantify protein expression, post-translational modifications and protein-protein interactions. Furthermore, we aim for establishing new methods to optimize proteomics for cardiovascular research.

Experimentelle Stammzellbank
ID 81Z7300171
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Wolfram-Hubertus Zimmermann
Standort Göttingen
Projektart Standortprojekt
Fördersumme 2090025.26€ 2.090.025,26
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails

Informations-und Datenmanagement
ID 81Z7300173
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Tim Friede
Standort Göttingen
Projektart Standortprojekt
Fördersumme 578972.98€ 578.972,98
Beginn 2012-01-0101.01.2012
Ende 2018-12-3131.12.2018
Projektdetails

Metabolomics
ID 81Z7400171
Institution Universitätsmedizin Greifswald
Projektleiter Matthias Nauck
Standort Greifswald
Projektart Standortprojekt
Topic genetics of cardiovascular diseases
Fördersumme 832828.34€ 832.828,34
Beginn 2013-01-0101.01.2013
Ende 2018-12-3131.12.2018
Projektdetails
metabolomics, metabolic profiles, risk stratification, molecular intervention monitoring
Changes in individual metabolic profiles can give hints on subcliinical deseases and might be a source for the discovery of new biomarkers. Furthermore, metabolic profiles can provide information on specific food consumption habits or environmental exposures. Therefore, measurements of metabolic profiles are the basis for individualized diagnostics and therapy in patients. NMR and mass pectroscopy provide deep insights into metabolom changes in urine or blood plasma samples. The major aim of this project is to provide a platform for investigating metabolic changes due to prevention measure in cardiovascular diseases and to generate new hypotheses for the investigation and development of new diagnostic and theraputic approaches. Data from population-based studies like SHIP or Inter99 will complement these investigations by comparing patient cohorts to the general population. Furthermore, metabolic profiles that can be used as intervention (e.g. exercise training) monitoring tools will be investigated. Finally, a comprehensive data analysis of transcriptome, proteome and metabolome data will be carried out for risk stratification and therapeutic prognosis in DCM and heart failure.

Proteomics
ID 81Z7400172
Institution Universitätsmedizin Greifswald
Projektleiter Uwe Völker
Standort Greifswald
Projektart Standortprojekt
Topic genetics of cardiovascular diseases
Fördersumme 1427830.24€ 1.427.830,24
Beginn 2013-01-0101.01.2013
Ende 2018-12-3131.12.2018
Projektdetails
proteomics, transcriptomics, integrated data analysis, risk stratification, molecular intervention monitoring
The identification of new biomarkers from easily obtainable biomaterials like blood or urine is a key in individualized approaches for diagnostics and therapy. Proteomics provides promising approaches that are ivestigated worldwide for many different diseases. The major aim of this project is analyse unique population-based cohorts in Greifswald which can be used as control groups for investigations in patients. Furthermore, proteomics shall provide characterictic proteome profiles for primary and secondary prevention approaches of cardiovascular diseases that can be used for intervention monitoring or as prognostic factors. Complementary transcriptome analyses to baseline and during the intervention (follow-up) will be done and a comprehensive data analysis of transcriptome, proteome and metabolome data will be carried out for risk stratification and therapeutic prognosis in DCM and heart failure.

Biobanking
ID 81Z7400173
Institution Universitätsmedizin Greifswald
Projektleiter Matthias Nauck
Standort Greifswald
Projektart Standortprojekt
Topic genetics of cardiovascular diseases
Fördersumme 512493.38€ 512.493,38
Beginn 2014-01-0101.01.2014
Ende 2018-12-3131.12.2018
Projektdetails
biobanking, clinical chemistry, biomarker, integrated molecular approaches
This project provides the platform for longtime storage of biomaterials (blood, urine, DNA) for investigations regarding the discovery of new biomarkers or biomarker profiles with genomic, transcriptomic, proteomic and metabolomic approaches. A fully automated biobank will be used for storage of biomaterials at -80°C. Furthermore, this project provides standardized and quality controlled workflows for obtaining and processing of biomaterials. Finally, all laboratory diagnostic measurements will be carried in this project as interface to the other partner site projects.

Integrated Data Management and Telemedical Monitoring
ID 81Z7400174
Institution Universitätsmedizin Greifswald
Projektleiter Wolfgang Hoffmann
Standort Greifswald
Projektart Standortprojekt
Topic Health services/health systems research
Fördersumme 477719.96€ 477.719,96
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails
telemedicine, telemonitoring, IT systems, integrated data management, quality assurance
This project supports the investigation of primary and secondary prevention approaches. The major aim of this project is to develop an integrated IT system for documentation, quality assurance, and data storage and provision for population-based field studies and clinical trials regarding cardiovascular disease prevention. Telemedical approaches like monitoring of physical activity and personalized feedback systems will also be investigated.

Sequenzierplattform: Resources for deep-sequencing/genomics
ID 81Z7600173
Institution Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Projektleiter Thomas Meitinger
Standort München
Projektart Standortprojekt
Fördersumme 885175.24€ 885.175,24
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails

Phenotyping Mouse Models
ID 81Z7600174
Institution Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Projektleiter Martin Hrabé de Angelis
Standort München
Projektart Standortprojekt
Topic cardiac hypertrophy/remodeling
Fördersumme 212627.90€ 212.627,90
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails
phenoytping, mouse models, echocardiography, electrocardiography, cardiovascular screening
Engineered mouse models are essential tools for cardiovascular research because they facilitate studies of the phenotypic consequences of genetic alterations in a large-scale fashion. We established a cardiovascular screen to investigate such mouse models. We aimed at establishing non-invasive echocardiography of the left and right ventricle, Doppler echocardiography and electrocardiography in awake mice. Our protocol allows the diagnosis of biventricular cardiac pathologies and to study symptom occurrence and disease progression non-invasively in high throughput. Many new cardiac phenotypes have been successfully identified in mice.

Large Animal Models
ID 81Z7600274
Institution Klinikum der Universität München
Projektleiter Christian Kupatt
Standort München
Projektart Standortprojekt
Topic cardiac hypertrophy/remodeling
Fördersumme 464116.00€ 464.116,00
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails
Large animal, pig, acute myocardial ischemia, chronic myocardial ischemia, cardiovascular risk factors
The Large Animal platform offers preclinical models of acute or chronic myocardial ischemia (including cardiovascular risk factors) as well as hypertensive / hypertrophic heart failure in pigs. Besides an ischemia-reperfusion model (60-120min occlusion of a coronary artery, up to 8 weeks follow-up) a model of hibernating myocardium (reducing stent gradual coronary occlusion, loss of function in the target area) and a model of hypertrophic heart failure (percutaneous aortic constriction) is available. These models allow for patient care techniques, instrumentation and catheterization. Therapeutic agents (drugs, viral vectors, microRNA inhibitors and cell therapy) can be tested in systemic or regional (intravascular/intra-myocardial) applications. Besides morphological changes, global and regional myocardial function, myocardial perfusion, inflammation and vascular changes can be analyzed.

Platform Reprogramming
ID 81Z7600671
Institution Klinikum rechts der Isar der Technischen Universität München
Projektleiter Laugwitz/Moretti
Standort München
Projektart Standortprojekt
Topic iPSC
Fördersumme 707459.52€ 707.459,52
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails
induced pluripotent stem cells, disease modelling, drug/intervention testing
The focus of this project is the generation of patient-specific models of monogenic and complex cardiovascular diseases using induced pluripotent stem cells (iPSCs) in order to study the molecular pathways that drive the disease and screen for both genes and drugs that can block the disease onset or progression at a cellular level. We work on optimization of reprogramming methods and differentiation protocols into the cardiovascular lineages as well as the development of high-throughput functional assays and CRISPR/Cas9-based genome editing in iPSCs.

Platform Biomedical Informatics
ID 81Z7600672
Institution Klinikum rechts der Isar der Technischen Universität München
Projektleiter Klaus Kuhn
Standort München
Projektart Standortprojekt
Topic Health services/health systems research
Fördersumme 143336.45€ 143.336,45
Beginn 2011-10-1515.10.2011
Ende 2018-12-3131.12.2018
Projektdetails
information technology, data integration, biobanking
This project has focused on supporting the integration of databases of the Munich Heart Alliance in order to improve shared access to data. Specific aspects are management of biobank data, integration of data into registers, secondary use of clinical data for research questions, and security/privacy issues in compliance with TMF concepts. Existing software modules have been further developed, and an open source solution will be established.

CVRC Echo Core Facility
ID 81Z7710101
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Thomas Eschenhagen
Standort Hamburg/Kiel/Lübeck
Projektart Standortprojekt
Topic imaging
Fördersumme 243335.92€ 243.335,92
Beginn 2014-10-2929.10.2014
Ende 2018-12-3131.12.2018
Projektdetails
small animal experimentation, echocardiography, core facility
The CVRC Echo Core Facility at the UKE offers all members of the DZHK access to a Visualsonics Vevo 2100® high frequency ultrasonograph for small animals. Transthoracic echocardiography is performed by trained staff. They provide a strong background in the evaluation of animal models and can help design protocols to answer research questions. Researchers are introduced into the handling of the technique and receive support for their individual scientific projects.

SMART-MI-DZHK9: DZHK-Biobanking
ID 81X1600205
Institution Klinikum der Universität München
Projektleiter Axel Bauer
Standort München
Projektart Klinische Studie
Fördersumme 59624.23€ 59.624,23
Beginn 2016-02-0101.02.2016
Ende 2021-07-3131.07.2021
Projektdetails
https://smart-mi.dzhk.de/

SMART-MI-DZHK9: Biometrie
ID 81X1600702
Institution Ludwig-Maximilians-Universität München
Projektleiter Ulrich Mansmann
Standort München
Projektart Klinische Studie
Fördersumme 42000.00€ 42.000,00
Beginn 2016-05-0101.05.2016
Ende 2021-07-3131.07.2021
Projektdetails
https://smart-mi.dzhk.de/

FAIR-HF2-DZHK5: Biometrie
ID 81X1300106
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Tim Friede
Standort Göttingen
Projektart Klinische Studie
Fördersumme 116018.80€ 116.018,80
Beginn 2016-04-0101.04.2016
Ende 2024-09-3030.09.2024
Projektdetails
https://fair-hf2.dzhk.de/

FAIR-HF2-DZHK5: Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality
ID 81X1710102
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Mahir Karakas
Standort Hamburg/Kiel/Lübeck
Projektart Klinische Studie
Fördersumme 6514115.02€ 6.514.115,02
Beginn 2016-05-0101.05.2016
Ende 2024-09-3030.09.2024
Projektdetails
https://fair-hf2.dzhk.de/

FAIR-HF2-DZHK5: DZHK-Biobanking
ID 81X1710103
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Mahir Karakas
Standort Hamburg/Kiel/Lübeck
Projektart Klinische Studie
Fördersumme 37088.48€ 37.088,48
Beginn 2016-07-0101.07.2016
Ende 2024-09-3030.09.2024
Projektdetails
https://fair-hf2.dzhk.de/

IPSC-EHT transplantation for cardiac repair - towards first-in-patient
ID 81X2600702
Institution Ludwig-Maximilians-Universität München
Projektleiter Eckhard Wolf
Standort München
Projektart Translational Research Project
Fördersumme 170759.26€ 170.759,26
Beginn 2016-10-0101.10.2016
Ende 2021-11-3030.11.2021
Projektdetails

IPSC-EHT transplantation for cardiac repair - towards first-in-patient
ID 81X2600613
Institution Klinikum rechts der Isar der Technischen Universität München
Projektleiter Christian Kupatt
Standort München
Projektart Translational Research Project
Fördersumme 293688.26€ 293.688,26
Beginn 2016-10-0101.10.2016
Ende 2021-11-3030.11.2021
Projektdetails

IPSC-EHT transplantation for cardiac repair – towards first-in-patient
ID 81X2710146
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Thomas Eschenhagen
Standort Hamburg/Kiel/Lübeck
Projektart Translational Research Project
Fördersumme 1118692.96€ 1.118.692,96
Beginn 2016-09-0101.09.2016
Ende 2021-11-3030.11.2021
Projektdetails
End-stage heart failure patients suffer from high mortality rates and have very limited treatment options. The availability of cardiomyocytes from human induced pluripotent stem cells (hiPSC) opens the possibility of allogeneic transplantation of new heart muscle mass. A recent study gives compelling evidence that transplantation of hiPSC-derived cardiomyocytes in the form of engineered heart tissue (EHT) improves cardiac function in a guinea pig myocardial infarction model. To pave the way for a first clinical trial, two critical issues will be addressed: 1) determination of the minimal effective dose/size in guinea pig and 2) translation to a large animal model (minipig myocardial infarction). Major endpoints are the therapeutic efficacy of small doses/sizes of EHTs in guinea pig myocardial infarction model, survival and growth of EHT in minipig under optimized immunosuppression and therapeutic efficacy in minipig.

Gene therapy for neonatal sacromeric cardiomyopathies: towards first-in-patient.
ID 81X2600413
Institution Technische Universität München
Projektleiter Angelika Schnieke
Standort München
Projektart Translational Research Project
Fördersumme 132507.00€ 132.507,00
Beginn 2016-10-0101.10.2016
Ende 2019-12-3131.12.2019
Projektdetails

Gene therapy for neonatal sacromeric cardiomyopathies: towards first-in-patient.
ID 81X2600614
Institution Klinikum rechts der Isar der Technischen Universität München
Projektleiter Christian Kupatt
Standort München
Projektart Translational Research Project
Fördersumme 199110.23€ 199.110,23
Beginn 2016-10-0101.10.2016
Ende 2019-12-3131.12.2019
Projektdetails

Gene therapy for neonatal sacromeric cardiomyopathies: towards first-in-patient.
ID 81X2600703
Institution Ludwig-Maximilians-Universität München
Projektleiter Eckhard Wolf
Standort München
Projektart Translational Research Project
Fördersumme 92430.00€ 92.430,00
Beginn 2016-10-0101.10.2016
Ende 2019-12-3131.12.2019
Projektdetails

Gene therapy for neonatal sarcomeric cardiomyopathies: towards first-in-patient
ID 81X2710148
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Lucie Carrier
Standort Hamburg/Kiel/Lübeck
Projektart Translational Research Project
Fördersumme 19656.12€ 19.656,12
Beginn 2016-10-0101.10.2016
Ende 2019-12-3131.12.2019
Projektdetails
Homozygous or compound heterozygous truncating mutations in MYBPC3 encoding cardiac myosin-binding protein C (cMyBP?C) cause neonatal cardiomyopathy, which rapidly evolves into systolic heart failure and death within the first year of life. We recently provided evidence of longterm disease prevention by Mybpc3 gene therapy in homozygous Mybpc3?targeted knock?in mice, which genetically mimic human neonatal cardiomyopathies. In the absence of alternative treatment options except heart transplantation, gene therapy is a realistic treatment option for this subset of infants with severe and fatal neonatal cardiomyopathy. Our main objective towards clinical application is to reproduce our mouse findings in a larger animal model. Our gene therapy medicinal product is a recombinant adeno?associated virus serotype 9, which contains the human MYBPC3 cDNA under the control of human cardiac troponin T promoter. The project aims at the generation of a pig model of neonatal cardiomyopathy carrying bi?allelic truncating MYBPC3 mutations with the combination of CRISPR/Cas9 RNA?guide nuclease, somatic cell nuclear transfer and embryo transfer. We expect to produce bi?allelic truncating mutations that will result in a severe, fatal neonatal cardiomyopathy in pigs.

Off-pump transapical mitral valved stent implantation
ID 81X2700209
Institution Universitätsklinikum Schleswig-Holstein
Projektleiter Georg Lutter
Standort Hamburg/Kiel/Lübeck
Projektart Translational Research Project
Fördersumme 325107.48€ 325.107,48
Beginn 2016-01-0101.01.2016
Ende 2017-12-3131.12.2017
Projektdetails
The aim of this project is to develop and verify a new mitral valved stent, fully adapted to the anatomy of mitral regurgitation of diseased hearts by means of a transapical mitral-valve stent implantation in the beating heart without using a heart-lung machine. Focus of this project will be the evaluation in the mitral regurgitation animal model. The design of the stent is supposed to be further developed for the mitral position, so that a greater match with the natural anatomy is attained with a new oval shape. In addition to the apical fixation, another fixation system shall also be developed. The additional anchorage shall ensure the correct anatomical position of the stent.

GPR32 in arterial myeloid cell recruitment - Koop. mit Externen Partner
ID 81X2600242
Institution Klinikum der Universität München
Projektleiter Oliver Söhnlein
Standort München
Projektart Kooperation mit Externen
Fördersumme 15000.00€ 15.000,00
Beginn 2017-01-0101.01.2017
Ende 2019-12-3131.12.2019
Projektdetails

GPR32 in arterial myeloid cell recruitment - Koop. mit Externen Partner
ID 81X2800164
Institution Westfälische Wilhelms-Universität Münster
Projektleiter Alexander Zarbock
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 11696.07€ 11.696,07
Beginn 2017-01-0101.01.2017
Ende 2019-12-3131.12.2019
Projektdetails

The inflammasome Aim2 links arterial inflammation and lipid metabolism
ID 81X2800156
Institution Technische Universität Dresden
Projektleiter Triantafyllos Chavakis
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 15000.00€ 15.000,00
Beginn 2016-09-0101.09.2016
Ende 2018-08-3131.08.2018
Projektdetails

The inflammasome Aim2 links arterial inflammation and lipid metabolism
ID 81X2600238
Institution Klinikum der Universität München
Projektleiter Oliver Söhnlein
Standort München
Projektart Kooperation mit Externen
Fördersumme 15000.00€ 15.000,00
Beginn 2016-09-0101.09.2016
Ende 2018-06-3030.06.2018
Projektdetails

Characterization of HCN-Channels in neural heart rate control
ID 81X2710149
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Christian Meyer
Standort Hamburg/Kiel/Lübeck
Projektart Kooperation mit Externen
Fördersumme 13781.69€ 13.781,69
Beginn 2016-10-0101.10.2016
Ende 2019-01-3131.01.2019
Projektdetails

Characterization of HCN-Channels in neural heart rate control
ID 81X2800159
Institution Heinrich-Heine-Universität Düsseldorf
Projektleiter Nikolaj Klöcker
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 11711.92€ 11.711,92
Beginn 2016-10-0101.10.2016
Ende 2019-01-3131.01.2019
Projektdetails

Elucidating the role of DENND5B in congenital heart disease -
ID 81X2800168
Institution Universitätsklinikum Ulm
Projektleiter Michael Kühl
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 13870.01€ 13.870,01
Beginn 2017-02-0101.02.2017
Ende 2018-01-3131.01.2018
Projektdetails

Elucidating the role of DENND5B in congenital heart disease - Koop. mit Externen Partner
ID 81X2600619
Institution Klinikum rechts der Isar der Technischen Universität München
Projektleiter Karl-Ludwig Laugwitz
Standort München
Projektart Kooperation mit Externen
Fördersumme 14991.20€ 14.991,20
Beginn 2017-01-0101.01.2017
Ende 2018-01-3131.01.2018
Projektdetails

Analysis of Rho/actin-mediated regulation of MRTF and WT1 in the pathogenesis of ARVC using iPSC-derived CMs - Koop. mit Externen Partner
ID 81X2600618
Institution Klinikum rechts der Isar der Technischen Universität München
Projektleiter Alessandra Moretti
Standort München
Projektart Kooperation mit Externen
Fördersumme 15000.00€ 15.000,00
Beginn 2017-01-0101.01.2017
Ende 2017-12-3131.12.2017
Projektdetails

Analysis of Rho/actin-mediated regulation of MRTF and WT1 in the pathogenesis of ARVC using iPSC-derived CMs - Koop. mit Externen Partner
ID 81X2800167
Institution Philipps-Universität Marburg
Projektleiter Robert Grosse
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 14985.49€ 14.985,49
Beginn 2017-01-0101.01.2017
Ende 2017-12-3131.12.2017
Projektdetails

In vivo monitoring of brain hypoxia in cerebrovascular disease
ID 81X2200133
Institution Johann Wolfgang Goethe-Universität Frankfurt am Main
Projektleiter Andreas Zeiher
Standort RheinMain
Projektart Kooperation mit Externen
Fördersumme 5998.42€ 5.998,42
Beginn 2016-04-0101.04.2016
Ende 2017-12-3131.12.2017
Projektdetails

In vivo monitoring of brain hypoxia in cerebrovascular disease
ID 81X2800146
Institution Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (MPG)
Projektleiter Friedemann Kiefer
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 14000.00€ 14.000,00
Beginn 2016-04-0101.04.2016
Ende 2017-12-3131.12.2017
Projektdetails

Koop. mit Ext: Genotype-dependent effects of smoking on atherosclerotic plaque formation in an in vivo-model
ID 81X2600517
Institution Deutsches Herzzentrum München
Projektleiter Heribert Schunkert
Standort München
Projektart Kooperation mit Externen
Fördersumme 4808.45€ 4.808,45
Beginn 2017-03-0101.03.2017
Ende 2019-12-3131.12.2019
Projektdetails

Koop. mit Ext: Genotype-dependent effects of smoking on atherosclerotic plaque formation in an in vivo-model
ID 81X2800170
Institution Justus-Liebig-Universität Gießen
Projektleiter Norbert Weißmann
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 20995.61€ 20.995,61
Beginn 2017-03-0101.03.2017
Ende 2019-12-3131.12.2019
Projektdetails

Message in a micro-bottle: Extracellular vesicles as transmitters of HDL’s immunomodulatory capacity - Koop. mit Ext
ID 81X2600244
Institution Klinikum der Universität München
Projektleiter Christian Weber
Standort München
Projektart Kooperation mit Externen
Fördersumme 15000.00€ 15.000,00
Beginn 2017-01-0101.01.2017
Ende 2018-04-3030.04.2018
Projektdetails

Message in a micro-bottle: Extracellular vesicles as transmitters of HDL’s immunomodulatory capacity - Koop. mit Ext
ID 81X2800169
Institution Universitätsklinikum Aachen
Projektleiter Joachim Jankowski
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 15000.00€ 15.000,00
Beginn 2017-01-0101.01.2017
Ende 2018-04-3030.04.2018
Projektdetails

Molecular mechanisms involved in apoptotic cell death in T. cruzi-infected cardiomyocytes
ID 81X2300157
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Thomas Meyer
Standort Göttingen
Projektart Kooperation mit Externen
Fördersumme 9391.20€ 9.391,20
Beginn 2017-01-0101.01.2017
Ende 2018-09-3030.09.2018
Projektdetails

Molecular mechanisms involved in apoptotic cell death in T. cruzi-infected cardiomyocytes
ID 81X2800160
Institution Philipps-Universität Marburg
Projektleiter Ralph T. Schwarz
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 10738.58€ 10.738,58
Beginn 2017-01-0101.01.2017
Ende 2018-09-3030.09.2018
Projektdetails

Quantitative pluripotency assessment of selected human induced pluripotent stem cell (hiPSC) lines and analysis of correlation to their cardiac differentiation potential
ID 81X2710153
Institution Universitätsklinikum Hamburg-Eppendorf
Projektleiter Bärbel Ulmer
Standort Hamburg/Kiel/Lübeck
Projektart Kooperation mit Externen
Fördersumme 15881.54€ 15.881,54
Beginn 2017-01-0101.01.2017
Ende 2017-12-3131.12.2017
Projektdetails

Quantitative pluripotency assessment of selected human induced pluripotent stem cell (hiPSC) lines and analysis of correlation to their cardiac differentiation potential
ID 81X2800163
Institution Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
Projektleiter Ole Pleß
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 19000.00€ 19.000,00
Beginn 2017-01-0101.01.2017
Ende 2017-12-3131.12.2017
Projektdetails

STAT1 regulierte miRNAs als diagnostische Biomarker und putative Targets für die Behandlung des Myokardinfarkts
ID 81X2800166
Institution Philipps-Universität Marburg
Projektleiter Volker Ruppert
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 38806.00€ 38.806,00
Beginn 2017-01-0101.01.2017
Ende 2018-09-3030.09.2018
Projektdetails

STAT1-regulated microRNAs as diagnostic biomarkers and putative targets for the treatment of myocardial infarction
ID 81X2300166
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Thomas Meyer
Standort Göttingen
Projektart Kooperation mit Externen
Fördersumme 32215.17€ 32.215,17
Beginn 2017-01-0101.01.2017
Ende 2018-09-3030.09.2018
Projektdetails

Understanding key gene regulatory nodes programming vertebrate cardiac regeneration
ID 81X2500156
Institution Universitätsklinikum Heidelberg
Projektleiter Christoph Dieterich
Standort Heidelberg/Mannheim
Projektart Kooperation mit Externen
Fördersumme 31938.76€ 31.938,76
Beginn 2017-01-0101.01.2017
Ende 2017-12-3131.12.2017
Projektdetails

Understanding key gene regulatory nodes programming vertebrate cardiac regeneration
ID 81X2800165
Institution Universität zu Köln
Projektleiter Leo Kurian
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 31939.46€ 31.939,46
Beginn 2017-01-0101.01.2017
Ende 2017-12-3131.12.2017
Projektdetails

Identification of novel arrhythmia susceptibility genes in survivors of sudden cardiac arrest using next generation sequencing
ID 81X2500204
Institution Ruprecht-Karls-Universität Heidelberg
Projektleiter Martin Borggrefe
Standort Heidelberg/Mannheim
Projektart Kooperation mit Externen
Fördersumme 2834.85€ 2.834,85
Beginn 2016-09-0101.09.2016
Ende 2017-12-3131.12.2017
Projektdetails

Identification of novel arrhythmia susceptibility genes in survivors of sudden cardiac arrest using next generation sequencing
ID 81X2800157
Institution Westfälische Wilhelms-Universität Münster
Projektleiter Eric Schulze-Bahr
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 39667.85€ 39.667,85
Beginn 2016-11-0101.11.2016
Ende 2017-12-3131.12.2017
Projektdetails

Characterization of inward rectifying potassium current (IK1) as a potential contributor to atrial arrhythmias in a porcine model of ischemic heart failure.
ID 81X2600232
Institution Klinikum der Universität München
Projektleiter Stefan Kääb
Standort München
Projektart Kooperation mit Externen
Fördersumme 9934.00€ 9.934,00
Beginn 2016-04-0101.04.2016
Ende 2019-07-3131.07.2019
Projektdetails

Characterization of inward rectifying potassium current (IK1) as a potential contributor to atrial arrhythmias in a porcine model of ischemic heart failure. DZHK B 15-015 Ext
ID 81X2800145
Institution Universitätsklinikum Regensburg
Projektleiter Lars Maier
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 10175.82€ 10.175,82
Beginn 2016-04-0101.04.2016
Ende 2019-07-3131.07.2019
Projektdetails

Identification and characterization of proteins that regulate cardiac gene expression through interference with microRNA precursor processing.
ID 81X2600411
Institution Technische Universität München
Projektleiter Stefan Engelhardt
Standort München
Projektart Kooperation mit Externen
Fördersumme 15000.00€ 15.000,00
Beginn 2016-04-0101.04.2016
Ende 2017-09-3030.09.2017
Projektdetails

Identification and characterization of proteins that regulate cardiac gene expression through interference with microRNA precursor processing.
ID 81X2800147
Institution Universitätsklinikum Regensburg
Projektleiter Gunter Meister
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 15000.00€ 15.000,00
Beginn 2016-03-0101.03.2016
Ende 2017-09-3030.09.2017
Projektdetails

Role of Nucleoside Diphosphate Kinases in Clinical and Experimental Atrial Fibrillation
ID 81X2500205
Institution Ruprecht-Karls-Universität Heidelberg
Projektleiter Thomas Wieland
Standort Heidelberg/Mannheim
Projektart Kooperation mit Externen
Fördersumme 18453.76€ 18.453,76
Beginn 2016-10-0101.10.2016
Ende 2017-12-3131.12.2017
Projektdetails

Establishing of a recombinant Zebrafish line carrying the New Foundland mutation TMEM43 p.S358L for drug screening and evaluation of the underlying pathomechanism
ID 81X2700210
Institution Universitätsklinikum Schleswig-Holstein
Projektleiter Hans-Heiner Kramer
Standort Hamburg/Kiel/Lübeck
Projektart Kooperation mit Externen
Fördersumme 25000.00€ 25.000,00
Beginn 2016-09-0101.09.2016
Ende 2017-08-3131.08.2017
Projektdetails

Role of Nucleoside Diphosphate Kinases in Clinical and Experimental Atrial Fibrillation
ID 81X2800161
Institution Universitätsklinikum Essen
Projektleiter Dobromir Dobrev
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 18500.00€ 18.500,00
Beginn 2016-09-0101.09.2016
Ende 2017-08-3131.08.2017
Projektdetails

Establishing of a recombinant Zebrafish line carrying the New Foundland mutation TMEM43 p.S358L for drug screening and evaluation of the underlying pathomechanism
ID 81X2800158
Institution Krankenhausbetriebsgesellschaft Bad Oeynhausen mbH
Projektleiter Hendrik Milting
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 23609.30€ 23.609,30
Beginn 2016-08-0101.08.2016
Ende 2017-07-3131.07.2017
Projektdetails

Evaluation of functional calcium handling abnormalities contributing to the atrial arrhythmogenic substrate in a porcine model of ischemic heart failure.
ID 81X2600234
Institution Klinikum der Universität München
Projektleiter Stefan Kääb
Standort München
Projektart Kooperation mit Externen
Fördersumme 9681.00€ 9.681,00
Beginn 2016-04-0101.04.2016
Ende 2019-07-3131.07.2019
Projektdetails

Evaluation of functional calcium handling abnormalities contributing to the atrial arrhythmogenic substrate in a porcine model of ischemic heart failure.
ID 81X2800150
Institution Universitätsklinikum Regensburg
Projektleiter Lars Maier
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 10675.00€ 10.675,00
Beginn 2016-04-0101.04.2016
Ende 2019-07-3131.07.2019
Projektdetails

Development of a physical activity program for patients 65 years of age or older after myocardial infarction
ID 81X2800154
Institution Friedrich-Alexander-Universität Erlangen-Nürnberg
Projektleiter Susanne Wurm
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 21715.92€ 21.715,92
Beginn 2016-05-0101.05.2016
Ende 2017-12-3131.12.2017
Projektdetails

Development of a physical activity program for patients 65 years of age or older after myocardial infarction DZHK B 16-010 Ext
ID 81X2400127
Institution Universitätsmedizin Greifswald
Projektleiter Sabina Ulbricht
Standort Greifswald
Projektart Kooperation mit Externen
Fördersumme 18785.56€ 18.785,56
Beginn 2016-05-0101.05.2016
Ende 2017-12-3131.12.2017
Projektdetails

Nanomedical approach for generating arterial ‘teflon’ endothelium
ID 81X2600236
Institution Klinikum der Universität München
Projektleiter Oliver Söhnlein
Standort München
Projektart Kooperation mit Externen
Fördersumme 9999.81€ 9.999,81
Beginn 2016-04-0101.04.2016
Ende 2017-06-3030.06.2017
Projektdetails

Nanomedical approach for generating arterial ‘teflon’ endothelium
ID 81X2800152
Institution Universitätsklinikum Aachen
Projektleiter Twan Lammers
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 10000.00€ 10.000,00
Beginn 2016-04-0101.04.2016
Ende 2017-06-3030.06.2017
Projektdetails

Role of the cardiac inflammasome in Coxsackievirus B3-induced myocarditis
ID 81X2100235
Institution Charité - Universitätsmedizin Berlin
Projektleiter Sophie Van Linthout
Standort Berlin
Projektart Kooperation mit Externen
Fördersumme 9445.06€ 9.445,06
Beginn 2016-01-0101.01.2016
Ende 2018-03-3131.03.2018
Projektdetails

Role of the cardiac inflammasome in coxsackievirus B3-induced myocarditis
ID 81X2800143
Institution Technische Universität Berlin
Projektleiter Jens Kurreck
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 14000.00€ 14.000,00
Beginn 2016-01-0101.01.2016
Ende 2018-03-3131.03.2018
Projektdetails

Die Rolle von TRPC-Kanälen für die Regulation der Ca2+ Homöostase beim kardialen Remodeling in kardialen Fibroblasten in vitro und in vivo
ID 81X2500148
Institution Universitätsklinikum Heidelberg
Projektleiter Marc Freichel
Standort Heidelberg/Mannheim
Projektart Kooperation mit Externen
Fördersumme 17004.92€ 17.004,92
Beginn 2016-03-0101.03.2016
Ende 2017-05-3131.05.2017
Projektdetails

Die Rolle von TRPC-Kanälen für die Regulation der Ca2+ Homöostase beim kardialen Remodeling in kardialen Fibroblasten in vitro und in vivo
ID 81X2800142
Institution Universität des Saarlandes
Projektleiter Peter Lipp
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 20500.00€ 20.500,00
Beginn 2016-03-0101.03.2016
Ende 2017-05-3131.05.2017
Projektdetails

Does Aerobic Exercise provide a safe and effective Therapy for Arterial Hypertension?
ID 81X2800155
Institution Justus-Liebig-Universität Gießen
Projektleiter Klaus-Dieter Schlüter
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 11962.48€ 11.962,48
Beginn 2016-06-0101.06.2016
Ende 2017-12-3131.12.2017
Projektdetails

Does Aerobic Exercise provide and effective Therapy for Arterilal Hypertension?
ID 81X2200201
Institution Kerckhoff-Klinik, Gesellschaft mit beschränkter Haftung
Projektleiter Christian Hamm
Standort RheinMain
Projektart Kooperation mit Externen
Fördersumme 7752.19€ 7.752,19
Beginn 2016-06-0101.06.2016
Ende 2017-12-3131.12.2017
Projektdetails

Functional analysis of heart failure-regulated lncRNAs (lnc-FAIL)
ID 81X2200134
Institution Johann Wolfgang Goethe-Universität Frankfurt am Main
Projektleiter Andreas Zeiher
Standort RheinMain
Projektart Kooperation mit Externen
Fördersumme 4000.00€ 4.000,00
Beginn 2016-04-0101.04.2016
Ende 2017-05-3131.05.2017
Projektdetails

Functional analysis of heart failure-regulated lncRNAs (lnc-FAIL)
ID 81X2800148
Institution Medizinische Hochschule Hannover
Projektleiter Thomas Thum
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 16000.00€ 16.000,00
Beginn 2016-04-0101.04.2016
Ende 2017-05-3131.05.2017
Projektdetails

Heart failure with preserved ejection fraction – Improvement of diagnosis and risk prediction
ID 81X2300162
Institution Georg-August-Universität Göttingen - Universitätsmedizin
Projektleiter Rolf Wachter
Standort Göttingen
Projektart Kooperation mit Externen
Fördersumme 7247.41€ 7.247,41
Beginn 2016-12-0101.12.2016
Ende 2018-12-3131.12.2018
Projektdetails

Assessment of heart function and injury-induced hypertrophy in a guinea-pig model of engineered cardiac repair
ID 81X2800149
Institution Medizinische Hochschule Hannover
Projektleiter Sandor Batkai
Standort Extern
Projektart Kooperation mit Externen
Fördersumme 8247.16€ 8.247,16
Beginn 2016-03-0101.03.2016
Ende 2017-02-2828.02.2017